JULY 201 19 Natio Ca Kingdom Saudi onal Heal Saudi C ancer In Sa m of Saud Health C lth Inform Cancer R ncidenc udi Ara 2016 di Arabia Council mation C Registry ce Rep abia a Center ort 1
JULY 20119
Natio
Ca
KingdomSaudi
onal HealSaudi C
ancer InSa
m of SaudHealth Clth InformCancer R
ncidencudi Ara2016
di ArabiaCouncil mation C
Registry
ce Repabia
a
Center
ort
1
2 2
Heal
Heal
Mr.
General
M
Direct
Natio
Director, O
Oncology, H
Kin
Ms. Wa
th Data Anal
Saudi C
Mr. Zeya
th Data Anal
Saudi C
. Mohamm
Manager As
anagement,
Informati
Dr. Hind
tor of Nationa
onal Health I
Saudi Hea
Dr. Hani A
Oncology Cen
Hematology a
ng Fahad Sp
afa Al-Zah
lyst and Qua
Cancer Regis
ad Al-Sha
lyst and Qua
Cancer Regis
med Al-She
sistant of He
National He
on Center
Al-Mutlaq
al Health Re
nformation C
alth Council
Al-Hashm
nter, Consult
and Stem Ce
pecialist Hosp
Rev
Pre
rani
ality Specialis
stry
hrani
ality Specialis
stry
ehri
ealth Data
ealth
q
gistries
Center
i
tant Medical
ell Transplan
pital
viewed
epared
st
st
H
Con
nt
Exec
He
d by
by
Mr. A
Health Data A
Sau
Ms.
Data Manag
trol and Prev
Sau
Dr
cutive directo
And Preven
Hospit
Dr. S
ad, Section o
Center
Hospit
Ms. M
Acting Mana
National H
Sa
Ahmed Al
Analyst and Q
udi Cancer R
Amal Al-M
ger of Golf Ce
vention (KFS
udi Cancer R
r. Ali Al-Za
or, Gulf Cente
ntion , King F
tal & Resear
houki Baz
of Medical O
r, King Faisa
tal & Resear
Malak Al-J
ager, Saudi C
Health Inform
audi Health C
-Rawaji
Quality Spec
Registry
Madouj
enter for Can
SH&RC) - Ad
Registry
ahrani
er for Cance
Faisal Specia
rch Center
zarbashi
Oncology, On
l Specialist
rch Center
Jamaan
Cancer Regi
mation Cente
Council
cialist
ncer
dviser for
r Control
alist
ncology
stry
er
3
Cancer Registry Annual Reports
Cancer Registry Dashboard
4 4
Introduct
This is
published by
publications
years: 1994
reports until 2
This repo
that can be
measuremen
cancer.
The strucoutlined aPart I- Ma
This part
the backgrou
Registry used
present the
tumor topogr
at the time of
programs we
Part II- Ov
Part II pr
Saudi Arabia
December 20
are used to p
age groups.
common can
addition, incid
number of c
(ASR), Crud
Rates (per 1
primary canc
demonstrate
by gender in
Saudi Arabia
Part III- CCommon
In this pa
cancers repo
are outlined.
and proporti
ASR, and th
gender are a
most commo
with the ASR
developing c
tion
the twentieth
y the Saudi
included the
- 1996,1997 -
2015.
rt provides st
used for be
nt on early de
cture of thas followsaterials an
of the report
und and met
d in collecting
basics of c
raphy, morpho
f diagnosis. A
e have used to
verview o
resents the o
a diagnosed b
016. Figures
present cance
Morphology
ncers are als
dence tables
cases, Age-St
e Incidence R
100,000 popu
cer site. Sepa
distribution o
n each of the
a.
Cancer Incn Sites 201
art, the incide
orted among t
For each ca
ons of all ne
e correspond
also presente
on cancers a
R reported fro
ountries.
h cancer inc
Cancer Reg
Incidence R
-1998,1999-20
tatistics on ca
etter planning
etection and m
his report cs: nd Method
t contains info
thods of the
g and analyzin
oding and c
ology and ext
lso we describ
o analyze the d
f Cancer I
overall cance
between 01 J
s, tables, line
er distribution
distributions
so presented
are used to p
tandardized I
Rate (CIR), a
ulation) by ge
arate bar char
of the most co
13 administra
cidence fo16
ence of the
he saudi male
ancer site, the
ewly diagnos
ing cancer ra
ed. In addition
among Saudis
om selected d
cidence repo
istry. Previou
Reports for th
000, and year
ancer incidenc
g and effectiv
management o
can be
ds
ormation abou
Saudi Cance
ng the data. W
classification o
tent of diseas
be the softwar
data.
Incidence
er incidence
anuary and 3
and bar chart
by gender an
for the mos
d in tables. I
resent the tota
ncidence Rat
and Cumulativ
ender for eac
rts are used t
ommon cancer
ative regions o
r Most
most commo
es and female
e total numbe
sed cases, th
anking for eac
n, ASR for th
s is compare
developed an
ort
us
he
rly
ce
ve
of
ut
er
We
of
se
re
in
31
ts
nd
st
In
al
te
ve
ch
to
rs
of
on
es
er
he
ch
he
ed
nd
PS
t
c
s
p
a
P
a
t
P
S
Part IV-CaSaudis
This part pr
he Non-Saud
cancer. The a
separately du
population in w
and 44 years e
Part V-Inc
This part c
all newly diag
he Non-Saudi
Distributio
age group
Distributio
Saudis by
Cancer In
among Sa
Cancer In
among No
Age-stand
frequencie
gender an
Part VI- Ar
It is enc
Statistics in S
ancer Incid
resents numb
dis including t
analysis of the
ue to the n
which large pr
especially amo
idence Ta
contains the fo
nosed cancer
is diagnosed i
n of cancer
and gender
n of cance
age group a
ncidence (pe
audis by age
ncidence (pe
on-Saudis by
ardized inci
es among S
d administra
rabic Sum
losed an Ara
audi Arabia fo
dence amo
ers of cancer
he most com
e Non-Saudis
nature of th
roportion aged
ong males.
ables
ollowing detai
r types for the
n 2016.
cases amon
.
er cases a
and gender.
er 100,000
group and g
er 100,000
y age group a
dence rate
Saudis by c
ative regions.
mmary
abic summar
or the Year 20
ong Non-
cases among
mon types of
is performed
he expatriate
d between 25
iled tables for
e Saudis and
ng Saudis by
mong Non-
populations)
ender.
populations)
and gender.
and relative
cancer site,
.
ry of Cancer
16.
5
g
f
d
e
5
r
d
y
-
)
)
e
,
r
6 6
Table of c
Introduction
PART I
MATERIALS A
Background on S
Saudi Cancer Re
Definitions of Sta
PART II
OVERVIEW O
Cancer Incidence
Cancer Distributi
Cancer Incidence
Childhood Cance
Distribution of Ca
International Com
PART III
CANCERS INC
Cancer Incidence
Female Breast C
Colorectal Cance
Thyroid Cancer (
Non- Hodgkin's L
Leukaemia (C91
Hodgkin's Lymph
Corpus Uteri Can
Lung Cancer (C3
Liver Cancer (C2
Prostate Cancer
PART IV
CANCER AMO
Cancer Incidence
PART V
INCIDENCE TA
Table 5.1.1
Table 5.1.2
Table 5.1.3
Table 5.1.4
Table 5.2.1
ontents
AND MOTHEDS
Saudi Arabia
egistry
atistical Terms
F CANCER INC
e in Saudi Arabia,
ion Among Saudi
e Among Adults (>
er Reported to Sa
ancer Cases in 13
mparison of Age-S
CIDENCE FOR
e for Most Commo
Cancer (C50)
er (C18-C20)
(C73)
Lymphoma (C82-C
-C95)
homa (C81)
ncer (C54)
33-C34
22)
(C61)
ONG NON-SAU
e Among Non-Sau
ABLES
Number of Cas
Number of Cas
Age-Spesific InPrimary Site an
Age-Spesific InPrimary Site an
Number of CasSaudi Males ( p
S
CIDENCE, 2016
, 2016
Nationals, 2016
> 14 Years), 2016
udi Cancer Regis
3 Administrative R
Standardized Incid
MOST COMMO
on Sites, 2016
C85; C96)
UDI 2016
udi Population. 20
ses Among Saudi
ses Among Saudi
cidence Rate (AIRnd Age groups, 20
cidence Rate (AIRnd Age groups, 20
ses, Relative Frequper 100,000) by P
6
6
try (≤ 14 Years), 2
Regions of Saudi A
dence Rates
ON SITES 2016
016
Males by Primary
Females by Prima
R), Age Standardi016.
R), Age Standardi016
uency, Crude Incirimary Site, Age G
2016
Arabia, 2016
6
y Site And Age Gro
ary Site And Age G
sed Incidence Ra
sed Incidence Ra
dence Rate (CIR)Groups and Regio
oups, 2016
Groups, 2016
ate (ASR) Among S
ate (ASR) Among S
) Age-Standardiseons 2016
Saudi Males (per
Saudi Females (p
ed Incidence Rate
r 100,000) by
per 100,000) by
(ASR) Among
5
9
9
12
15
18
21
22
26
31
33
34
36
38
40
42
44
46
48
50
52
56
60
61
62
63
64
Table 5.2.2
Table 5.2.3-
Table 5.2.4-
Table 5.3.1
Table 5.3.2
Table 5.3.3
Table5.3.4
Table 5.4.1
Table 5.4.2
Table 5.4.3
Table 5.4.4
Number Of CasSaudi Males ( p
Number Of CasSaudi Males ( p
Number Of CasSaudi Males ( p
Number Of CasSaudi Females
Number Of CasSaudi Females
Number of CasSaudi Females
Number Of CasSaudi Females
Number of Cas
Number of Cas
Age-Spesific Inby Primary Site
Age-Spesific Inby Primary Site
Acknowledgme
Arabic Summar
ses, Relative Freqper 100,000) by P
ses, Relative Freqper 100,000) by P
ses, Relative Freqper 100,000) by P
ses, Relative Freq( per 100,000) by
ses, Relative Freq( per 100,000) by
ses, Relative Freq( per 100,000) by
ses, Relative Freq( per 100,000) by
ses Among Non-S
ses Among Non-S
cidence Rate (AIRe and Age groups,
cidence Rate (AIRe and Age groups,
ent
ry
quency, Crude Incrimary Site, Age G
quency, Crude Incrimary Site, Age.
quency, Crude Incrimary Site, Age G
quency, Crude Incy Primary Site, Ag
quency, Crude Incy Primary Site, Ag
quency, Crude Incy Primary Site, Ag
quency, Crude Incy Primary Site, Ag
audi Males by Pri
audi Females by P
R), Age Standardi 2016
R), Age Standardi 2016
cidence Rate (CIRGroups and Regio
cidence Rate (CIR
cidence Rate (CIRGroups and Regio
cidence Rate (CIRe Groups and Re
cidence Rate (CIRe Groups and Re
cidence Rate (CIRe Groups and Re
cidence Rate (CIRe
mary Site And Ag
Primary Site And
sed Incidence Ra
sed Incidence Ra
) Age-Standardiseons 2016
) Age-Standardise
) Age-Standardiseons 2016.
) Age-Standardisegions 2016
) Age-Standardisegions 2016
R) Age-Standardizegions 2016
) Age-Standardise
e Groups, 2016
Age Groups, 2016
ate (ASR) Among
ate (ASR) Among
ed Incidence Rate
ed Incidence Rate
ed Incidence Rate
ed Incidence Rate
ed Incidence Rate
ed Incidence Rate
ed Incidence Rate
6
Non-Saudi Males
Non-Saudi Femal
e (ASR) Among
e (ASR) Among
e (ASR) Among
e (ASR) Among
e (ASR) Among
e (ASR) Among
e (ASR) Among
(per 100,000)
es (per 100,000)
65
66
67
68
69
70
71
72
73
74
75
76
79
7
8 8
MATE
PAERIALS
ARTS AND
T I D METH
HODS
Backgrou
Saudi A
fifths of the
Arabian Gulf
approximatel
divided into 1
Figure 1.Saudi Ara
The estim
31,787,580.
20,081,582 o
9,850,218 (4
The Non-
8,028,355 (6
females. Fig
Saudi popul
respectively.
Figure 1.2Saudis (%2016.
und on Sa
Arabia is a va
Arabian Pe
f in the east to
ly 2,149,700*
13 administrat
1 : Adminabia.
mated populatio
Saudi natio
of these 10,2
9%) were fem
-Saudi popul
69%) were ma
ures 1.2 and
ation pyramid
2 : Popula%) by gend
audi Arabi
ast country ex
eninsula. It st
o the Red Se
square kilome
ive regions Fi
istrative r
on for Saudi A
onals were
31,364 (51%
males.
ation was11,
ales and 3,67
1.3 show the
ds by gende
ation pyrader and ag
a
xtending over
tretches from
a in the west
eters in area a
igure 1.1.
regions of
Arabia in 2016
estimated to
) were males
705,998 of t
77,643 (31%)
e Saudi and
er and age g
mids of ge group,
four-
m the
. It is
and is
f
6 was
o be
s and
these
were
Non-
group
FigSau201
Sau
T
base
the
Fais
In 2
the
for H
Org
T
data
regio
facil
regis
T
revie
prov
addi
natio
gure 1.3 : Pudis (%) b16.
udi cance
The Saudi Ca
ed registry es
Ministry of H
sal Specialist H
014; SCR wa
department o
Health Informa
ganization
The SCR cons
a collection fr
onal offices to
ities in the K
stry is support
The committee
ews cancer
vides help in
ition to ensu
onal and intern
Populationby gender
r registry.
ancer Registr
stablished in 1
Health (MOH)
Hospital and r
as moved to S
of National Re
ation.
nal structu
sists of the m
rom all over
o ensure full
Kingdom as s
ted by registry
e provides sc
statistics rep
disseminatin
uring data co
national guide
n pyramidand age g
.
ry (SCR) is
1992 under th
) in the prem
research Cen
Saudi Health C
egistries in Na
ure.
main office wh
the country
coverage of
shown in Fig
y committee.
cientific guida
ports, data re
ng reliable in
onfidentiality
elines.
ds of Non-group,
a population-
he authority of
mises of King
ter in Riyadh.
Council under
ational Center
hich oversees
through five
all healthcare
gure 1.4. The
ance to SCR,
equests, and
nformation; In
according to
9
-
f
g
.
r
r
s
e
e
e
,
d
n
o
153463 75+ 161494
108210 70-74 110862
148312 156808
243697 227960
336326 308905
431579 407708
541114 45- 49 511696
643959 40- 44 619628
760653 35- 39 741778
867516 30- 34 851823
963289 25- 29 941694
1037331 20- 24 949321
896157 15- 19 864870
948277 10-14 921048
1063173 5-9 1025746
1088308 0-4 1048877
10231364 9850218
10.6
10.4
9.3
8.8
10.1
9.4
8.5
7.4
6.3
5.3
4.2
3.3
2.4
1.4
1.1
1.5
024681012
Males
10.6
10.4
9.4
8.8
9.6
9.6
8.6
7.5
6.3
5.2
4.1
3.1
2.3
1.6
1.1
1.6
0 2 4 6 8 10 12
Females
27442 75+ 10874
32802 70- 74 18347
71669 28410
206541 46059
385823 64380
644397
65- 69
60 - 64
55 - 59
50 - 54 98491
946332 45- 49 261977
1286648 40- 44 487949
1362508 35- 39 535049
927661 30- 34 416233
708776 25- 29 418649
278503 20- 24 206601
235852 15- 19 219171
287737 10-14 271257
349437 5-9 332676
276227 0-4 261520
8028355 3677643
3.4
4.4
3.6
2.9
3.5
8.8
11.6
17.0
16.0
11.8
8.0
4.8
2.6
0.9
0.4
0.3
0 5 10 15 20
7.1
9.0
7.4
6.0
5.6
11.4
11.3
14.5
13.3
7.1
2.7
1.8
1.3
0.8
0.5
0.3
0 2 4 6 8 10 12 14 16
Males Females
65-69 60-64 55-59 50-54
10 10
Regional
Each of t
director who
Staffing cons
SCR Main O
accuracy an
Quality cont
morphology,
patient), and
prepares ann
community,
organizations
Offices
the SCR offic
o is responsib
sists of senio
Office supervi
d quality of d
trol processe
staging inform
consolidation
nual reports fo
government
s and the publ
ces operates
ble for the d
or and junior
ises regional
data collected
es include ve
mation, case l
n of data. The
or disseminat
t departmen
lic.
under a reg
aily managem
r tumor regist
offices to en
d from all reg
erification of
inkage (tumor
e Main Office
tion to the me
nts, internat
gional
ment.
trars.
nsure
gions.
site,
r and
also
edical
tional
Sa
(D
(Je
Ma
(M
audi CanceO
Centra
(Riyadh, Q
Easter
ammam, Ahs
Weste
eddah, Makka
Southe
(Asir, Baha,
adinah & N
Madinah, Tab
er RegistrOffice
al Regio
Qassim & Ha
rn Regio
sa & Hafar A
rn Regio
ah, Taif & Qu
ern Regio
, Jazan & Naj
Northern R
uk, Jouf & N
ry Main
n ail)
on
Al Batin)
on unfudah)
on
jran)
Region
orthern
Data ma
A royal
mandatory
opportunity
SCR strives
government
laboratories
Cancer
medical r
histopatholo
registrars.
identification
demograph
number, na
date, prima
basis of dia
and histolog
identified a
Classificatio
(ICD-O-3),
Organizatio
changes we
behaviors a
Summary S
consistency
Manual 200
The case
were classi
While there
nagement
decree has
modifiable
for compreh
s for full acc
tal and priv
s throughout
data are
records ba
ogical diagno
Abstracted
ns (name,
ic informa
ationality), a
ry site, histo
agnosis). Th
gy (morpholo
nd coded ac
on of Diseas
published
on (WHO), 20
ere made in
as well as
Stage 2000
y in stage co
00 is availabl
es diagnosed
fied accordi
e have not
t
s categorize
disease. Th
hensive data
cess to canc
vate hospita
the Kingdom
abstracted
ased on
osis by SCR
data inc
ID Number
tion (addre
nd tumor de
logy, behavi
he primary s
ogy) of the m
ccording to
ses for Onco
by the
000. Starting
coding of c
staging acco
to increase
oding SEER
e on the web
d on or after 0
ng to the up
been any
ed cancer a
his ensures
a collection.
cer data from
als, clinics
m.
from patie
clinical an
R trained ca
cludes pers
r, gender, a
ess, teleph
etails (diagn
or, grade, st
site (topogra
malignancies
the Internati
ology 3rd Ed
World He
from year 2
cancer types
ording to S
e accuracy
Summary S
b.
01 January 2
pdated ICD-
changes in
as a
the
The
m all
and
ents’
nd/or
ancer
sonal
age),
hone
nosis
tage,
aphy)
s are
ional
dition
ealth
2001,
and
EER
and
Stage
2008
-O-3.
the
prim
rega
lym
that
cou
that
now
lym
hem
in e
with
cha
the
note
for a
S
hem
soft
Inte
(IAR
for
effo
info
and
mal
ana
wer
mary site co
arding histo
phoma are
t were prev
nted as mali
t were previo
w considered
phoma and
matopoietic d
ither the repo
h the SEER
nges reflect
pathology a
ed that ICD-
analysis purp
Since the W
matopoietic
ware, Can
ernational A
RC), Lyon, F
analysis and
ort is made to
rmation, to e
consolidate
ignancy is
alysis. Data
re generated
odes, there
ology (cell
particularly
viously cons
gnant. Also s
ously coded a
d benign. Co
d leukemia
diseases will
ort's ability o
R staging
t advances
nd behavior
-O-3 codes a
poses.
WHO has no
disease b
nReg 4.33
Agency for
France) cann
d they have
o accurately
ensure that a
ed, as app
counted on
entry and
by CanReg
are significa
types). Leu
affected. S
idered benig
small numbe
as borderline
unts of ovar
a as well
change due
or definition.
guidelines,
in the unde
of cancers.
are converte
ot yet conve
ehavior ch
(develope
Research
not include t
e been exclu
code patien
all data revie
propriate, so
nly once fo
incidence ta
software.
ant changes
ukemia and
Some cases
gn are now
er of cancers
e tumors are
rian cancers,
as some
e to changes
However, as
the ICD-O
rstanding of
It should be
ed to ICD-10
rted ICD-10
anges, our
d by the
on Cancer
these cases
uded. Every
nt and tumor
ewed, linked,
o that each
or statistical
ables output
11
s
d
s
w
s
e
,
e
s
s
O
f
e
0
0
r
e
r
s
y
r
,
h
l
t
12 12
Notificati
This rep
between Ja
cases ident
reported in
anticipated
will decreas
improved d
reporting la
publishing t
years wh
completene
DefinitionSpecific I
The num
specific per
gender gro
population o
Age-Stan
The Ag
measure of
had a stan
necessary w
differ with
frequently u
Standard P
incidence i
Incidence R
populations
on
port covers
anuary and
ified after thi
n subsequen
that the num
se as case a
during past
p between y
the incidence
ile mainta
ess of data.
ns of StatiIncidence
mber of canc
riod in a pop
up, divided
of that age a
ndardized
ge-standardiz
f a rate that
ndard age s
when compa
respect to
used standa
Population (s
is known a
Rate. The rat
s.
data that w
December
is date (late r
nt incidence
mber of late
ascertainmen
years. Our
year of diagn
e report to a
ining high
istical Ter Rate (AIR
er cases oc
ulation of a s
by the num
nd gender g
Rate (ASR
zed rate i
a population
structure. St
aring several
age struct
ard populatio
see below).
as the Worl
te is express
were diagno
2016. Incid
reporting) wi
e reports. I
e-reported ca
nt processes
aim is red
nosis and yea
a maximum
quality
rms Age-R)
ccurring durin
specific age
mber of midy
roup.
R)
is a summ
n would have
andardizatio
populations
ture. The m
on is the W
The calcula
ld Standard
sed per 100
osed
dent
ll be
It is
ases
has
duce
ar of
of 2
and
ng a
and
year
mary
e if it
on is
that
most
World
ated
ized
.000
Wo
*DolCont
Cru
T
tota
the
num
indi
100
age
dem
the
crud
alte
acro
diffe
ord
com
betw
stan
orld Stand
Age Cla
0 - 4 5 - 9 10 -14 15 -19 20 - 2425 - 2930 - 3435 - 3940 - 4445 - 4950 - 5455 - 5960 - 6466 - 6970 - 74 75 +
Total
l R. Payne P.Wtinents Vol.I. Int
ude Incide
The crude in
al number of
total popu
mber of ca
viduals. All
0.000 popula
e and the cru
mographic st
population
de rate ove
ered. It is not
oss geograp
erent popula
er to assess
mpare incide
ween regis
ndardize the
dard Popu
ass
4 9 4 9 4 9 4 9 4 9 4
Waterhouse J. Caternational Unio
ence Rate
cidence rate
f cases regis
lation. It de
ases occurr
rates are t
ation. Cance
ude rate is st
tructure of th
structure c
er that per
t appropriate
phical areas
ation age s
s time trend
ence across
stries it is
rates with re
lation
Popula
12.0010.00 9.000 9.000 8.000 8.000 6.000 6.000 6.000 6.000 5.000 4.000 4.000 3.000 2.000 2.000
100.0
ancer Incidenceon against Canc
(CIR)
e for a cance
stered as a p
enotes the
ring in eac
thus, expres
r rates vary
trongly influe
he populatio
changes ove
riod may b
e to compare
of cancer re
structures. T
s in registra
geographic
s necessar
espect to age
ation
00 00 0 0 0 0 0 0 0 0 0 0 0 0 0 0
000
e in Five cer. 1966
er site is the
proportion of
approximate
ch 100.000
ssed as per
greatly with
enced by the
on. Hence, if
er time the
be artificially
e crude rates
egistries with
Therefore, in
ation data or
cal areas or
ry to first
e.
e
f
e
0
r
h
e
f
e
y
s
h
n
r
r
t
Cumulati
Cumulati
risk of indiv
specified pe
number of
who would
cancer befo
had the rat
the age sta
between po
this report t
used. The c
cancer age
five-year ag
ICD - 10
The Wo
Classificatio
ICD - O -
The Wo
Classificatio
has been
neoplasms
includes a
four-digit nu
for behavio
aggressiven
Incidence
An incide
a new even
as the num
population
the populati
ve inciden
ve incidence
viduals deve
eriod. For ca
new born ch
be expect
ore the age
tes of cance
andardized
opulations of
the age rang
cumulative r
e-specific rate
ge intervals.
rld Health
on of Disease
3
orld Health
on of Diseas
the stan
for over 25
four charact
umeric code
or and a
ness (grade)
e rate
ence rate is
nt occurs in a
ber of new c
over a defin
ion at risk of
nce rate
e rate is th
eloping the d
ancer, it is e
hildren (out o
ed to deve
of 65 (or 70
ers currently
rate, it perm
f different ag
ges 0-64 and
rate is the su
es; which ar
Organization
es, tenth edit
Organization
es for Onco
dard codin
5 years. The
ter code for
for cell type
one-digit c
.
defined as t
a population
cases of dise
ned time pe
developing t
he probability
disease durin
xpressed as
of 100, or 10
lop a partic
0, or 75) if
y observed.
mits compar
ge structures
d 0-74 years
ummation of
re computed
n’s Internati
tion.
n’s Internati
logy, 3rd Ed
ng system
e coding sys
r primary sit
e, one-digit c
code for tu
he rate at w
n. It is calcula
ease arising
eriod, divided
that disease
y or
ng a
s the
000)
cular
they
Like
rison
s. In
s are
f the
d for
onal
onal
ition
for
stem
te, a
code
umor
which
ated
in a
d by
.
Me
T
num
Me
T
arra
Me
M
orig
lym
Ra
It
min
Ra
T
spe
of t
the
pop
Ra
It
qua
den
Re
T
can
of a
Su
S
bro
dise
ean
The simple m
mbers.
edian
The midpoin
anged in orde
etastasis
Metastasis is
ginal site to
ph nodes, sk
nge
t is the diffe
nimum values
nk
This measu
ecific cancer
the number
most and
pulation acco
tio
t is the relati
antity is a
nominator.
elative freq
This statistic
ncer cases re
all cancer. It i
mmary St
Staging is t
ad categori
ease.
mathematical
nt of the ra
er of value.
s the distant s
other organ
keletal and o
erence betw
s in a set of o
re reflects
site relative
of registrati
least frequ
ording to thei
ion between
numerator
quency
is defined a
egistered rela
is expressed
tage
he grouping
ies based
l average of
ange numbe
spread of ca
s of the bod
or visceral org
ween the ma
observations
the import
e to other sit
ons. Rankin
uent cancer
r frequency.
two quantiti
and the se
as the numbe
ative to the t
d as a percen
g of cancer
on the ext
two or more
ers that are
ncer from its
dy, including
gans.
aximum and
s.
tance of a
tes, in terms
ng illustrates
sites in a
ies. The first
econd is a
er of specific
total number
ntage.
cases into
tent of the
13
e
e
s
g
d
a
s
s
a
t
a
c
r
o
e
14 14
OVERVIE
PAEW OF
ARTCANC
2016
T II CER INCIDENNCE
Cancer in
Between
the total nu
reported to
17,602. Ove
than men;
9,558 (54.3%
reported am
Saudi, and 2
Total of 16
13,161 (78.
(21.9%) wer
Total of 7
analysis: 2
nationalities
to ICD-10 c
not include
Table 2.1.
Table 2.1Saudi Ca
Analyz
Male Femal
5803 7358
Table 2.2
Region Riyadh Makkah Eastern Asir Madinah Qassim Jazan Tabuk Hail Jouf Najran Baha Northern Unknown International
Total
**unknown nat
ncidence i
January 01
mber of new
the Saudi C
erall cancer
it affected
%) females.
mong Saudi n
206 of unkno
6,859 cases
.1%) were S
re Non-Saud
743 cases
206 cases
s, and 537 c
codes. The
in situ case
: Distribuancer Regi
Saudiszed
le Total M
8 13161 1
2 : Distribu
l
tionalities, in situ
in Saudi A
and Decem
wly diagnose
Cancer Regi
was more
8,044 (45.7
Total of 13,5
nationals, 3,8
own nationali
were analy
Saudi nation
di.
were exclu
of them w
ases failed t
software (C
es in the stat
ution of anistry by na
s Non Analyze
Male Female
184 217
ution of ca
Male 1604 1352 1094 498 293 225 149 154 79 92 87 82 67 26 1
5803
u and ICD-10 co
Arabia, 201
mber 31, 20
ed cancer ca
stry (SCR) w
among wom
7%) males
562 cases w
834 among n
ity.
yzed, of wh
nals and 3,
uded from
were unkno
to be conver
CanReg-4) d
tistical analy
nalyzed anationality
Unked
Total Male
401 111
ancer case
% 27.6 23.3 18.9 8.6 5.0 3.9 2.6 2.7 1.4 1.6 1.5 1.4 1.2 0.4 0.0
100.0
onversion failure
16.
016,
ases
was
men
and
were
non-
hich
698
the
own
rted
oes
ysis,
Am
(55
100
can
100
The
74.
Eas
ma
/10
wh
am
40.
,Ta
nd non-anand gende
known Natio
e Female
95
es among
ASR 96.4 73.2
104.3 68.7 54.7 56.5 33.7 67.1 33.7 71.4 53.9 49.3 69 NA NA 74.7
e are excluded
mong Saudis 5,803 (44.1%5.9%) were fe
0 to 126. Th
ncers were
0,000 in fema
e overall age-s
7/100,000 in m
stern region
ales and fe
00,000 for
ereas, Jazan
mong males
.6/100,000 fo
able 2.2 and F
alyzed caer, 2016.
onality
Total Male
206 1872
Saudi nat
Female 2093 1673 1445 520 328 330 206 200 151 124 122 80 58 25 3
7358 1
from analysis
emales with a
e crude incid
56.6/100,000
ales.
standardized
males and 91.
reported th
emales (104
males and
n region rep
and femal
or males an
Figure 2.1.
ncer case
NoAnalyzed
e Female T
2 1826 3
tionals by
% A28.4 1322.7 8719.6 137.1 664.5 604.5 802.8 402.7 782.1 641.7 951.7 71.1 370.8 530.3 N0.0 N
100.0 91
) were males
a male to fem
dence rates
0 in males
incidence rate
.3/100,000 in f
he highest A
4.3/100,000
females re
ported the lo
les (33.7/10
d females re
es reported
on –Saudis Non
Total Male
3698 74
y regions,
ASR Al30.1 3697.7 302
31.3 2536.2 1010.6 6210.8 5550.6 3558.1 3544.6 2305.5 2161.7 2097.5 1623.8 125
NA 51NA 4 1.3 1316
s and 7,358
male ratio of
(CIR) of all
and 74.5 /
e (ASR) was
females.
ASR among
and 131.3
espectively),
owest ASR
00,000 and
espectively)
d to
n Analyzed
Female Total
62 136
2016.
l % 97 28.1 25 23.0 39 19.3
8 7.7 1 4.7 5 4.2 5 2.7 4 2.7 0 1.7 6 1.6 9 1.6 2 1.2 5 0.9 0.4
0.0 61 100.0
15
l
16 16
Bah
Jaza
Norther
Madina
Ha
As
Najra
Tabu
Qassim
Makka
Jou
Riyad
Easter
Figure 2.2016.
*ASR per 100,
The age-
diagnosis w
Figure 2.2.
Figure 2.2
1
10
100
1000
0
AIR
(Per
100
,000
)
0
ha
an
rn
ah
ail
sir
an
uk
m
ah
uf
dh
rn
1 : Age St
000 population.
-specific incid
was 57 years
2 : Age-Sp
0 -5 -1
20
tandardize
.
dence rate (
with a range
pecific Inc
10 -15 -2
37.5
40.6
49
33.7
33.7
40
ed Rate (A
(AIR) increas
e of (0 -116)
cidence Ra
20 -25 -
53.8
60.6
64.6
66.2
9.3
69
54.7
68
53.9
67.
56.5
60
Male Fem
ASR)* of al
sed with adv
) for males, a
ate (AIR) f
-30 -35 -
Age Gro
Male F
2
71.7
78.1
80.8
87
9
8.7
1
73.2
71.4
80
male
ll cancer s
vancing age
and 51 years
for all can
-40 -45
ups
Female
.7
95.5
96.4
104.3
100
sites amon
in both gend
s with a rang
cer amon
-50 -55
3
120
ng Saudi n
ders. The me
ge of (0-116)
g Saudis,
-60 -65
130.1
131.3
140
nationals,
edian age at
for females,
2016.
-70 75+
t
,
1
1
2
2
3
3
Confirma
hematologic
reports (2.0
laboratory te
of cases, Ta
Table 2.3
Basis of
Histology
Cytology /
Histology
Medical Im
DCO (Dea
Unknown
Surgical
Laborator
Autopsy
Total
Cancer D
In female
2,451 (33.3
(60-74) yea
Figure 2.3groups, 2
0.0
5.0
10.0
15.0
20.0
25.0
30.0
35.0
0-14
6.6
ation of ma
cal and cyto
0%), and de
ests for tumo
able 2.3.
3 : Basis o
f Diagnosis
of primary
/ Haematolo
of metastas
maging
ath Certificat
ry test (Tumo
Distributio
es the highe
%) cancer ca
rs, with a tot
3 : Distrib2016.
4 1
8
3.8
alignancy w
ological repo
eath certificat
or markers w
f diagnos
s
gical
es
te Only)
or Markers)
n among S
st number o
ases. Where
tal of 1,649 (2
bution of c
15-29
.6 8.6
was based
rts (4.9%), t
te only (1.2%
were the sou
is of canc
Saudi Nat
of cancer cas
eas, in males
28.5%) canc
cancer cas
30-44
13.6
22.1
Male Fema
mainly on
then histolog
%). Other s
rce is about
cer cases,
tionals,201
ses reported
s the highest
cer cases.
ses among
45-59
25.5
33.3
le
histopatholo
gy of metast
ources such
0.1%, and u
2016.
No
11521
645
548
259
154
26
5
2
1
13161
16.
d for the age
number of c
g Saudi na
60-74
28.5
22.5
ogy reports
tases (4.2%
h as surgica
unknown sou
e group (45-5
cases was re
ationals b
75+
17.3
5
9
(87.5%), f
), then med
l and clinica
urce was pres
%
87.5
4.9
4.2
2.0
1.2
0.2
0.0
0.0
0.0
100.0
59) years, w
eported for th
y gender
9.8
followed by
ical imaging
al notes and
sent in 0.2%
0
with a total of
he age group
and age
17
y
g
d
%
f
p
18 18
Figure 2.4by gende
4 : Distriber and age
butions of e groups, 2
most freq2016.
quent type
es of cancer among Saudi nattionals
16.7
2.2
3.8
4.4
5.4
5.6
7.4
10.5
11.7
14.1
18.1
5 10 15 20 25 30
Other SitesNasopharynxColorectal
ThyroidBrain, CNSBoneTestisLeukaemiaNHLHodgkin lymphoma
15.1
1.6
2.7
2.7
3.0
5.7
5.9
6.0
12.2
18.6
26.4
051015202530
Other Sites Colorectal
Connective,Soft tissue Bone
Brain, CNS
LeukaemiaNHL
Ovary
Breast Hodgkin lymphoma
Thyroid
Male (497)Female (629 )
15-29 Years
Connective,Soft tissue
6.53.6
4.34.7
5.46.56.5
7.69.1
13.432.2
10203040
Other Sites Eye
Thyroid Adrenal gland
Connective,Soft tissueNHL
Kidney Bone
Hodgkin lymphoma Brain, CNS
Leukaemia
Female (276 )
0-14 Years
7.62.12.4
3.13.7
5.07.1
11.013.4
15.529.1
0 10 30 40
Other SitesKidneyTestisConnective,Soft tissueAdrenal glandEyeBoneNHLHodgkin lymphomaBrain, CNSLeukaemia
20
Male (381)
27.0
3.3
4.3
4.8
5.4
5.9
6.6
7.6
8.4
11.2
15.4
10 20 30 40 50
Other SitesStomachKidneyBrain, CNSNasopharynxTestisLeukaemiaHodgkin lymphomaThyroidNHLColorectal
14.2
1.7
1.7
2.3
2.6
2.7
3.3
3.3
6.5
20.6
41.1
01020304050
Other Sites Cervix Uteri Brain, CNS
Ovary Corpus Uteri
Hodgkin lymphoma
LeukaemiaNHL
Colorectal
ThyroidBreast
Female (1622 ) Male (785 )
30-44 Years
34.3
3.7
4.0
4.0
4.2
4.5
4.7
4.9
6.0
6.9
22.9
0 10 20 30 40 50
Other SitesBrain, CNSProstateNasopharynxBladderKidneyThyroidLiverLungNHLColorectal
Male (1474)
18.8
1.8
1.8
2.0
2.3
2.6
3.8
6.8
10.1
11.3
38.7
1020304050
Other Sites Kidney
Cervix Uteri Lung
Leukaemia Ovary
NHL
Corpus Uteri Thyroid
ColorectalBreast
45-59 Years
Female (2451 )
23.8
2.7
2.8
3.2
3.4
3.7
3.7
7.1
11.9
12.8
25.0
010203040
Other SitesPancreas
LungOvary
Gallbladder etc.Thyroid
LiverNHL
Corpus UteriColorectal
Breast
Female (1658 )
28.1
2.3
3.8
4.4
4.7
4.9
6.5
6.8
7.7
12.1
18.7
10 30 40
Other SitesLeukaemiaKidneyStomachPancreasBladderNHLLiverLungProstateColorectal
20
Male (1649 )
60-74 Years
Table 2.4
Sites Breast Colorectal
Thyroid
NHL
Leukaemia
Hodgkin’s
Corpus Ut
Lung
Liver
Prostate
Table 2.5
Male
Colorectal
NHL
Prostate
Leukaemia
Lung
Liver
Hodgkin’s
Bladder
Thyroid
Brain, CNS
4 : Most co
a
lymphoma
eri
: Most co
a
lymphoma
S
ommon ca
ommon ca
ancers am
N2216
10
8
6
4
4
4
4
4
ncers amo
No
955
469
405
334
298
290
265
299
222
212
ong Saud
No. 282 659
076
841
610
495
454
446
417
405
ong Saud
% Fem
16.5 Bre
8.1 Thy
7.0 Colo
5.8 Cor
5.1 NHL
5.0 Leu
4.6 Hod
3.9 Ova
3.8 Bra
3.7 Lun
di national
i nationals
male
ast
yroid
orectal
rpus Uteri
L
ukaemia
dgkin’s lymph
ary
in, CNS
ng
s, 2016.
11
8
6
4
3
3
3
3
3
s by sex, 2
homa
% 7.3 2.6
8.2
6.4
4.6
3.8
3.4
3.4
3.2
3.1
2016.
No
2240
854
704
454
372
276
230
219
155
148
%
30.4
11.6
9.6
6.2
5.1
3.8
3.1
3.0
2.1
2.0
19
29.6
2.2
2.5
2.8
5.6
5.9
6.0
6.1
8.7
14.3
16.4
10 30 40
Other Sites
Leukaemia
Oesophagus
Pancreas
Stomach
Bladder
NHL
Lung
Liver
Prostate
Colorectal
Male (1004 )
32.6
3.1
3.1
3.5
3.5
3.8
4.5
6.3
7.4
13.9
18.4
010203040
Other Sites
Ovary
Liver
Lung
Stomach
Gallbladder etc.
Thyroid
Corpus Uteri
NHL
Colorectal
Breast
Female (717 )
75+ Years
36.6
3.7
3.8
3.9
4.6
5.0
5.1
5.8
7.0
8.1
16.5
00 10 20 30 40
Other Sites
Brain, CNS
Thyroid
BladderHodgkin lymphoma
Liver
Lung
Leukaemia
Prostate
NHL
Colorectal
23.2
2.0
2.1
3.0
3.1
3.8
5.1
6.2
9.6
11.6
30.4
3040
Other Sites
Lung Brain, CNS
Ovary
Leukaemia
NHL
Corpus Uteri
Colorectal
Thyroid
Breast
All Ages
Female (7358 ) Male (5803 )
20
Hodgkin lymphoma
1020
20 20
TableSaud
ICD-
All
Not C44
C00
C01-C02
C03-C06
C07-C08
C09
C10
C11
C12-C13
C14
C15
C16
C17
C18
C19-C20
C21
C22
C23-C24
C25
C30-C31
C32
C33-C34
C37-C38
C40-C41
C43
C44
C45
C46
C47;C49
C50
C51
C52
C53
C54
C55
C56
C57
C58
C60
C61
C62
C63
C64
C65
C66
C67
C68
C69
C70-C72
C73
C74
C75
C81
C82-C85
C88
C90
C91
C92-C94
C95
Other
e 2.6 : Numdi Nationa
-10 S
All sites Tota
All sites but C
Lip
Tongue
6 Mouth
Salivary gland
Tonsil
Other Oropha
Nasopharynx
Hypopharynx
Pharynx unsp
Oesophagus
Stomach
Small intestin
Colon
Rectum
Anus
Liver
4 Gallbladder e
Pancreas
Nose, sinuses
Larynx
4 Trachea,Bron
Other Thorac
Bone
Melanoma of
Other Skin
Mesothelioma
Kaposi sarco
Connective,S
Breast
Vulva
Vagina
Cervix Uteri
Corpus Uteri
Uterus unspe
Ovary
Other Female
Placenta
Penis
Prostate
Testis
Other male ge
Kidney
Renal Pelvis
Ureter
Bladder
Other Urinary
Eye
Brain, Nervou
Thyroid
Adrenal gland
Other Endocr
Hodgkin dise
5;C96 Non-Hodgkin
Immunoprolif
Multiple Myel
Lymphoid Le
4 Myeloid Leuk
Leukaemia un
Other & unsp
mber, perals by prim
Site N
l 58
C44 55
1
6
5
ds 2
3
arynx 4
x 15
x 7
pec. 2
7
20
ne 3
58
37
2
29
etc. 8
17
s etc. 1
6
nchus,Lung 29
cic organs 1
9
Skin 1
20
a 1
ma 2
Soft tissue 8
4
ec.
e Genital
4
40
12
enital 3
19
7
8
22
y organs 7
3
us system 2
22
d 2
rine 5
ease 26
lymphoma 46
ferative dis. 0
oma 7
ukaemia 16
kaemia 14
nspec. 2
pecified 13
centage, Cmary cance
o. % CR
803 100.00%
596 96.40%
6 0.30%
60 1.00%
59 1.00%
23 0.40%
3 0.10%
4 0.10%
54 2.70%
7 0.10%
2 0.00%
78 1.30%
07 3.60%
37 0.60%
81 10.00%
74 6.40%
24 0.40%
90 5.00%
80 1.40%
70 2.90%
8 0.30%
69 1.20%
98 5.10%
6 0.30%
93 1.60%
4 0.20%
07 3.60%
1 0.20%
27 0.50%
89 1.50%
42 0.70%
- -
- -
- -
- -
- -
- -
- -
- -
4 0.10%
05 7.00%
23 2.10%
3 0.10%
96 3.40%
7 0.10%
8 0.10%
29 3.90%
7 0.10%
30 0.50%
12 3.70%
22 3.80%
22 0.40%
5 0.10%
65 4.60%
69 8.10%
0 0.00%
72 1.20%
65 2.80%
42 2.40%
27 0.50%
37 2.40%
CIR, ASR er site and
Male
Crude Rate
ASR World
56.6 74.7
54.6 72
0.2 0.2
0.6 0.8
0.6 0.8
0.2 0.3
0 0
0 0.1
1.5 1.8
0.1 0.1
0 0
0.8 1.1
2 2.9
0.4 0.5
5.7 7.8
3.6 5.1
0.2 0.3
2.8 4.2
0.8 1.2
1.7 2.5
0.2 0.2
0.7 0.9
2.9 4.4
0.2 0.2
0.9 0.9
0.1 0.2
2 2.7
0.1 0.2
0.3 0.4
0.9 1
0.4 0.6
- -
- -
- -
- -
- -
- -
- -
- -
0 0
4 6.3
1.2 1.1
0 0
1.9 2.6
0.1 0.1
0.1 0.1
2.2 3.2
0.1 0.1
0.3 0.3
2.1 2.3
2.2 2.5
0.2 0.2
0 0.1
2.6 2.6
4.6 5.6
0 0
0.7 1
1.6 1.8
1.4 1.5
0.3 0.3
1.3 1.7
and Cumud gender,
e
d
Cumul
0-64
39.95
39.05
0.125
0.34
0.39
0.135
0.03
0.015
1.425
0.035
0.02
0.53
1.26
0.27
4.595
2.945
0.165
1.805
0.555
1.285
0.115
0.58
2.13
0.135
0.535
0.04
0.955
0.015
0.175
0.57
0.41
-
-
-
-
-
-
-
-
0.045
1.87
0.695
0.03
1.635
0.08
0.03
1.725
0.065
0.17
1.625
1.7
0.14
0.04
1.675
3.195
0
0.505
0.915
1.02
0.18
1.12
ulative Ra2016.
lative Rate
0-74
81.8
79.3
0.205
1.045
0.95
0.28
0.03
0.06
1.895
0.125
0.02
1.055
3.32
0.645
8.96
6.1
0.37
4.885
1.675
3.26
0.345
1.175
5.42
0.18
0.71
0.12
2.555
0.24
0.505
0.925
0.59
-
-
-
-
-
-
-
-
0.045
7.76
0.795
0.065
3.065
0.08
0.155
3.465
0.1
0.17
1.965
2.47
0.14
0.04
2.135
5.795
0
1.165
1.36
1.42
0.305
1.76
ates (per 1
No. %
7358 100.00%
7192 97.70%
6 0.10%
47 0.60%
60 0.80%
30 0.40%
2 0.00%
2 0.00%
59 0.80%
14 0.20%
1 0.00%
50 0.70%
111 1.50%
32 0.40%
447 6.10%
257 3.50%
11 0.10%
127 1.70%
113 1.50%
104 1.40%
5 0.10%
7 0.10%
148 2.00%
10 0.10%
53 0.70%
25 0.30%
166 2.30%
7 0.10%
4 0.10%
70 1.00%
2240 30.40%
9 0.10%
8 0.10%
111 1.50%
454 6.20%
40 0.50%
219 3.00%
18 0.20%
4 0.10%
- -
- -
- -
- -
138.0 0.0
2.0 0.0
0.0 0.0
59.0 0.0
2 0.00%
16 0.20%
155 2.10%
854 11.60%
19 0.30%
6 0.10%
230 3.10%
372 5.10%
0 0.00%
48 0.70%
105 1.40%
158 2.10%
13 0.20%
110 1.50%
00,000) am
Female
Crude Rate
ASWor
74.5 91.
72.9 89.
0.1 0.1
0.5 0.7
0.6 0.8
0.3 0.4
0 0
0 0
0.6 0.7
0.1 0.2
0 0
0.5 0.7
1.1 1.5
0.3 0.4
4.5 6.1
2.6 3.4
0.1 0.2
1.3 1.9
1.1 1.7
1.1 1.5
0.1 0.1
0.1 0.1
1.5 2
0.1 0.1
0.5 0.5
0.3 0.3
1.7 2.1
0.1 0.1
0 0.1
0.7 0.8
22.7 27.
0.1 0.1
0.1 0.1
1.1 1.4
4.6 6.6
0.4 0.5
2.2 2.7
0.2 0.2
0 0
- -
- -
- -
- -
1.4 1.8
0.0 0.0
0.0 0.0
0.6 0.8
0 0
0.2 0.2
1.6 1.8
8.7 8.9
0.2 0.2
0.1 0.1
2.3 2.3
3.8 4.9
0 0
0.5 0.6
1.1 1.2
1.6 1.7
0.1 0.1
1.1 1.5
mong
e
R rld
Cumulativ
0-64
3 62.75
2 61.7
1 0.025
7 0.435
8 0.46
4 0.255
0.005
0.015
7 0.535
2 0.08
0.01
7 0.275
5 0.765
4 0.27
1 4.09
4 2.34
2 0.15
9 1.005
7 0.73
5 0.71
1 0.055
1 0.025
1.185
1 0.095
5 0.305
3 0.125
1 1
1 0.085
1 0.01
8 0.415
2 21.46
1 0.1
1 0.06
4 0.83
6 4.76
5 0.345
7 1.755
2 0.17
0.02
-
-
-
-
8 1.16
0 0.02
0 0
8 0.39
0.035
2 0.095
8 1.16
9 7.005
2 0.095
1 0.035
3 1.535
9 3.01
0
6 0.455
2 0.635
7 1.275
1 0.05
5 0.805
ve Rate
0-74
99.35
97.2
0.055
0.83
0.925
0.33
0.05
0.015
0.745
0.2
0.01
0.69
1.615
0.44
7.13
3.685
0.18
2.585
2.305
1.985
0.1
0.1
2.355
0.17
0.35
0.28
2.135
0.085
0.055
0.645
29.67
0.145
0.06
1.475
8.475
0.605
3.075
0.245
0.02
-
-
-
-
1.89
0.065
0
0.89
0.035
0.14
1.755
7.985
0.095
0.035
1.825
5.435
0
0.775
0.97
1.62
0.095
1.895
Cancer In
Between
Cancer regi
Saudis and
7,566 (45.1
Table 2.7.1
Table 2.7to Saudi
AnalyMale Fem5409 707
Table 2.7
Sites Breast Colorecta
Thyroid
NHL
Corpus Ut
Lung
Hodgkin’s
Liver
Leukaemi
Prostate
Table 2.7
Male
Colorectal
NHL
Prostate
Lung
Liver
Bladder
Leukaemia
Thyroid
Hodgkin’s l
Stomach
ncidence a
January and
istry among
d 3,703 were
%) cases we
.
7.1 : DistribCancer Re
Saudi
yzed male Total 77 12486
7.2 : Most c
l
teri
s lymphoma
a
7.3 : Top te
a
lymphoma
among Ad
d December
adults aged
e among non
ere males an
bution of aegistry by
s
Non AnalyMale Female181 213
common c
en cancers
dults (>14
r 2016, the to
above 14 ye
n-Saudis, an
nd 9,210 (54
analyzed ay nationali
Un
yzed e Total Mal
394 103
cancers a
s reported
No %
950 17
427 7
405 7
297 5
287 5
227 4
223 4
219 4
214 4
207 3
years), 20
otal number
ears was 16,
nd unknown
.9%) were fe
and non-aty and ge
nknown Nation
le Female 3 90
mong Sau
A2216
10
78
45
44
41
41
41
40
d among S
% F
7.6 B
.9 T
.5 C
.5 C
.3 N
.2 O
.1 H
.0 L
.0 L
.8 L
016.
of cancer in
,776. Of thos
nationality w
emales with
analyzed ander, 2016
ality
Total Male 193 1799
udi adults
All 280 653
059
81
54
45
19
13
10
05
Saudi adu
Female
Breast
Thyroid
Colorectal
Corpus Uteri
NHL
Ovary
Hodgkin’s lym
Leukaemia
Lung
Liver
cidence cas
se,12,880 ca
was reported
a male to fem
adult canc6.
No
Analyzed Female To1768 35
, 2016.
lts by gen
mphoma
es reported
ancer cases w
d in 193 cas
male ratio of
cer cases
on –Saudis
Nonotal Male 567 74
% 18.3 13.2
8.5
6.3
3.6
3.6
3.4
3.3
3.3
3.2
nder, 2016
No
223
840
703
454
354
215
205
187
148
126
to the Saudi
were among
ses. Total of
f 100 to 121,
reported
n Analyzed Female Total
62 136
.
o %
38 31.6
0 11.9
3 9.9
4 6.4
4 5.0
5 3.0
5 2.9
7 2.6
8 2.1
6 1.8
21
i
g
f
,
22 22
Childhoo
Total of 8
4.6% of the
that cancer
340 (42.4%
were among
were786 inc
were girls, T
Table 2.8and gend
Analy
Boys Girl381 276
Childhoo
children wa
NHL (9.1%)
Table 2.8
Sites LeukaemiBrain CN
Hodgkin’s
NHL
Bone
Eye
Connectiv
Adrenal,g
Kidney
Thyroid
Table 2.8
Male
Leukaemia
Brain, CNS
Hodgkin's
NHL
Bone
Eye
Adrenal gl
Connectiv
Testis
Kidney
od cancers
803 cancer c
total numbe
was more c
%) were repor
g non-Saudi
cluding 657 S
Table 2.8.1.
8.1 : Distribder, 2016.
Saudyzed
ls Total B6 657
d cancers a
s leukemia (
), Table 2.8.2
8.2 : Top te
a S
s lymphoma
ve, soft tissue
land
8.3 : Distrib
a
S
lymphoma
and
e, Soft tissue
s reported
cases were
er of cancers
common amo
rted among g
s, and 10 ca
Saudis, and1
bution of r
is Non Analyz
Boys Girls 3 4
accounted fo
(30.4 %), foll
2.
en Cancer
e
bution of t
No
111
59
51
42
27
19
14
e 12
9
8
d to Saudi
diagnosed a
s reported to
ong boys tha
girls. Total of
ases were w
129 non-Sau
reported c
Unzed
Total Bo7 7
or 4.9% of a
lowed by bra
rs among
top ten ca
o %
1 29.1
15.5
13.4
11.0
7.1
5.0
3.7
3.1
2.4
2.1
Cancer re
among childr
Saudi Canc
an girls, 463
f 664 cancer
ith unknown
udis. Among
childhood
known Nati
oys Girls 7 3
all cancer am
ain tumors (1
Saudi chi
N29
7
6
4
2
2
2
2
ancer sites
Fe
Leu
Bra
Hod
Bon
Kid
NH
Co
Adr
Thy
Eye
egistry (≤
ren aged be
er Registry i
(57.6 %) ca
r cases were
nationality.
Saudi, 381(5
d cancer in
ionality
Total B10
mong Saudis
14.6 %), then
ldren, 201
No 200 96
76
60
48
29
27
27
26
15
s by gend
male
ukaemia
ain, CNS
dgkin's lymp
ne
dney
HL
nnective, So
renal gland
yroid
e
14 years)
tween 0 and
n 2016. The
ases were re
reported am
The total nu
58.0 %) were
n Saudi Ar
NAnalyzed
Boys Girls 72 57
s. The leadin
n Hodgkin’s
6.
ers, 2016.
phoma
oft tissue
, 2016.
d 14 years a
reported inc
eported amon
mong Saudi c
umber of ana
e boys and 2
rabia by n
Non –Saudis Non
Total Boys 129 0
ng cancer a
lymphoma (
% 30.4 14.6
11.6
9.1
7.3
4.4
4.1
4.1
4.0
2.3
No
89
37
25
21
18
18
15
13
12
10
accounted to
cidents show
ng boys and
children, 129
alyzed cases
276 (42.0 %)
ationality
n Analyzed
Girls Total 0 0
mong Saudi
11.6 %) and
%
32.2
13.4
9.1
7.6
6.5
6.5
5.4
4.7
4.3
3.6
o
w
d
9
s
)
i
d
P
Table 2.8reported
Primary Site
Leukaemia
Brain, CNS
Hodgkin's lymphoma
8.4 : Distribamong Sa
e Code 98363
98353
98613
98373
98013
98663
98263
98003
98913
99103
94703
94403
93803
93913
93923
94713
94003
94503
94243
95083
96633
96523
96593
96503
96673
96513
bution of maudi child
MorpholPrecursorPrecursor
Acute my
Precursor
Acute leu
Acute pro
Burkitt ce
Leukemia
Acute mo
Acute me
Others
Total
MedulloblGlioblasto
Glioma, m
Ependym
Ependym
Desmopla
Astrocyto
Oligodend
Pleomorp
Atypical te
Others
Total
Hodgkin l
Hodgkin l
Hodgkin lpredomin
Hodgkin l
Hodgkin l
Hodgkin l
Total
morpholoren by ge
logy r B-cell lympr cell lympho
yeloid leukem
r T-cell lymp
kemia, NOS
omyelocytic le
ll leukemia
a, NOS
onocytic leuke
egakaryoblas
lastoma, NOoma, NOS
malignant
moma, NOS
moma, anapla
astic nodular
ma, NOS
droglioma, N
phic xanthoas
eratoid/rhabd
ymphoma, n
ymphoma, m
ymphoma, nance
ymphoma, N
ymphoma, n
ymphoma, ly
ogical typender, 2016
hoblastic leuoblastic leuke
mia, NOS
hoblastic leu
S
eukemia,
emia
stic leukemia
OS
astic
r medulloblas
NOS
strocytoma
doid tumor
nodular sclero
mixed cellula
nodular lymp
NOS
nodular sclero
ymphocyte-r
es for the m6.
ukemia emia, NOS
ukemia
stoma
osis, NOS
rity, NOS
hocyte
osis, grade 2
ich
most com
Male 41
24
11
8
6
4
4
3
2
1
7
111
22
7
6
4
3
3
2
2
1
0
9
59
24
10
9
6
2 1
1
51
mmon canc
% Fem36.9 4
21.6
9.9
7.2
5.4
3.6
3.6
2.7
1.8
0.9
6.3
100.0 8
37.3
11.9
10.2
6.8
5.1
5.1
3.4
3.4
1.7
0.0
15.3
100.0 3
47.1
19.6
17.6
11.8
2.0
2.0
100.0 2
cers
male %41 46.
15 16.9
14 15.7
2 2.2
5 5.6
4 4.5
1 1.1
0 0.0
2 2.2
1 1.1
4 4.5
89 100
10 27.0
6 16.2
2 5.4
0 0.0
2 5.4
1 2.7
2 5.4
1 2.7
2 5.4
2 5.4
9 24.3
37 100
16 64.0
5 20.0
0 0.0
3 12.0
0 0.0
1 4.0
25 100
23
1
9
7
2
6
5
1
0
2
1
5
.0
0
2
4
0
4
7
4
7
4
4
3
.0
0
0
0
0
0
0
.0
24 24
P
Co
rimary Site
NHL
Bone
Eye
nnective,Sotissue
e Code
96873 97293
97143
97003
95913
96803
97543
97283
95903
97023
92603
91803
91813
92303
92313
93703
89203
91863
92503
95103
95133
89003
89103
89203
80713
oft
89003
90403
89103
88063
89023
89203
88003
88013
90803
95003
Morpho
Burkitt lymPrecurso
Anaplastcell type Mycosis f
Malignan
Malignan
Langerha
Precurso
Malignan
Mature T
Others
Total
Ewing sa
Osteosar
Chondrob
Chondrob
Myxoid c
Chordom
Alveolar
Central o
Giant cel
Total
Retinobla
Retinobla
Rhabdom
Embryon
Alveolar
Squamou
Total
Rhabdom
Synovial
Embryon
Desmopl
Mixed typ
Alveolar
Sarcoma
Spindle c
Teratoma
Neurobla
Others
Total
ology
mphoma, NOor T-cell lymp
ic large cell l
fungoides
nt lymphoma,
nt lymphoma,
ans cell histio
or B-cell lymp
nt lymphoma,
T-cell lympho
arcoma
rcoma, NOS
blastic osteo
blastoma, ma
hondrosarco
ma, NOS
rhabdomyos
osteosarcoma
l tumor of bo
astoma, NOS
astoma, diffu
myosarcoma,
al rhabdomy
rhabdomyos
us cell carcin
myosarcoma,
sarcoma, NO
al rhabdomy
astic small ro
pe rhabdomy
rhabdomyos
a, NOS
cell sarcoma
a, malignant,
astoma, NOS
OS phoblastic lym
lymphoma, T
, non-Hodgk
, large B-cell
ocytosis, diss
phoblastic lym
, NOS
ma, NOS
osarcoma
alignant
oma
sarcoma
a
one, maligna
S
se
, NOS
yosarcoma, N
sarcoma
noma, keratin
, NOS
OS
yosarcoma, N
ound cell tum
yosarcoma
sarcoma
, NOS
S
mphoma
T cell and Nu
in, NOS
l, diffuse, NO
seminated
mphoma
nt
NOS
nizing, NOS
NOS
mor
Male 14
6
ull 5
4
2
OS 2
2
2
2
1
2
42
16
5
3
1
1
1
0
0
0
27
14
2
1
1
1
0
19
2
2
1
1
1
1
1
1
0
0
2
12
% F33.3
14.3
11.9
9.5
4.8
4.8
4.8
4.8
4.8
2.4
4.8
100.0
59.3
18.5
11.1
3.7
3.7
3.7
0.0
0.0
0.0
100.0
73.7
10.5
5.3
5.3
5.3
0.0
100.0
16.7
16.7
8.3
8.3
8.3
8.3
8.3
8.3
0.0
0.0
16.7
100.0
Female %7 38
1 5
0 0
1 5
3 16
3 16
2 1
1 5
0 0
0 0
0 0
18 10
9 42
6 28
3 14
0 0
0 0
0 0
1 4
1 4
1 4
21 10
8 80
1 10
0 0
0 0
0 0
1 10
10 10
2 1
0 0
2 1
1 6
1 6
1 6
0 0
0 0
2 1
2 1
4 26
15 10
% 8.9
5.6
0.0
5.6
6.7
6.7
1.1
5.6
0.0
0.0
0.0
00.0
2.9
8.6
4.3
0.0
0.0
0.0
4.8
4.8
4.8
00.0
0.0
0.0
0.0
0.0
0.0
0.0
00.0
3.3
0.0
3.3
6.7
6.7
6.7
0.0
0.0
3.3
3.3
6.7
00.0
P
A
Primary Site
Adrenal glan
Kidney
Thyroid
e Code
d 95003
94903
80103
89603
83123
82603
83433
83403
85103
80103
MorpholNeuroblas
Ganglione
Carcinoma
Total
Nephrobla
Renal cell
Total
Papillary a
Papillary c
Papillary c
Medullary
Carcinoma
Total
ogy stoma, NOS
euroblastoma
a, NOS
astoma, NOS
carcinoma,
adeno carcin
carcinoma, e
carcinoma, fo
carcinoma,
a, NOS
a
S
NOS
noma, NOS
encapsulated
ollicular varia
NOS
d
ant
Male 12
2
0
14
7
1
8
2
1
0
0
0
3
% Fe85.7
14.3
0.0
100.0
87.5
12.5
100.0
66.7
33.3
0.0
0.0
0.0
100.0
emale %12 92
0 0
1 7
13 10
18 10
0 0
18 10
6 50
0 0
3 25
2 16
1 8
12 10
25
% 2.3
.0
.7
0.0
0.0
.0
0.0
0.0
.0
5.0
6.7
.3
0.0
26 26
Other sit
Brain, C
Liv
Stoma
Hodgkin's lympho
Bladd
Lu
NH
Leukaem
Prost
Colorec
Distributio
The follow
regions of S
site reporte
and thyroid
cancers am
cases. This
advanced c
regions see
Figure 2.5
Figure 2.5
Other s
Kid
Hodgkin's lymph
L
Leukaem
Brain, C
Thy
L
Pros
N
Colore
3.4
4.2
4.3
4.7
4.7
5.7
7.4
7.8
8.4
0 10
tes
NS
ver
ach
ma
der
ung
HL
mia
tate
ctal
Males ( 1352 ) M
on of Canc
wing bar cha
Saudi Arabia
d by perman
cancers we
mong men. It
s can be attri
cancer care c
eking for trea
5.1 : Riyadh
5.2 : Makka
4.1
4.2
4.3
4.4
4.4
5.1
6.3
6.4
8.0
0 10
sites
dney
oma
Lung
mia
CNS
yroid
Liver
state
NHL
ectal
Males ( 1604 )
33.7
15.6
20 30 40
Makkah Region
cer Cases in
arts show th
a by gender.
nent address
ere the leadi
is worth not
buted to the
centers whic
tment.
h Region, 2
h Region, 2
34
18.5
20 30 4Riyadh Region
7
0
Othe
Cervi
Hodgkin's lym
Leuk
Corpu
T
Col
n the 13 Ad
he distributio
These sites
s (region) of
ng cancers
ting that Riya
e high popula
h led to migr
2016 (Relat
2016 (Rela
Ot
Br
Hodgkin's ly
Leu
Corp
C
4.4
40
2.0
2.2
2.7
3.2
4.2
5.8
6.9
8.1
8.
0 10
er sites
ix Uteri
Kidney
mphoma
Ovary
kaemia
NHL
us Uteri
Thyroid
lorectal
Breast
Females (16
dministrati
n of the mos
are listed on
f the patient
among wom
adh, Makkah
ation density
ration of can
ive Freque
tive Freque
2.3
2.5
2.7
2.9
3.2
4.5
6.
0 10
ther sites
Lung
ain, CNS
ymphoma
ukaemia
Ovary
NHL
pus Uteri
Colorectal
Thyroid
Breast
Females ( 2
21.5
1
.8
34
20 30 40
673 ) Makkah Region
ve Regions
st common c
n the basis o
at the time
men, while C
h and Easter
in these reg
cer patients
ency Distrib
ency Distri
22.6
5
.2
9.8
16.3
26.9
0 20 30
2093 ) Riyadh Region
.5
0
n
Oth
Hodgkin's lym
Corp
Leu
C
s of Saudi
cancer sites
of the total n
of diagnosis
olorectal and
rn Province r
gions in addi
from remote
bution).
ibution).
40
n
O
Br
Hodgkin's ly
Cor
Le
C
2.7
3.4
3.6
3.8
3.8
5.5
5.
6
0 10
her sites
Kidney
Lung
mphoma
Prostate
pus Uteri
Thyroid
ukaemia
NHL
olorectal
Breast
All (3025 )
Arabia, 20
in the 13 ad
umber of cas
. In most reg
d NHL were
represent the
tion to the d
e areas to the
3.2
3.4
3.4
3.5
3.5
3.9
6
0 1
Other sites
Lung
rain, CNS
ymphoma
rpus Uteri
eukaemia
Liver
NHL
Thyroid
Colorectal
Breast
All ( 369
5
9
.5
11.9
19.4
0 20 30
) Makkah Region
16.
dministrative
ses for each
gions breast
e the leading
e majority of
istribution of
e three main
5
5
9
6.0
11.4
13.6
15.3
10 20 30
97 ) Riyadh Region
33.5
40
e
h
t
g
f
f
n
32.8
40
Other sit
Brain, CN
Kidn
Hodgkin's lymphom
Bladd
Thyro
Leukaemi
NH
Lu
Prosta
Colorect
Other site
Brain, CN
Bladd
Stomac
Nasopharyn
Lun
Hodgkin's lymphom
Leukaemia
Liv
NH
Colorect
Figure 2.5
Figure 2.5
Figure 2.5
Other site
Stoma
Oesophag
Hodgkin's lymphom
Kidn
Tes
Lun
Pancre
Prosta
colorect
NH
3.6
3.7
4.0
4.1
4.2
5.2
7.4
7.5
8.6
0 10
tes
NS
ney
ma
der
oid
ia
HL
ung
ate
tal
Males (1094 ) Ea
3.8
3.8
4.1
4.1
4.8
5.1
6.8
6.8
8.2
0 10 2
es
NS
der
ch
nx
ng
ma
a
ver
HL
tal
Males (293 ) Mad
5.3 : Easter
5.4 : Madina
5.5 : Northe
3.0
3.0
4.5
4.5
4.5
4.5
4.5
6.0
9.0
10.4
0 10 20
es
ch
gus
ma
ney
tis
ng
eas
ate
al
HL
Males (67 ) North
35.6
16.1
20 30 40
astern Region
31.7
20.8
20 30 40
dinah Region
rn Region, 2
ah Region,
ern Region
46.3
30 40 50
hern Region
6
Other
Hodgkin's lymp
O
Leuka
Brain
Th
Corpus
Colo
B
Other sites
Pancreas
Oesophagus
Salivary glands
NHL
Ovary
Lung
Leukaemia
Thyroid
colorectal
Breast
2016 (Rela
2016 (Rela
, 2016 (Rel
3
Females (144
2.4
3.0
3.0
4.3
4.6
5.2
7.3
7.6
9.
0
r sites
Liver
phoma
Ovary
emia
n, CNS
NHL
hyroid
s Uteri
orectal
Breast
Females (32
1.7
1.7
1.7
5.2
5.2
5.2
6.9
0 10Females (58 ) North
tive Freque
ative Frequ
ative Frequ
45 ) Eastern Region
25.0
5
28.0
20 4
28 ) Madinah Region
2
13.8
13.8
19.0
20hern Region
ency Distri
uency Distr
uency Dist
O
Cor
Hodgkin's l
Le
C
Oth
Nasop
Hodgkin's lym
Corpu
Brai
T
Leuk
Co
40
25.9
30
ibution).
ribution).
ribution).
O
O
Hodgkin's l
L
2.7
3.4
3.5
3.7
4.
4.
5
0 1
Other sites
Kidney
rpus Uteri
lymphoma
Prostate
eukaemia
Lung
NHL
Thyroid
Colorectal
Breast
All (2539
2.7
4.0
4.0
4.2
4.5
5.0
5.5
6.6
0 10
er sites
pharynx
mphoma
us Uteri
in, CNS
Liver
Thyroid
kaemia
NHL
lorectal
Breast
All (621 ) M
2.4
3.2
3.2
3.2
4.0
4.8
0 10
Other sites
esophagus
lymphoma
Prostate
Pancreas
Leukaemia
Lung
NHL
Thyroid
Breast
colorectal
All (125
3
4
5
7
6
.7
5.8
6.8
12.3
21.2
10 20 30
9 ) Eastern Region
6
14.8
15.1
20 30Madinah Region
0
8
8.0
8.0
8.8
11.2
0 20 30 40) Northern Region
27
31.3
40
33.5
40
43.2
0 50
20.7
2.0
2.4
2.6
3.1
4.1
4.5
6.0
8.8
9.4
36.4
0 40
Other sites
Cervix Uteri
Ovary
Lung
Hodgkin'slymphoma
Leukaemia
NHL
Corpus Uteri
Thyroid
Colorectal
BreastBreast
20 3010
28 28
Other site
Lun
Leukaemia
Liv
Prosta
Nasopharyn
NH
Stomac
Thyro
Hodgkin's lymphom
Colorecta
0
Other sites
Kidney
Stomach
Bladder
Prostate
Tongue
Leukaemia
Liver
Mouth
NHL
Colorectal
Males
Other
To
Pro
La
Hodgkin's lymph
Nasopha
Leukae
Th
Color
Figure 2.5
Figure 2.5
Figure 2.5
3.6
4.4
4.4
4.9
4.9
5.3
5.3
5.8
7.6
0 10
es
ng
a
ver
ate
nx
HL
ch
oid
ma
al
Males (225 ) Qass
3.4
3.4
4.0
5.4
5.4
6.0
6.0
8.7
11.4
11.4
10 20
s (149) Jazan Region
2.5
3.8
3.8
5.1
5.1
6.3
6.3
7.6
1
0 10
sites
ongue
ostate
arynx
homa
arynx
emia
Bone
yroid
NHL
rectal
Males (79 ) Ha
5.6 : Qassim
5.7 : Jazan
5.8 : Hail Re
33.3
20.4
20 30 40
sim Region
34.9
30 40
32.9
11.4
15.2
20 30 40ail Region
m Region, 2
Region, 20
egion, 2016
oth
Connective,So
P
Nasop
Hodgkin's lym
Corp
T
Col
Other
Salivary gl
Hodgkin's lymph
To
Leukae
N
M
Colore
Corpus U
Thy
B
0
2016 (Relat
016 (Relativ
6 (Relative
Ot
Br
Gallbla
Hodgkin's ly
Cor
C
1.5
1.5
1.8
2.1
5.5
5.8
6.7
7.3
9
0 10
her sites
oft tissue
Pancreas
Ovary
pharynx
NHL
mphoma
us Uteri
Thyroid
lorectal
Breast
Females (3
1.9
2.4
2.9
3.4
5.8
5.8
7.3
8.3
1
0 10
sites
lands
homa
ongue
emia
NHL
Mouth
ectal
Uteri
yroid
reast
Females (206)
tive Freque
ve Frequen
Frequency
2.0
2.0
2.0
2.0
2.6
5.3
6
0 10
ther sites
rain, CNS
Kidney
adder etc.
Stomach
Ovary
ymphoma
pus Uteri
Colorectal
Thyroid
Breast
Females (
18.8
7
3
9.4
3
20 30 40330 ) Qassim Region
24.3
1.2
26.7
20 30 40
Jazan Region
ency Distri
ncy Distribu
y Distributi
15.9
3
6.6
15.2
15.9
30.5
0 20 30(151 ) Hail Region
39.7
Oth
Hodgkin's lym
Leuk
Corpu
T
Col
0
O
Na
L
Co
Hodgkin's
bution).
ution).
ion).
Ot
Leu
Naso
Corp
Hodgkin's ly
Co
5
40
2.8
3.4
3.9
4.5
4.8
7.0
7.
8
9
0 10
her sites
mphoma
Liver
Tongue
kaemia
us Uteri
Mouth
Thyroid
NHL
lorectal
Breast
All (355) Ja
2.2
2.2
3.0
3.0
4
5
5
0
Other sites
Kidney
asopharynx
Leukaemia
Bone
orpus Uteri
NHL
lymphoma
Thyroid
Colorectal
Breast
All (230
2.3
2.5
2.7
3.2
4.0
5.
6
6
0 10
ther sites
ukaemia
Liver
Stomach
opharynx
pus Uteri
NHL
ymphoma
Thyroid
olorectal
Breast
All (555 )
3
0
3
8.2
9.0
16.1
20 30
azan Region
25.7
0
0
.3
5.2
5.2
13.0
15.2
20.9
10 20 30
0 ) Hail Region
28.
4
6.5
6.7
13.9
24.1
0 20 30 Qassim Region
33.0
40
40
.6
40
Other sit
L
Prosta
Hodgkin's lymphom
Liv
Colorect
Leukaemi
Other Sk
NH
Brain, CN
Thyro
Other s
B
To
Nasopha
L
Stom
Hodgkin's lymph
Bla
Oesoph
Color
N
Other
K
Bla
Pan
Hodgkin's lymp
Sto
Leukae
Pro
Colo
Figure 2.5
Figure 2.5
Figure 2.5
3.4
4.6
5.7
5.7
5.7
6.9
8.0
9.2
9.2
10.3
0 10
es
Lip
ate
ma
ver
tal
ia
kin
HL
NS
oid
Males (87 ) Najra
2.4
2.4
3.7
4.9
4.9
6.1
6.1
6.1
9.8
0 10
sites
Bone
ngue
arynx
Lung
mach
homa
adder
hagus
rectal
NHL
Males (82 ) Bah
2.2
3.2
4.0
4.6
5.6
6.8
7.0
8.6
9.4
0 10
r sites
Kidney
adder
ncreas
phoma
omach
emia
Liver
ostate
NHL
rectal
Males (498 ) A
5.9 : Najran
5.10 : Baha
5.11 : Asir R
31.0
20 30 40
an Region
3
14.6
20 30 40ha Region
30.9
6
4
17.5
20 30 4
Asir Region
Region, 20
Region, 20
Region, 201
Other
Pan
Corpus
Color
Leuka
O
Hodgkin's lymp
Th
B
Other sites
Tongue
Lip
Ovary
Stomach
Thyroid
Other Skin
Corpus Uteri
NHL
Colorectal
Breast
9.0
O
Hodgkin's l
Cor
Le
C
40
016 (Relati
016 (Relativ
16 (Relativ
2.5
2.5
3.3
4.1
4.9
5.7
5.7
7.4
0 10
r sites
ncreas
Liver
s Uteri
NHL
rectal
aemia
Ovary
phoma
hyroid
Breast
Females (122 )
2.5
2.5
3.8
5.0
6.3
6.3
8.8
10.0
0 10
e
p
y
h
d
n
i
L
t
Females (80 ) Bah
2.5
2.7
3.5
3.5
4.
5
0 1
Other sites
Stomach
lymphoma
Ovary
Liver
rpus Uteri
eukaemia
NHL
Colorectal
Thyroid
Breast
Females
ve Frequen
ve Frequen
e Frequenc
23.8
14.8
25.4
20 30 40) Najran Region
20.0
16.3
18.8
20 30ha Region
26.3
5
5
.8
5.6
6.7
11.7
12.9
19.8
10 20 30
(520) Asir Region
ncy Distrib
ncy Distrib
cy Distribu
Other
O
Brain,
Color
Other
Leukae
Hodgkin's lymp
Th
B
0
40
40
bution).
bution).
ution).
O
O
Nas
Hodgkin's l
Co
O
C
Hodgkin's
L
3.3
3.8
4.3
5.3
5.7
6.2
6.2
6.7
0 10
r sites
Ovary
Liver
, CNS
rectal
r Skin
emia
NHL
phoma
hyroid
Breast
All (209 ) Naj
3.1
3.1
3.7
4.
4.
4
0 1
Other sites
esophagus
sopharynx
lymphoma
Thyroid
rpus Uteri
Stomach
Breast
Other Skin
NHL
Colorectal
All (162
3
4
4
4
0
Other sites
lymphoma
Stomach
Other Skin
Prostate
Liver
Leukaemia
Thyroid
NHL
Breast
Colorectal
All (10
30.6
12.9
14.8
20 30 4
jran Region
1
1
7
3
3
.9
9.3
10.5
12.3
13.0
10 20 30) Baha Region
3.6
4.0
4.1
4.2
5.2
6.2
7.4
8.1
10.3
14.5
10 20 30
018) Asir Region
29
40
31.5
40
32.3
40
30 30
Other
Hodgkin's lymph
Brain,
L
Bla
Thy
Oesoph
Leukaem
Colore
L
N
Other
Leukae
Th
Brain,
Bla
Other
Hodgkin's lymp
Pro
Color
Figure 2.5
Figure 2.5
3.9
3.9
3.9
4.5
5.2
5.2
6.5
8.4
9.1
1
0 10
sites
homa
CNS
Liver
adder
yroid
hagus
mia
ectal
Lung
NHL
Males (154
4.3
4.3
4.3
4.3
4.3
5.4
5.4
6.5
0 10
r sites
emia
hyroid
CNS
adder
r Skin
homa
ostate
NHL
Lung
rectal
Females (92
5.12 : Tabuk
5.13 : Jouf R
3
1.7
20 30 40
4 ) Tabuk Region
3
12.0
12.0
20 30 4
) Jouf Region
k Region, 2
Region, 20
7.7
37.0
40
Other sites
Lung
Stomach
Kidney
NHL
Ovary
Other Skin
Leukaemia
Colorectal
Thyroid
Breast
2016 (Relat
016 (Relativ
Ot
Gallbla
Corp
Hodgkin's ly
Leu
Co
2.4
2.4
3.2
4.0
5.6
6.5
7.3
8.1
12.9
0 10
Males (124 ) Jouf Reg
tive Freque
ve Frequen
2.5
2.5
3.5
3.5
4.0
4.5
5.0
7
0 10
ther sites
Kidney
adder etc.
pus Uteri
Lung
NHL
ymphoma
ukaemia
olorectal
Thyroid
Breast
Females (
22.6
9
25.0
20 30
gion
ency Distri
cy Distribu
21.5
5
0
7.5
20.5
25.0
0 20 30
(200 ) Tabuk Region
40
bution).
ution).
40
O
Gallb
B
O
Hodgkin's
L
C
O
Hodgkin's
L
2.8
3.1
3.1
4
0
Other sites
bladder etc.
Brain, CNS
Oesophagus
lymphoma
eukaemia
Lung
NHL
Colorectal
Thyroid
Breast
All
2.8
3.
3
0
Other sites
Stomach
Ovary
lymphoma
NHL
Other Skin
Leukaemia
Lung
Thyroid
Colorectal
Breast
All (216
8
1
1
.2
5.6
5.9
7.3
7.9
13.8
14.7
10 20 30l (354 ) Tabuk Region
8
.2
.7
5.1
5.6
6.0
6.5
9.3
9.7
15.3
10 20 30
6 ) Jouf Region
31.4
40n
32.9
40
Saudi AraCamero
InOm
KuwMoro
UBahr
QaJord
Egch
SingapArgent
AustIrela
UNorw
Austra
Saudi ArabiOmaInd
CamerooMoroccBahraiKuwa
chinEgy
JordaSingapo
QatArgentin
UAAustri
UNorwa
AustralIrelan
US
Internatio
Figure 2.6
Figure 2.6
*ASR per 100,** Source for th
0
bia oondia
manwait occoUAEain atardan gypthinaporeina UK
tria andUSAway alia
0
ia ania oncoin
ait na
yptan oretarna AEia
UKay ia ndSA
nal Compa
6.1 : Compa
6.2 : Compa
000 his information i
74
50
50
arison of Ag
arison of A
arison of A
is summarized o
4.7
81.2
92.4
92.8
116.9
122
123
1
1
100
91.3
87.1
97.4
11
11
100
ge-Standar
ASR* for Sa
ASR* for Sa
on page 54.
9
.7
3.6
30.7
132.9
153.3
158.4
150 2
4.1
14.4
133.6
137.5
139.9
147.8
157
150
rdized Incid
audi males
audi female
211.2
218.8
230.4
200 25
.8
198.7
21
21
2
200
dence Rate
with selec
es with sele
4
284.0
29
0 300
10.1
11.8
214.9
222.7
250
es.
ted countr
ected coun
0
95.2
343.
347
0 350
267.3
277.1
278.6
278.9
297.4
300
ries**
ntries**
.3
7.0
368.7
373.9
400
4
350
31
32 32
I
CAN
NCIDE
CERS
PA
ENCE O
DIAGN
NATIO
ART
OF MO
NOSED
ONALS
T III
OST CO
D AMO
S,2016
OMMO
ONG SA
ON
AUDI
Cancer Inc
This sect
between Ja
geographica
presents co
developed a
Table 3.1
Site
Breast
Colorectal
Thyroid
NHL
Leukaemia
Hodgkin's
Corpus Ut
Lung
Liver
Prostate
cidence fo
tion demonst
anuary and D
al area. Dat
omparisons
and developi
: Most com
l
a
lymphoma
teri
r Most Com
trates the mo
December 20
ta presented
of cancer in
ing countries
mmon canc
mmon Sites
ost common
016. It shows
d as absolute
ncidence am
s.
cer among
Ma
42
95
22
46
33
26
0
29
29
40
s among S
cancers dia
s the distribu
e numbers,
mong Saudis
Saudis by
ale
2
55
22
69
34
65
0
98
90
05
Saudi Natio
gnosed amo
tion of the m
relative freq
s with cance
y gender, 20
Female
2240
704
854
372
276
230
454
148
127
0
onals, 2016
ong Saudi na
most common
quency, and
er incidence
016.
All
2282
1659
1076
841
610
495
454
446
417
405
.
ationals durin
n cancers by
incidence r
reported fro
ng the period
y gender and
rates. It also
om selected
%
17.3
12.6
8.2
6.4
4.6
3.8
3.4
3.4
3.2
3.1
33
d
d
o
d
34 34
Female Br
Breast ca
female brea
nationals, a
Saudi fema
at 46.7/100
and Jouf wi
and 103 yea
Figure 3.12016.
Table 3.1.
ICD-O-385003 85203
85223
80103
85233
80003
84803
85753
85103
90203
Total
Figure 3.1
reast Canc
ancer was ra
ast cancer c
and 30.4% fr
le population
,000, followe
ith 25.0/100,
ars).
.1 : Age-Sp
1 : Morpho
3 InfiltratingLobular c
Infiltrating
Carcinom
Infiltrating
Neoplasm
Mucinous
Metaplas
Medullary
Phyllode
Others
.2 : Stage d
cer (C50).
anked First a
cases. Breas
rom all cance
n. The five re
ed by Riyadh
,000 (Figure
pecific Inci
ological dis
Mg duct carcincarcinoma, N
g duct and lo
ma, NOS
g duct mixed
m, malignant
s adenocarc
stic carcinom
y carcinoma
s tumor, mal
distributio
Loca40
among femal
st cancer ac
ers reported
egions with th
h with 33.8/10
3.1.3). The
idence Rat
stribution o
Morthologynoma, NOS NOS
obular carcin
d with other t
t
inoma
ma, NOS
, NOS
lignant
n of breast
alised.8%
Unknown7.0%
es, between
ccounted to
among fem
he highest A
00,000, Qass
median age
e (AIR) for
of breast ca
y
oma
ypes of carc
t cancer am
n January an
17.3% from
ales at all a
ASR per 100
sim with 31.7
e at diagnosis
breast can
ancer amon
inoma
mong Saud
Distant 12.5%
Regional39.7%
d December
m all cancers
ges. The AS
0,000 populat
7/100,000 M
s was 50 ye
ncer among
ng Saudi fe
NO. 1745 139
85
48
38
27
22
21
20
13
82
2240
di females,
r 2016, there
s reported a
SR was 27.2
tion were Ea
akkah with 2
ears (ranged
g Saudi fem
emales, 20
7
1
2016.
e were 2,240
mong Saudi
2/100,000 for
astern region
29.7/100,000
between 17
males,
16.
% 77.9 6.2
3.8
2.1
1.7
1.2
1.0
0.9
0.9
0.6
3.7
00.0
0
i
r
n
0
7
0
1
10
100
00 -5 -10 -15 -20 -25 -30 -35 -40 -45 -50 -55 -60 -65 -70 75+Age Groups
Bah
Norther
Jaza
Asi
Madina
Najra
Ha
Tabu
Jou
Makka
Qassim
Riyad
Easter
chiOmInd
Saudi ArabCamero
MorocKuwa
EgyBahraJorda
SingapoAustr
ArgentinNorwa
UQat
AustralIrela
UU
Figure 3.1
*ASR per 100,
Figure 3.1
*ASR per 100,
** Source for th
0 5
a
n
n
ir
h
n
il
k
uf
h
m
h
n
0
inamandia bia on
ccoait yptain an oreria na ay AEtarlia ndSAUK
.3 : Region
000
.4 : Compa
000
his information i
7.0
9.4
1
5 10
10 20
nal distribu
arison of A
is summarized o
10.4
12.6
15.9
1
15
22.1
22.7
25.8
27.2
30
ution of bre
ASR* for Sa
on page 54.
9
17.4
19.0
19.8
20 2
35.2
40.8
40 5
east cancer
audi female
25.0
29.
5 30
49.1
49.5
53.8
6
50 60
r (ASR*) am
es breast ca
7
31.7
33.8
35
61.0
65.7
68.0
71.2
73
7
70
mong Saud
ancer with
40 4
3.1
73.9
75.3
86.
80 9
di females,
selected c
46.7
5 50
.0
92.3
92.9
95.0
0 100
2016.
countries.
35
36 36
Localised
29%
Un
Colorecta
There we
2016 amon
affected 955
12.9/100,00
Riyadh at
12.7/100,00
/100,000, f
and Qassim
between 20
Figure 3.2nationals,
Table 3.2.
Code 81403
84803
84903
82633
82613
80103
80003
81443
82463
82103
Total
Figure 3.2
known5%
l cancer (C
ere 1,659 ca
g Saudi nati
5 (57.6%) m
00 for males
18.9 /100,00
00, and Mad
followed by E
m at 8.6/100
0 and 96 yea
2.1 : Age-Sp 2016.
1 : Morpho
Adenocarci
Mucinous a
Signet ring
Adenocarci
Adenocarci
Carcinoma,
Neoplasm,
Adenocarci
Neuroendo
Adenocarci
Others
2.2 : Stage d
MaleDistant
24%
Regional42%
C18-C20).
ases of color
ionals. Color
males and 70
and 9.5/100
00 Eastern r
inah at 12.5/
Eastern regio
,000 (Figur
rs) and 57 ye
pecific Inci
ological dis
Morp
noma, NOS
adenocarcino
cell carcinom
noma in tubu
noma in villo
, NOS malignant
noma, intest
crine carcino
noma in ade
distributio
e
rectal cancer
rectal cancer
4 (42.4%) fe
0,000 for fem
region at 17.
/100,000. In
on at 13.6/10
re 3.2.3). Th
ears in fema
idence Rat
stribution o
hology
oma
ma
ulovillous ad
ous adenoma
tinal type
oma, NOS
enomatous p
n of colore
Localised24%
Unkno8%
Age Groups
r accounting
r was ranked
emales with a
males. The f
3/100,000, f
females, reg
00,000, then
e median ag
les (ranged b
e (AIR) for
of colorecta
enoma
a
olyp
ectal cance
D
own Female
for 12.6% o
d first among
a male to fem
five regions w
followed by A
gions with th
n Hail at 10.2
ge at diagno
between 14 a
colorectal
al cancer a
Male 748
61
27
25
18
13
11
11
9
6
26
955
er among S
Distant31%
Regional37%
of all newly d
g males and
male ratio of
with the high
Asir at 12.9/1
he highest A
2/100,000, th
osis was 59
and 95 years
cancer am
among Sau
% Fe78.3
6.4
2.8
2.6
1.9
1.4
1.2
1.2
0.9
0.6
2.7
100
Saudi natio
Localised
27%
Unknow6%
diagnosed ca
d third among
f 136:100. Th
hest ASR in
100,000, the
ASR were Riy
hen Jouf at 9
years in ma
s).
mong Saud
di national
emale 577
44
12
23
9
8
7
5
4
6
9
704
nals, 2016.
D
Reg4
wn All
ases in year
g females. It
he ASR was
males were
n Qassim at
yadh at 14.0
9.2/100,000,
ales (ranged
di
ls, 2016.
% 82.0
6.3
1.7
3.3
1.3
1.1
1.0
0.7
0.6
0.9
1.3
100
.
Distant27%
gional40%
r
t
s
e
t
0
,
d
0
1
10
100Male Female
0 -5 -10 -15 -20 -25 -30 -35 -40 -45 -50 -55 -60 -65 -70 75+
Najran
Jazan
Baha
Hai
Tabuk
Northern
Jou
Makkah
Madinah
Qassim
Asi
Eastern
Riyadh
CameroEgyInd
MorocOm
UASaudi Arab
chiKuwa
BahraQat
UArgentin
JordaAustr
USingapo
NorwaIrela
Austral
Figure 3.22016.
*ASR per 100,
Figure 3.2countries*
*ASR per 100,
** Source for th
0 2
n
n
a
il
k
n
uf
h
h
m
r
n
h
33.
0
onyptdia ccoanAE
bia na
ait in tarSAna an ria UKoreay ndlia
2.3 : Region
000
2.4 : Compa**
000
his information i
3.6
3.13.2
3.9
2 4
3.3
5.2
5.1
7.3
8.5
9.5
2
6.1
7.2
9
5 10
nal distribu
arison of A
is summarized o
5.7
6.2
6.4
4.5
5.3
5.8
6.
6
5
11.6
14.2
13.2
9.9
10.6
12.6
12.9
1
15
ution of col
ASR* for co
on page 54.
8.2
9.2
8.4
8.6
8.2
8
8.9
8 10Male Fem
20.6
21.1
22.0
19.1
21.2
19.6
16.9
17.8
21.3
23
20 2Male Fem
lorectal can
olorectal ca
10.2
11.3
0 12ale
24.4
28.0
27.7
3.4
28.5
29
29
25 30ale
ncer (ASR*
ancer amon
13.6
14.0
12.5
12.7
12.9
14
35.8
32.0
.8
.8
34.0
36
35
*) among S
ng Saudis w
17.
16 18
6.8
40.1
42.6
43.
40 45
Saudi natio
with ASR in
3
18.9
8 20
1
45.5
5 50
nals,
n selected
37
38 38
Localised52%
Unk
Thyroid ca
Thyroid c
1076 thyroi
nationals. T
of 385:100.
highest AS
Najran at 9.
regions with
region at 3
age at diag
between 9 a
Figure 3.32016.
Table 3.3
Code
82603 83403
83413
83433
80503
83353
83303
85103
83443
82903
Total
Figure 3.3
Distan8%
known6%
Male
ancer (C73
cancer was
id cases can
Thyroid cance
. The ASR w
R for female
.9/100,000, t
h the highes
.4/100,000, t
nosis was 4
and 92 years
3.1 : Age-Sp
.1 : Morpho
Papillary Papillary
Papillary
Papillary
Papillary
Follicular
Follicular
Medullary
Papillary
Oxyphilic
Others
3.2 : Stage d
nt
Regional34%
3).
ranked seco
ncer accoun
er affected 8
was 8.9/100
es were Riy
then Jouf at
t ASR were
then Qassim
1 years in fe
s).
pecific Inci
ological dis
Mo
adenocarcincarcinoma,
microcarcino
carcinoma,
carcinoma,
r carcinoma,
r adenocarcin
y carcinoma
carcinoma,
c adenocarci
distributio
Localised66%
U
ond among
nting to 8.2%
854 (79.4%)
,000 for fem
yadh region
9.8/100,000
Najran at 4.
m at 3.1/100
emales (rang
idence Rat
stribution o
rphology
noma, NOS follicular var
oma
encapsulate
NOS
minimally in
noma, NOS
, NOS
columnar ce
noma
n of thyroid
Distant 3%
nknown6%
Female
Saudi fema
% from all n
females and
males and 2
at 16.6/100
, then Hail a
.8/100,000, f
,000, and Ta
ged between
e (AIR) for
of thyroid c
iant
d
vasive
ell
d cancer a
Regional25%
les and nint
ewly diagno
d 222 (20.6%
.5/100,000 f
0,000, followe
nd Eastern r
followed by R
abuk at 2.5/
3 and 93 ye
thyroid ca
cancer amo
Male
125 29
18
7
4
5
6
6
10
3
9
222
mong Saud
th among Sa
osed cancers
%) males, wit
for males. T
ed by Tabu
region both a
Riyadh at 4.
100,000 (Fig
ears) and 48
ancer amon
ong Saudi
e %
56.3 13.1
8.1
3.2
1.8
2.3
2.7
2.7
4.5
1.4
4.1
100.0
di national
Localised63%
Unknow6%
audi males.
s in 2016 a
th a female t
he five regio
k at 12.9/10
at 9.6/100,00
4/100,000, t
gure 3.3.3).
8 years in ma
ng Saudi na
nationals,
Female
438 132
116
26
24
22
19
18
18
16
25
854
s, 2016.
Distant 4%
wn
All
There were
mong Saudi
to male ratio
ons with the
00,000, then
00. In males,
then Eastern
The median
ales (ranged
ationals,
2016.
%
51.3 15.5
13.6
3.0
2.8
2.6
2.2
2.1
2.1
1.9
2.9
100.0
Regional27%
e
i
o
e
n
,
n
n
d
Age Groups
0
1
10
100Male Female
0 -5 -10 -15 -20 -25 -30 -35 -40 -45 -50 -55 -60 -65 -70 75+
Ba
Madin
Jaz
Qass
North
Makk
A
East
H
J
Naj
Tab
Riya
Camero
Ind
Eg
Irela
Bahra
ch
Moro
Singap
Norw
Aust
Jord
Austra
Argenti
Om
Qa
Saudi Arab
Kuw
U
U
Figure 3.3
*ASR per 100,
Figure 3.3countries*
*ASR per 100,
** Source for th
1
0.
1
0
aha
nah
zan
sim
ern
kah
Asir
ern
Hail
ouf
ran
buk
adh
1.0.2
0.7
1
1
1
1
1.1
0.8
0
oon
dia
ypt
and
ain
hina
UK
cco
ore
way
tria
dan
alia
ina
man
atar
bia
wait
UAE
USA
3.3 : Region
000
3.4 : Compa**
000
his information i
2.21.0
1.2
.9
3.1
1.4
1.5
1.0
3
2.4
2.3
2.5
2
2
1.7
3.8
4.1
4.1
4.4
4
1.5
1.5
1.9
.3
1.5
1
2.1
2.3
1.9
4.1
1.7
2.1
2.5
2.0
1.9
5
nal distribu
arison of A
is summarized o
3.7
4.1
5.5
5.7
5
.4
4.8
4.4
4 6
4
4.9
5.5
6.0
6.0
6.0
7.2
7.2
7.4
7.6
5.6
6.4
ution of thy
ASR* for thy
on page 54.
7
5.9
7.4
8Male
8.5
8.9
10.1
10male Fem
yroid cance
yroid cance
9.6
9.6
9.8
9.9
10Female
15male
er (ASR*) a
er among S
12.9
12
17.5
among Sau
Saudis with
9
14 16
20.0
20
di national
h ASR in s
16.6
6 18
25
ls, 2016.
elected
39
40 40
Non-Hodg
Non-Hod
841 cases a
(55.8%) ma
for males a
7.5/100,000
and Asir at
by Riyadh a
(Figure 3.4.
57 years in
Figure 3.4
Table 3.4.
Code 96803 M
96873 B
95913 M
97003 M
97143 A
96913 F
96983 F
95903 M
96993 M
96903 F
OTotal
Figure 3.4
Localised38%
U
gkin Lymph
gkin Lympho
accounted to
ales, and 372
and 4.9/100,
0, followed b
6.5/100,000
at 6.3/100,00
.3). The med
females (ran
4.1 : Age-Sp
1 : Morpho
Malignant lymp
Burkitt lympho
Malignant lymp
Mycosis fungo
Anaplastic larg
ollicular lymp
ollicular lymp
Malignant lymp
Marginal zone
ollicular lymp
Others
4.2 : Stage d
Re1
Unknown6%
Male
homa (C82-
oma (NHL) w
o 6.4% from
2 (44.2%) fem
,000 for fem
y Baha at 7.
. In females,
00, then Asir
dian age at d
nged betwee
pecific Inci
ological dis
Morpphoma, large
oma, NOS
phoma, non-H
ides
ge cell lympho
phoma, grade
phoma, grade
phoma, NOS
B-cell lymph
phoma, NOS
distributio
Distant 44%
gional12%
Localised37%
Unknow10%
-C85; C96)
was ranked
all cancers d
males, with a
males. The fi
.2/100,000, t
regions with
r at 5.3/100,0
diagnosis wa
en 1 and 115
idence Rat
stribution o
phology B-cell, diffus
Hodgkin, NOS
oma, T cell an
2
3
oma, NOS
n of NHL a
Regional12%
wnFemale
.
second amo
diagnosed am
a male to fem
ive regions
then Riyadh
h the highest
000, then Ma
as 50 years i
years).
e (AIR) for
of NHL amo
e, NOS
S
nd Null cell ty
among Sau
Distant 41%
ong males a
mong Saudi
male ratio of
with the hig
at 7.0/100,0
t ASR were E
akkah at 5.2/
in males (ran
NHL amon
ong Saudi
Male236
31
23
20
ype 19
19
13
12
11
10
75
469
di national
Localised38%
Unkno8%
nd fifth amo
nationals in
126:100. Th
ghest ASR in
000, then Eas
Eastern regio
/100,000 and
nged betwee
ng Saudi na
nationals,
e % 50.3
6.6
4.9
4.3
4.1
4.1
2.8
2.6
2.3
2.1
16.0
100.0
ls, 2016.
Region12%
own%
All
ong females.
2016. NHL a
he ASR was
n males we
stern region
on 6.4/100,0
d Qassim at
en 1 and 105
ationals, 2
2016.
Female 211
8
26
20
3
10
7
14
16
7
50
372
Distant 42%
al
There were
affected 469
5.6/100,000
re Tabuk at
6.6/100,000
000, followed
4.5/100,000
5 years) and
016.
% 56.7
2.2
7.0
5.4
0.8
2.7
1.9
3.8
4.3
1.9
13.4
100.0
e
9
0
t
0
d
0
d
Age Groups
0
1
10
100Male Female
0 -5 -10 -15 -20 -25 -30 -35 -40 -45 -50 -55 -60 -65 -70 75+
Qa
N
Mad
J
Nort
Ma
Ea
Ri
T
I
c
Saudi Ar
Jor
Q
O
Argen
Ku
Mor
Came
E
Au
Bah
Singa
Nor
Ire
Aust
Figure 3.4
*ASR per 100,
Figure 3.4
*ASR per 100,
** Source for th
0
assim
ajran
Hail
dinah
Jazan
Jouf
thern
akkah
Asir
stern
iyadh
Baha
Tabuk
0
ndia
china
rabia
rdan
Qatar
Oman
ntina
wait
rocco
UAE
eroon
Egypt
stria
hrain
apore
UK
rway
eland
ralia
USA
4.3 : Region
000
4.4 : Compa
000
his information i
1.2
1
1.5
2.02
2
nal distribu
arison of A
is summarized o
2
4.9
4.3
5
4.6
2.9
3.1
4
ution of NH
ASR* for NH
on page 54.
3.4
2.6
2.8
3.5
3.3
2.8
3
Male Fe
9
6.0
.0
5.3
7.0
6.1
5.6
6.3
5.6
5.8
6.2
7.
7
7
6male Fem
HL (ASR*) a
HL among S
4.5
3.8
4.1
5
3.8
3.9
4.0
4.3
4.6
4
emale
8.3
8.0
0
8.5
8.9
9.2
1
.2
7.3
7.7
8.0
8.2
8.6
8.6
8.7
8 1male
among Sau
Saudis wit
5.2
5.3
6
5.0
5.2
5
10.1
2
10.2
10.2
10.1
10 12
di national
h selected
6.4
6.3
6.5
6.6
6 7
11.9
12.3
12.5
2 14
ls, 2016.
countries*
7.0
7.2
7.5
8
14.4
14.7
16
*
41
42 42
Leukaemi
Leukaem
to 4.6% of
males and 2
and 3.0/100
5.3/100,000
both at 3.4/
at 4.9/100,0
median age
(ranged bet
Figure 3.5
Table 3.5.
Code 98363
98613
98353
98233
98633
98663
98013
98003
98373
99403
Total
a (C91-C95
mia was ranke
all cancer c
276 (45.2%)
0,000 for fe
0, followed b
100,000. In f
000, then A
e at diagnosi
tween 1 and
5.1 : Age-Sp
1 : Morpho
Precursor B-c
Acute myeloid
Precursor cel
B-cell chronic
Chronic myelo
Acute promye
Acute leukem
Leukemia, NO
Precursor T-c
Hairy cell leuk
Others
5).
ed third amo
cases diagno
females wit
emales. The
y Asir at 4.3
females, reg
Asir and Najra
is was 27 ye
87 years).
pecific Inci
ological dis
Mocell lymphobla
d leukemia, N
l lymphoblasti
c lymphocytic l
oid leukemia,
elocytic leukem
mia, NOS
OS
cell lymphobla
kemia
ong males an
osed among
h a male to f
five regions
3/100,000, th
gions with the
an both at 3
ears in males
idence Rat
stribution o
orphologyastic leukemia
OS
ic leukemia, N
leukemia/sma
NOS
mia, t(15;17) (
stic leukemia
nd the sixth a
Saudi natio
female ratio
s with the h
en Eastern r
e highest AS
3.7/100,000,
s (ranged be
e (AIR) for
of leukaem
y
NOS
all lymphocytic
q22;q11-12)
among femal
onals in 201
of 121:100.
highest ASR
region at 4.2
SR were Jouf
and Makkah
etween 0 and
leukaemia
ia among S
M
c lymphom
les, there we
6. Leukaem
The ASR wa
R in males w
2/100,000, th
f at 5.7/100,0
h at 3.4/100,
d 98 years)
a among Sa
Saudi natio
Male %62 18.
57 17.
40 12.
37 11.
37 11.
16 4.8
14 4.2
13 3.9
11 3.3
7 2.1
40 12.
334 100
ere 610 case
ia affected 3
as 3.6/100,00
were Makka
hen Madinah
000, then Ea
000 (Figure
and 31 year
audi nation
onals, 2016
% Fema.6 52
.1 70
.0 21
.1 20
.1 49
8 11
2 9
9 3
3 5
1 2
.0 34
0.0 276
es accounted
334 (54.8%)
00 for males
ah region at
and Riyadh
astern region
3.5.2 ). The
rs in females
nals, 2016.
6.
ale % 18.8
25.4
7.6
7.2
17.8
4.0
3.3
1.1
1.8
0.7
12.3
100.0
d
)
s
t
h
n
e
s
Age Groups
0
1
10
100
Male Female
0 -5 -10 -15 -20 -25 -30 -35 -40 -45 -50 -55 -60 -65 -70 75+
Northern
Baha
Jazan
Hai
Qassim
Jouf
Tabuk
Najran
Riyadh
Madinah
Eastern
Asir
Makkah
Camer
In
Saudi ar
Moro
Om
c
Eg
Argent
Singap
Kuw
Bahr
Jor
Aus
Norw
Austr
Ire
Q
Figure 3.5
*ASR per 100,
Figure 3.5countries*
* ASR per 100
** Source for th
0.00
0
n
a
n
l
m
f
k
n
h
h
n
r
h
0.3
0
roon
ndia
abia
occo
man
hina
gypt
tina
pore
wait
rain
dan
stria
UK
way
USA
UAE
ralia
land
Qatar
5.2 : Region
000
5.3 : Compa**
,000
his information i
1
0.9
0.7
0.5
1.0
1
1.3
2.2
3
2.2
2.4
2.4
2
nal distribu
arison of A
is summarized o
1.31.8
1.9
2.0
2Mal
3.0
3.2
3.7
4.0
3.3
4.3
3.3
3.6
3.8
4.1
5.0
4m
ution of leu
ASR* for leu
on page 54.
2
2.2
0
2.6
2.8
3e Female
5.4
5.3
6.0
5.8
6.2
7.1
6.5
0
6.3
6.3
6.7
6male Fema
ukaemia (AS
ukaemia am
2.9
3.0
3
3.1
3
3.4
8
3.1
3.4
3.4
3
1
7.5
7.6
7.8
8.5
9.3
9.
8 1ale
SR*) amon
mong Saud
3.7
3.74.2
4.3
4
10.0
.5
10.3
11.4
11
10 12
ng Saudi na
dis with AS
4.9
5
5
12.74
1.7
12.5
2 14
ationals, 20
SR in select
5.7
5.3
6
15.1
16
016.
ted
43
44 44
Localised38%
Unkn6%
Hodgkin’s
Hodgkin’s
cases of Ho
2016. Hodg
female of 1
the highest
3.0/100,000
were Qassi
then Riyadh
years (rang
Figure 3.6nationals,
Table 3.6.2016.
Code
96633
96503
'96593
96523
96513
96673
96533
96653
96643
Total
Figure 3.6
Region21%
own%
Male
s Lymphom
s lymphoma
odgkin’s lym
gkin’s Lymph
15:100. The
t ASR in ma
0, then Hail a
m at 3.1/100
h and Easte
ed between
6.1 : Age-Sp 2016.
1 : Morpho
Hodgkin lym
Hodgkin lym
Hodgkin lym
Hodgkin lym
Hodgkin lym
Hodgkin lym
Hodgkin lym
Hodgkin lym
Hodgkin lym
6.2 : Stage d
Distant 35%
nal%
ma (C 81).
a was ranked
phoma acco
homa affecte
ASR was 2
ales were Q
at 2.6/100,00
0,000, follow
ern region bo
3 and 88 yea
pecific Inci
ological dis
M
mphoma, nod
mphoma, NO
mphoma, nod
mphoma, mix
mphoma, lym
mphoma, nod
mphoma, lym
mphoma, nod
mphoma, nod
distributio
d the sevent
ounted to 3.8
ed 265 (53.5%
2.6/100,000 f
Qassim and
00, and Riya
wed by Jouf a
oth at 2.7/10
ars) in males
idence Rat
stribution o
Morphology
dular scleros
OS
dular lympho
xed cellularit
mphocyte-ric
dular scleros
mphocyte dep
dular scleros
dular scleros
n of Hodgk
Localised32%
Unk1
th among Sa
8% of all can
%) males an
for males an
Najran both
adh at 2.5/10
at 3.0/100,00
00,000 (Figu
s and 25 yea
e (AIR) for
of Hodgkin
sis, NOS
ocyte predom
ty, NOS
h
sis, grade 2
pletion, NOS
sis, grade 1
sis, cellular p
kin’s lymph
Region26%
known0%
Fema
Loc
audi males a
ncer cases d
nd 230 (46.5
d 2.3/100,00
at 3.9/100,
00,000. In fem
00, then Ma
re 3.6.3). Th
ars (ranged b
Hodgkin’s
’s lymphom
minance
S
phase
homa amon
Distant 32%
al
le
calised35%
Unknow8%
and Saudi fe
diagnosed am
5%) females,
00 for female
000, followe
males, regio
kkah and Ba
he median a
between 4 an
s lymphom
ma among
Male
123 4
42 1
40 1
38 1
14
3
2
2
l
265 1
ng Saudi n
Dista33%
Regiona24%
wnAll
emales. The
mong Saudi
with a ratio
es. The five
ed by Easte
ns with the h
aha both at 2
age at diagn
nd 90) in fem
a among S
Saudi nati
% Fem
46.4 129
15.8 48
15.1 5
14.3 33
5.3 9
1.1 4
0.8 2
0.8 0
0.4 0
00.0 230
ationals, 2
ant %
al
re were 495
nationals in
n of male to
regions with
rn region at
highest ASR
2.9/100,000,
osis was 28
males.
Saudi
onals,
ale %
9 56.1
8 20.9
2.2
3 14.3
3.9
1.7
0.9
0.0
0.0
0 100.0
2016.
5
n
o
h
t
R
,
8
0
1
10Male Female
-30 -35 -400 -5 -10 -15 -20 -25 -45 -50 -55 -60 -65 -70 75+Age Groups
Bah
Jaza
Norther
Madina
Jou
As
Makka
Tabu
Riyad
Ha
Easter
Qassim
Najra
CCame
ISingaArgen
AusE
MorJor
AustO
Saudi Ar
Ire
NorBah
QKuw
Figure 3.62016.
*ASR per 100,
Figure 3.6selected c
*ASR per 100,
** Source for th
0
ha
n
rn
h
uf
ir
h
uk
h
ail
rn
m
n
0.10
0
Chinaeroonndia
aporentina stria
Egyptroccordan ralia
Omanrabia
UAEeland
UKUSA
rway hrain Qatarwait
6.3 : Region
000
6.4 : Compacountries**
000
his information i
0.70.4
0.8
1 1
1
0.5
0.5
0.7
0
0.7
0.2
0
1
nal distribu
arison of A*
is summarized o
1.3
1.1
1
1
1 2
1.0
1.1
0.8
0.8
0.9
1.0
1 2
ution of Ho
ASR* for Ho
on page 54.
2
1.7
.5
.5
1.6
2
2Male Fem
1.5
1.6
1.9
1.8
1.9
1.9
1.9
1.9
1.9
2Male Fem
dgkin’s lym
odgkin’s ly
.1
2.2
2.6
2
2
2.2
.1
2.2
2.5
2.6
3male
2.3
2.3
2.3
2.2
2.2
2.3
2.5
2.5
2.6
2.6
2.6
3male
mphoma (A
mphoma a
2.9
3.0
2.9
2.7
2.7
3.13.0
3
2.9
6
6
6
2.8
2.8
2.9
3.1
3
ASR*) amon
among Sau
3
3
4 4
4 4
ng Saudi n
dis with AS
3.9
3.9
4 5
4.0
4.1
4.2
4 5
nationals,
SR in
45
46 46
Corpus Ut
Corpus U
cancer cas
population.
region at
5.2/100,000
Figure 3.7females, 2
Table 3.7.
Code 83803 81403
84413
80103
89503
89313
89803
88903
84613
80003
Total
Figure 3.7
teri Cancer
Uteri cancer
ses diagnose
The five reg
9.1/100,000
0(Figure 3.7.3
7.1 : Age-Sp2016.
1 : Morpho
EndomeAdenoca
Serous c
Carcinom
Mulleria
Endome
Carcinos
Leiomyo
Serous s
Neoplas
Other
7.2 : Stage d
r (C54).
was ranked
ed among S
gions with the
0, then M
3). The med
pecific Inci
ological dis
Moretrioid adenoarcinoma, NO
cystadenoca
ma, NOS
n mixed tum
etrial stroma
sarcoma NO
osarcoma, N
surface papi
sm, maliqnan
distributio
Localised65.4%
Un5
fourth amo
Saudi female
e highest AS
Makkah at
ian age at di
idence Rat
stribution o
rthology ocarcinoma OS
arcinoma NO
or
l sarcoma lo
OS
OS
llary carcino
nt
n of corpus
Dista10.8
known5.5%
ng Saudi fem
es in 2016.
SR were Riy
6.7/100,000
agnosis was
e (AIR) for
of corpus u
NOS
OS
ow grade
ma
s uteri can
ant 8%
Regional18.3%
males with 4
The ASR
adh region a
0,Qassim a
s 60 years (ra
corpus ute
uteri cance
N24
2
1
1
3
4
cer among
454 cases ac
was 6.6/100
at 10.6/100,0
t 6.1/100,0
anged betwe
eri cancer
r among Sa
No 99 44
23
13
10
9
7
7
6
5
31
54
g Saudi fem
ccounted to
0,000 for S
000, followed
000, and M
een 18 and 9
among Sau
audi femal
% 65.99.7
5.1
2.9
2.2
2.0
1.5
1.5
1.3
1.1
6.8
100.0
males, 2016
6.2 % of all
audi female
d by Eastern
Madinah at
96 years).
udi
es, 2016.
9
0
6.
l
e
n
t
0
1
10
100
Age Groups
0 -5 -10 -15 -20 -25 -30 -35 -40 -45 -50 -55 -60 -65 -70 75+
Figure 3.72016.
*ASR per 100,
Figure 3.7in selected
*ASR per 100,
** Source for th
NorthNaj
JTaJa
AB
HMadi
QasMakEastRiya
InOm
MoroEg
BahrJord
Saudi AraKuw
Argentch
AustIrela
AustraU
Singap
NorwU
Camero
7.3 : Region
000
7.4 : Compad countries
000
his information i
0
hernjranJoufbuk
azanAsirahaHailnah
ssimkkahternadh
0
dia manoccogyptain
dan bia
wait ina
hinatria andalia UAEpore
UKway USAoon
nal distribu
arison of As**
is summarized o
1.2
2
2.3
2.4
3.0
3.8
4.1
5.2
6.6
6.
5
ution of cor
ASR* for co
on page 54.
2.7
3.1
3.3
3.5
3.7
3.
4
6
7
7.8
8.6
10.4
11.1
1
10
rpus uteri c
orpus uteri
7
8
4.8
5.2
1
12.1
13.3
13.9
13.9
16
15
cancer (AS
cancer am
6.1
6.7
6
6.9
19.5
20
SR*) among
mong Saudi
8
25
g Saudi fem
females w
9.1
10
30.0
30
males,
with ASR
10.6
12
35
47
48 48
Regional 17%
Localised16%
Un
Lung Can
Lung can
of lung can
affected 298
4.4/100,000
Jouf at 10.1
4.6/100,000
regions eac
Riyadh at 3
males (rang
Figure 3.82016.
Table 3.8.
Code 81403 A80703 S80413 S80463 N80003 N80103 C85503 A80723 S
84803 M85603 A
OTotal
Figure 3.8
nknown7%
Male
cer (C33 - C
ncer was ran
ncer accoun
8 (66.8%) m
0 for males a
1/100,000, fo
0 and Makka
ch at 4.1/100
.4/100,000,
ged between
8.1 : Age-Sp
1 : Morpho
AdenocarcinoSquamous ceSmall cell carNon-small ceNeoplasm, mCarcinoma, NAcinar cell caSquamous cell
Mucinous adeAdenosquamOthers
8.2 : Stage d
Distant 60%
e
C34)
ked fifth amo
ted to 3.4 %
males and 14
and 2.0 /100
ollowed by E
ah at 4.5/100
0,000 and 4.
and Jouf at 2
22 and 94 y
pecific Inci
ological dis
Moma, NOS ell carcinomarcinoma, NOll carcinoma alignant
NOS arcinoma
carcinoma, lar
enocarcinomous carcinom
distributio
Regional 10%
Localised22%
U
ong Saudi m
% of all new
8 (33.2%) fe
0,000 for fem
Eastern regio
,000. In fema
.0/100,000 re
2.3/100,000
years) and 59
idence Rat
stribution o
Morpholog
a, NOS S
rge cell, nonke
ma ma
n of lung c
Unknown9%
Fem
males and ten
wly diagnose
emales with a
males. The fiv
n at 9.6/100
ales, regions
espectively,
(Figure 3.7.3
9 years in fem
e (AIR) for
of lung can
gy
ratinizing, NOS
cancer amo
Distant 59%
male
nth among S
ed cases am
a male to fem
ve regions w
,000, then T
s with the hig
followed by
3). The med
males (range
lung canc
cer among
Male 98 51 33 25 15 14 8
S 7 6 5 36
298
ong Saudi n
Regional 15%
Localised18%
U
audi females
mong Saudis
male ratio of
with the high
Tabuk at 8.0/
ghest ASR w
Eastern reg
ian age at di
ed between 2
er among S
g Saudi nat
% F32.9 17.1 11.1 8.4 5.0 4.7 2.7 2.3 2.0 1.7 12.1
100.0
nationals, 2
nknown7%
All
s. There wer
s in 2016. L
f 201:100. Th
est ASR for
/100,000, the
were Tabuk a
gion at 3.7/10
iagnosis was
20 and 94 ye
Saudi natio
tionals, 201
Female 67 11 5 7 14 10 3 1 3 2 25
148
2016.
Distant 60%
re 446 cases
Lung cancer
he ASR was
males were
en Riyadh at
and Northern
00,000, then
s 64 years in
ears).
onals,
16.
% 45.3 7.4 3.4 4.7 9.5 6.8 2.0 0.7 2.0 1.4 16.9
100.0
s
r
s
e
t
n
n
n
Age Groups
0
1
10
Male Female
0 -5 -10 -15 -20 -25 -30 -35 -40 -45 -50 -55 -60 -65 -70 75+
100
Hai
Najran
Jazan
Asi
Qassim
Baha
Madinah
Northern
Makkah
Riyadh
Tabuk
Eastern
Jou
Came
Saudi A
O
Ku
Ba
Mo
Jo
Arge
Aus
No
Sing
Ir
Au
Figure 3.8
*ASR per 100,
Figure 3.8Countries
*ASR per 100,
** Source for th
1
0
0.4
1
0.6
0.5
0.5
0.6
0.8
0
il
n
n
r
m
a
h
n
h
h
k
n
uf
1.0
2
1.
2
0
eroon
Arabia
Oman
UAE
uwait
India
Egypt
Qatar
hrain
orocco
ordan
ntina
tralia
orway
UK
apore
reland
ustria
USA
China
8.3 : Region
000
8.4 : Compa**
000
his information i
1
1.4
1
1.4
2.3
8
1.1
2
.0
3.2
.4
2.7
3.1
3.8
5.3
5.1
2.8
4.1
2.0
4.4
4.9
8.9
9.
10
nal distribu
arison of A
is summarized o
4
3.4
4.
3.7
2.7
3.2
3.3
4
4
11.8
15.5
5
11.0
11.2
14.0
14.1
2
ution of lun
ASR* for lun
on page 54.
.1
4.2
4.5
4.6
6Male Fem
21.5
26
25.
19.5
20.4
25.4
2
20male Fem
ng cancer (
ng cancer a
6male
6.1
.8
27.4
33.7
4
27.0
32.5
33.3
3
3
30male
ASR*) amo
among Sau
8
8
7
3
4.8
34.9
35.7
36.1
37.1
40
ong Saudi n
udis with A
9.6
10.1
10
44.2
50
nationals, 2
ASR in Sele
12
52.8
60
2016.
ected
49
50 50
Localised41%
Unknown22%
Liver Canc
Liver can
cancer case
affected 290
4.2/100,000
Riyadh regi
4.3/100,000
were Riyad
at 2.0/100,0
was 67 yea
100 years).
Figure 3.9.
Table 3.9.
Code
81703 80003
81603
81723
81403
19703
91203
82463
85503
88943
Total
Figure 3.9
Dista17%
Male
cer (C22)
ncer was rank
es accounted
0 (69.5%) m
0 for males a
ion at 7.2/10
0 for each re
h at 3.7/100,
000 and Mad
ars in males
1 : Age-Spe
1 : Morpho
HepatocellNeoplasm
Cholangioc
Hepatocell
Adenocarc
Hepatobla
Hemangio
Neuroendo
Acinar cell
Angiomyos
Others
9.2 : Stage d
ant %
Regional20%
ked sixth am
d to 3.2% of
males and 12
and 1.9/100,
00,000, follow
egion, and E
,000, followe
dinah and M
(ranged betw
ecific Inciden
ological dis
Morpho
lular carcino, malignant
carcinoma
lular carcino
cinoma, NOS
stoma
sarcoma
ocrine carcin
carcinoma
sarcoma
distributio
Localised46%
Unknown19%
mong Saudi m
all cancer ca
7 (30.5%) fe
,000 for fem
wed by Asir
Eastern regio
ed by Asir at
Makkah both
ween 0 and
nce Rate (A
stribution o
ology
ma, NOS
ma, scirrhou
S
noma, NOS
n of liver c
Distan18%
Female
males and tw
ases diagnos
emales with a
ales. The fiv
at 5.1/100,0
on at 4.1/100
2.5/100,000,
at 1.5/100,0
116 years) a
IR) for liver
of liver can
s
cancer amo
nt %
Regional17%
welfth among
sed among S
a male to fem
ve regions w
000, followed
0,000. In fem
, then Easter
000 (Figure 3
and 64 years
cancer amo
cer among
Male
220 30
15
12
3
3
2
2
1
1
1
290
ong Saudi n
Localised42%
Unknown21%
Saudi femal
Saudi nationa
male ratio of
with the highe
d by Madina
males, region
rn region at
3.9.3). The m
s in females
ong Saudi n
g Saudi nat
%
75.9 10.3
5.2
4.1
1.0
1.0
0.7
0.7
0.3
0.3
0.3
100.0
nationals, 2
Distant18%
All
les. There w
als in 2016.
f 228:100. Th
est ASR for
h and Najra
ns with the h
2.1/100,000
median age
(ranged bet
ationals, 20
tionals, 201
Female
82 6
19
2
6
0
0
3
0
0
9
127
2016
t
Regional19%
ere 417 liver
Liver cancer
he ASR was
males were
an regions at
highest ASR
, and Najran
at diagnosis
tween 8 and
016
16
%
64.6 4.7
15.0
1.6
4.7
0.0
0.0
2.4
0.0
0.0
7.1
100.0
r
r
s
e
t
R
n
s
d
Age Groups
0
1
10
100Male Female
-5 -10 -15 -20 -25 -30 -35 -40 -45 -50 -55 -60 -65 -70 75+0
MorBah
NorInQ
Saudi Ar
Argen
OKuwIre
JorAustr
CameAus
SingacE
Figure 3.9
*ASR per 100,
Figure 3.9countries*
* ASR per 100** Source for th
Ha
Bah
Norther
Jou
Jaza
Qassim
Makka
Tabu
Easter
Madina
Najra
Asi
Riyad
1.0
1.4
1
1
1
1.
1
2
1.
0
roccohrain
rway ndia
Qatar
abia UAE
ntina
Omanwait
eland
UKrdan ralia
roonstria USA
porechinaEgypt
9.3 : Region
000
9.4 : Compa**
,000 his information i
0.5
0
0
0.5
0.5
0
0
0
il
a
n
uf
n
m
h
k
n
h
n
ir
h
5.8
4
1.9
7.
1.9
3.1
2.5
1.8
5
2.2
1.9
3.0
2.1
2.5
2.8
2.8
4.1
5
2.5
2.9
3.5
3.6
4.2
4.4
4.4
4.4
4.4
4.5
4.6
5.4
6.4
7.3
8
5
nal distribu
arison of A
is summarized o
5
5
5
1.2
1.5
0.6
1.5
0.6
0.7
1
1.6
1
7
10.9
14
3
8.1
9.8
10 15
ution of live
ASR* for liv
on page 54.
2.1
2
2.5
6
1.8
2
4.1
15.8
5 20male Fem
er cancer (A
er cancer a
3.7
2.8
3.3
3.3
3 4Male Fem
25male
ASR*) amo
among Sau
7
4.1
4.3
4.3
4 5male
30
ong Saudi n
udis with A
5.1
6
33.7
38.1
35 40
nationals, 2
ASR in sele
7
1
0 45
2016
ected
7.1
8
51
52 52
Prostate C
Prostate
cancers cas
The five re
7.9/100,000
median age
Figure 3.12016.
Table 3.10
Code 81403
85503
80003
80103
84803
89103
84903
Total
Figure 3.1
Cancer (C6
cancer was
ses diagnose
egions with
0, then Makk
e at diagnosis
0.1 : Age-S
0.1 : Morph
Adenocar
Acinar ce
Neoplasm
Carcinom
Mucinous
Embryon
Signet rin
0.2 : Stage
61)
s ranked the
ed among Sa
the highest
kah at 7.5/10
s was 70 yea
Specific Inc
hological di
Morrcinoma, NO
ell carcinoma
m, malignant
ma, NOS
s adenocarci
al rhabdomy
ng cell carcin
e distributio
Localised49.9%
e tenth amo
audi Males in
t ASR were
00,000, Asir
ars (ranged b
cidence Ra
istribution
rphology OS
a
noma
yosarcoma, N
noma
on of prost
Unknown4.2%
ong Saudi m
n 2016. The
e Eastern re
at 6.6/100,0
between 15 a
ate (AIR) pr
of prostate
NOS
tate cancer
Distant35.1%
Regional10.9%
males with 40
ASR was 6.3
egion at 11
000, and Jou
and 101 yea
r
e cancers a
rs among S
05 cases ac
3/100,000 fo
.2/100,000,
uf at 5.0/100,
rs).
ostate cancer amon
among Sau
NO. 367
18
9
7
2
1
1
405
Saudi natio
ccounted to
or Saudi male
followed by
,000 (Figure
ng Saudi n
udi nationa
%90
4.4
2.
1.
0.
0.
0.
100
onals, 2016
3.1% of all
e population.
y Riyadh at
3.10.3).The
ationals,
als, 2016
% .6
4
2
7
5
2
2
0.0
6.
l
.
t
e
0
1
10
100
0 -5 -10 -15 -20 -25 -30 -35 -
Age Groups
40 -45 -50 -55 -60 -65 -70 75+
Baha
Hail
Madinah
Jazan
Tabuk
Qassim
Najran
Northern
Jouf
Asir
Makkah
Riyadh
Eastern
IndiaChina
Saudi ArabiaEgyptOmanQata
JordanBahrain
UAEKuwait
MoroccoCameroonSingaporeArgentina
UKAustria
USAIreland
AustraliaNorway
Figure 3.1
*ASR per 100,
Figure 3.1ASR in Se
*ASR per 100,
** Source for th
0.8
0.0
a
l
h
n
k
m
n
n
f
r
h
h
n
4.2
5.3
6.3
7.8
1
0
a a
a tnr
n n Et onea Ka Ada y
0.3 : Regio
000
0.4 : Compelected Cou
000
his information i
1.7
2.0
2.3
2
2.0
12.2
12.3
15.3
16.3
16.5
18
18.5
23
20
onal distrib
parison of Auntries**
is summarized o
2.7
3.1
3.7
4.0
33.1
44.1
40
bution of pr
ASR* for o
on page 54.
4.7
5.0
6.0
60
rostate can
of prostate
6.6
7.5
8
73.2
74.7
80
ncers(ASR*
cancers am
5
7.9
8.0
98.2
100
*) among S
mong Saud
10.0
114.2
115.1
120
Saudi natio
di nationals
11.2
12.0
129.7
140
onals, 2016
s with
53
54 54
1.
2.
Reference
GLOBOCAN
Research o
15- Year Ca
http://
es :
N 2012, Canc
on Cancer. Av
ancer Inciden
/ghc.sa/ar-s
cer Incidence
vailable from
nce among N
sa/Documen
e and Mortal
m: http://globo
Nationals of t
nts/GCCCP
ity Worldwid
ocan.iarc.fr/P
the GCC Sta
P/GCCCP%
e, IARC, Lyo
Pages/online
tes, 1998-20
%20-%20Re
on: Internatio
e.aspx
012
port%20-%
onal agency f
20Pages.pd
for
df
CANC
PACER IN
NON
ART CIDEN
N-SAU
2016
IV NCE AM
UDIS
MONGG
55
56 56
Cancer Inc
Between
population,
10 codes. T
and 1,826 (
The ratio of
and the fac
differences.
represented
During 2016
ages 15 to
median age
(ranged bet
Table 4.1
Breast
Colorecta
Thyroid
NHL
Skin
Lung
Prostate
Leukaem
Kidney
Stomach
Total
cidence Am
January and
147cases w
Therefore, th
51.4 %) were
f male to fem
ct that cance
. Those who
d 3.8%, and t
6, approxima
39 years, 5
e at diagnosi
tween 0 and
: Ten most
al
mia
mong Non-
d December
were excluded
he total numb
e females.
male was 10
er is primari
were under
the 15 to 59
ately 3.5 % o
5.9% were b
s was 54 ye
106).
t common c
Site
-Saudi Pop
2016, a tota
d from analy
ber of cases
02:100. Takin
ly a disease
15 represen
age group re
of all cancers
between the
ars in males
cancers am
pulation, 20
al of 3,845 ca
ysis due to In
analyzed w
ng into cons
e of the elde
nted 15.2% o
epresented 8
s occurred be
ages 40-64
s (ranged bet
mong Non-
3
016.
ancer cases
n Situ and m
was 3,698 Ou
sideration the
erly; the patt
of the populat
81% of Non-
efore the age
4, and 11.2 %
tween 0 and
-Saudi pop
NO. 807
421
214
198
171
157
144
133
115
112
3698
were reporte
mismatch bet
ut of this 1,8
e population
tern of canc
tion, those a
Saudi popula
e of 15, 29.4
% occurred a
103 years)
ulation, 20
ed among the
tween ICD-O
72 (48.6 %)
structure of
cer had som
aged 60 year
ation.
% occurred
after the age
and 49 year
016.
% 21.8
11.4
5.8
5.4
4.6
4.2
3.9
3.6
3.1
3.0
100.0
e Non-Saudi
O-3 and ICD-
were males
f non-Saudis
e significant
rs and above
between the
e of 64. The
rs in females
i
-
s
s
t
e
e
e
s
Table 4.2
NationaliYemen
Syrian Arab
Egypt
Sudan
Philippines
Pakistan
Gaza Strip(
India
Jordan
Bangladesh
Eritrea
Indonesia
Myanmar
United State
Ethiopia
Non-Saudi,
Lebanon
United King
Afghanistan
Bahrain
Sri Lanka
Morocco
Somalia
Canada
Chad
Others Nati
TOTAL
: Distributi
ty
b Republic
(Palestine)
h
es of Americ
NOS
gdom
n
onalities
on of canc
M
ca
1
cer cases a
Male 391
227
228
198
129
106
82
84
49
58
19
12
22
42
14
17
17
21
11
11
12
7
9
10
6
90
1872
among Non
% 20.9
12.1
12.2
10.6
6.9
5.7
4.4
4.5
2.6
3.1
1.0
0.6
1.2
2.2
0.7
0.9
0.9
1.1
0.6
0.6
0.6
0.4
0.5
0.5
0.3
4.8
100
n-Saudi by
Female 334
218
209
165
226
82
72
55
51
16
39
40
29
9
33
22
14
10
18
17
13
17
0
7
10
120
1826
nationality
% 18.3
11.9
11.4
9.0
12.4
4.5
3.9
3.0
2.8
0.9
2.1
2.2
1.6
0.5
1.8
1.2
0.8
0.5
1.0
0.9
0.7
0.9
0.0
0.4
0.5
6.6
100
y and gend
Total 725
445
437
363
355
188
154
139
100
74
58
52
51
51
47
39
31
31
29
28
25
24
19
17
16
200
3698
er, 2016.
% 19.6
12.0
11.8
9.8
9.6
5.1
4.2
3.8
2.7
2.0
1.6
1.4
1.4
1.4
1.3
1.1
0.8
0.8
0.8
0.8
0.7
0.6
0.5
0.5
0.4
5.4
100
57
58 58
Table 4.3
Male Colorecta
Prostate
Skin
NHL
Lung
Bladder
Kidney
Leukemia
Stomach
Brain,CNS
Figure 4.12016.
0
10
1000
: Most com
l
S
: Age-Spe
mmon canc
1872
299
144
135
133
124
92
89
84
73
73
ecific Incide
Ag
cers among
%
15.9
7.7
7.2
7.1
6.6
4.9
4.8
4.5
3.9
3.9
ence Rate
Male
ge Groups
g Non-Saud
Fem
9 Breas
7 Thyro
2 Color
Corp
6 Ovar
9 NHL
8 Cerv
5 Leuk
9 Stom
9 Skin
(AIR) for a
Female
di populatio
male
st
oid
rectal
us Uteri
y
ix Uteri
emia
mach
ll cancers a
on by gend
1826
787
146
122
78
77
65
51
49
39
36
among No
der, 2016.
6
7
6
2
n-Saudi po
%
43.1
8
6.6
4.3
4.2
3.6
2.8
2.7
2.1
2
opulation,
100
0 -5 -10 -15 -20 -25 -30 -35 -40 -45 -50 -55 -60 -65 -70 75+
INC
PACIDEN
ARTNCE T
T VTABLLES
59
60 60
Table
ICD (10th)
C00
C01-C02
C03-C06
C07-C08
C09
C10
C11
C12-C13
C14
C15
C16
C17
C18
C19-C20
C21
C22
C23-C24
C25
C30-C31
C32
C33-C34
C37-C38
C40-C41
C43
C44
C45
C46
C47;C49
C50
C60
C61
C62
C63
C64
C65
C66
C67
C68
C69
C70-C72
C73
C74
C75
C81
C82-C85;C96
C88
C90
C91
C92-C94
C95
Other
All
Not C44
5.1.1 : Numb
Site
Lip
Tongue
Mouth
Salivary glands
Tonsil
Other Oropharynx
Nasopharynx
Hypopharynx
Pharynx unspec.
Oesophagus
Stomach
Small intestine
Colon
Rectum
Anus
Liver
Gallbladder etc.
Pancreas
Nose, sinuses etc.
Larynx
Trachea,Bronchus,Lung
Other Thoracic organs
Bone
Melanoma of Skin
Other Skin
Mesothelioma
Kaposi sarcoma
Connective,Soft tissue
Breast
Penis
Prostate
Testis
Other male genital
Kidney
Renal Pelvis
Ureter
Bladder
Other Urinary organs
Eye
Brain, Nervous system
Thyroid
Adrenal gland
Other Endocrine
Hodgkin disease
Non-Hodgkin lymphoma Immunoproliferative dis.
Multiple Myeloma
Lymphoid Leukaemia
Myeloid Leukaemia
Leukaemia unspec.
Other & unspecified
All sites Total
All sites but C44
ber Of Cases
All Ages
Age unk
16 0
60 0
59 0
23 0
3 0
4 0
154 0
7 0
2 0
78 1
207 0
37 0
581 5
374 0
24 0
290 0
80 0
170 1
18 0
69 0
298 1
16 0
93 1
14 0
207 1
11 0
27 0
89 1
42 0
4 0
405 0
123 1
3 0
196 0
7 0
8 0
229 0
7 0
30 0
212 0
222 0
22 0
5 0
265 0
469 0
0 0
72 0
165 0
142 0
27 0
137 1
----- -----
5803 13
5596 12
Among Saud
0-4 5-9 10-14
0 0 1
0 0 0
1 0 1
0 0 0
0 0 0
0 0 0
0 0 4
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 1
3 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
1 0 0
4 10 13
0 0 0
1 1 1
0 0 0
0 0 0
5 2 5
0 0 0
0 0 0
0 0 0
6 1 2
0 0 0
4 3 1
0 0 0
0 0 0
2 0 0
0 0 0
18 1 0
24 23 12
0 1 2
12 1 1
0 0 2
4 23 24
14 17 11
0 0 0
0 0 0
36 23 19
14 5 5
4 3 2
5 1 1
----- ----- -----
158 115 108
157 114 107
di Males by P
4 15-19 20-24
0 0
0 0
0 2
0 4
0 0
0 0
4 4
0 0
0 0
0 0
1 3
0 0
0 5
0 1
0 0
0 0
0 1
0 0
0 1
0 0
0 1
0 3
20 11
0 0
1 6
0 0
0 0
2 11
0 1
0 0
1 0
12 17
0 0
0 0
0 0
0 0
0 0
0 0
1 1
2 16
4 6
2 1
0 1
24 33
16 25
0 0
0 0
15 8
11 12
2 0
1 4
----- -----
119 178
118 172
Primary Site A
25-29 30-34
0 0
1 1
1 1
4 3
0 0
0 0
3 12
0 0
0 0
1 2
2 8
1 0
7 16
6 10
0 0
1 4
0 0
5 2
2 1
1 0
4 5
1 0
6 6
0 1
9 7
0 1
0 0
9 6
2 0
0 0
0 0
23 32
0 0
8 6
0 0
0 0
1 3
0 0
0 0
10 14
17 21
1 0
1 0
33 38
29 30
0 0
0 5
3 5
7 14
0 2
1 5
----- -----
200 261
191 254
And Age Gro
35-39 40-44
0 0
4 4
1 5
1 1
0 0
1 0
13 17
0 0
0 0
0 2
10 8
1 2
20 33
18 24
0 3
4 7
1 3
2 8
0 3
2 4
5 6
3 0
4 3
0 0
10 9
0 0
2 0
8 4
2 2
1 0
0 1
6 8
0 0
12 16
0 0
0 0
8 13
0 0
1 0
15 9
25 20
0 1
0 0
16 6
28 30
0 0
3 3
4 1
13 11
1 1
5 6
----- -----
250 274
240 265
oups, 2016.
45-49 50-54 55
0 1
3 6
2 7
0 1
0 1
1 0
25 19
0 0
2 0
5 11
7 14
3 4
56 77
34 47
3 1
3 28
8 9
12 15
0 1
7 10
10 27
1 2
6 1
0 0
8 13
0 1
0 2
5 7
8 3
1 1
6 10
4 4
0 1
24 18
1 0
0 1
11 14 3
0 1
0 1
16 17
24 25
0 1
0 0
15 17
34 34 3
0 0
3 4
3 10
9 12
1 0
13 20
----- ----- -
374 499 6
366 486 5
5-59 60-64 65-6
6 1 1
5 5 10
6 6 3
1 2 3
0 1 0
0 0 0
15 19 3
1 1 0
0 0 0
7 11 6
26 22 20
3 6 7
74 76 42
49 47 39
1 4 2
41 35 38
9 10 10
20 29 19
0 3 0
15 6 8
51 41 54
1 2 0
1 2 1
1 1 1
16 11 16
0 0 4
5 3 3
4 5 5
2 11 4
0 1 0
43 51 79
0 1 3
0 1 1
24 26 22
2 2 0
0 1 1
37 36 27
1 2 1
1 2 0
22 14 6
21 14 16
1 1 0
0 1 0
10 5 4
33 41 39
0 0 0
10 10 10
6 5 5
10 6 5
2 3 1
18 16 8
---- ----- ----
601 599 527
585 588 511
69 70-74 75+
1 5
0 8 13
10 13
1 2
0 1
1 1
8 8
2 3
0 0
7 25
0 30 56
3 7
2 64 106
9 40 59
3 6
8 39 87
0 17 12
9 29 28
5 2
7 9
4 32 61
1 1
3 1
1 9
6 23 74
2 3
5 7
4 6
1 6
0 0
9 70 144
0 3
0 0
2 15 17
0 2
2 3
7 18 59
0 2
0 4
3 9
6 5 21
0 0
0 0
7 6
9 28 60
0 0
0 7 17
6 16
5 3
2 3
8 24
-- ----- -----
7 523 1004
1 500 930
Total (%)
0.30%
1.00%
1.00%
0.40%
0.10%
0.10%
2.70%
0.10%
0.00%
1.30%
3.60%
0.60%
10.00%
6.40%
0.40%
5.00%
1.40%
2.90%
0.30%
1.20%
5.10%
0.30%
1.60%
0.20%
3.60%
0.20%
0.50%
1.50%
0.70%
0.10%
7.00%
2.10%
0.10%
3.40%
0.10%
0.10%
3.90%
0.10%
0.50%
3.70%
3.80%
0.40%
0.10%
4.60%
8.10%
0.00%
1.20%
2.80%
2.40%
0.50%
2.40%
-----
100.00%
96.40%
Table
ICD (10th)
C00
C01-C02
C03-C06
C07-C08
C09
C10
C11
C12-C13
C14
C15
C16
C17
C18
C19-C20
C21
C22
C23-C24
C25
C30-C31
C32
C33-C34
C37-C38
C40-C41
C43
C44
C45
C46
C47;C49
C50
C51
C52
C53
C54
C55
C56
C57
C58
C64
C65
C66
C67
C68
C69
C70-C72
C73
C74
C75
C81
C82-C85;C96
C88
C90
C91
C92-C94
C95
Other
All
Not C44
5.1.2 : Numb
Site
Lip
Tongue
Mouth
Salivary glands
Tonsil
Other Oropharynx
Nasopharynx
Hypopharynx
Pharynx unspec.
Oesophagus
Stomach
Small intestine
Colon
Rectum
Anus
Liver
Gallbladder etc.
Pancreas
Nose, sinuses etc.
Larynx
Trachea,Bronchus,L
Other Thoracic orga
Bone
Melanoma of Skin
Other Skin
Mesothelioma
Kaposi sarcoma
Connective,Soft tissu
Breast
Vulva
Vagina
Cervix Uteri
Corpus Uteri
Uterus unspec.
Ovary
Other Female Genita
Placenta
Kidney
Renal Pelvis
Ureter
Bladder
Other Urinary organ
Eye
Brain, Nervous syste
Thyroid
Adrenal gland
Other Endocrine
Hodgkin disease
Non-Hodgkin lymph
Immunoproliferative
Multiple Myeloma
Lymphoid Leukaem
Myeloid Leukaemia
Leukaemia unspec.
Other & unspecified
All sites Total
All sites but C44
ber Of Cases
All Ages
6
47
60
30
2
2
59
14
1
50
111
32
447
257
11
127
113
104
5
7
Lung 148
ans 10
53
25
166
7
4
ue 70
2240
9
8
111
454
40
219
al 18
4
138
2
0
59
ns 2
16
em 155
854
19
6
230
homa 372
e dis. 0
48
mia 105
158
13
d 110
-----
7358
7192
Among Saud
Age unk 0-4 5
0 0
0 0
0 0
1 0
0 1
0 0
0 1
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 1
0 1
0 0
0 0
0 0
0 0
0 11
2 0
0 0
0 2
0 0
0 0
0 0
0 2
0 0
0 0
0 15
0 0
0 0
0 0
0 0
0 7
0 15 1
2 1
0 12
0 0
0 4
0 5
0 0
0 0
0 33 1
0 10
0 1
0 4
----- ----- --
5 126 6
5 126 6
di Females by
5-9 10-14 15-19
0 0 0
0 0 1
0 0 0
0 0 2
0 0 0
0 0 0
0 0 2
0 0 0
0 0 0
0 0 0
0 0 0
0 1 0
0 1 1
0 0 0
0 0 0
1 0 1
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
6 14 7
1 0 1
0 1 2
0 0 0
0 0 0
1 3 7
0 0 2
0 0 0
0 0 0
0 0 0
0 0 1
0 0 0
1 1 8
0 0 2
0 0 0
2 1 2
0 0 0
0 0 0
0 0 1
0 0 0
1 2 0
13 9 6
2 9 21
1 0 0
0 0 1
8 13 40
5 8 5
0 0 0
0 0 0
14 13 5
7 7 5
3 1 3
0 0 0
---- ----- -----
66 84 126
66 83 124
y Primary Sit
20-24 25-29 3
0 1
0 2
0 0
3 1
0 0
1 0
4 2
0 1
0 0
0 1
2 2
0 2
1 3
1 4
0 0
0 1
2 0
0 2
0 0
0 0
1 6
1 0
4 6
0 1
0 8
1 0
0 0
9 1
22 53
1 0
1 0
4 3
1 2
0 2
14 16
1 0
0 1
1 1
0 0
0 0
1 1
0 0
1 0
4 9
58 87
2 0
1 1
45 32
25 7
0 0
0 0
3 2
5 12
1 0
2 7
----- -----
223 280
223 272
te And Age G
30-34 35-39 40-44
0 0 0
0 0 2
3 1 2
2 2 1
0 0 0
0 0 0
3 8 4
0 1 0
0 0 0
7 0 2
3 5 14
1 1 2
11 21 31
8 16 18
0 0 0
1 2 2
0 1 1
3 4 6
0 0 1
0 0 0
5 8 6
0 1 1
2 5 1
1 2 4
15 6 6
0 0 1
0 0 0
8 1 4
124 227 315
0 1 0
0 1 0
5 9 10
7 18 17
0 2 5
9 8 21
0 0 3
2 1 0
5 7 12
0 0 0
0 0 0
4 0 6
0 0 0
0 0 1
7 11 9
101 116 117
2 1 0
1 0 0
22 10 12
14 23 17
0 0 0
1 7 2
4 2 1
19 19 8
1 0 0
4 3 1
----- ----- -----
405 551 666
390 545 660
Groups, 2016
4 45-49 50-54
0 0
6 7
6 5
3 3
0 0
1 0
9 9
3 1
0 1
0 6
5 13
4 3
41 70
33 43
3 2
6 8
6 7
10 7
0 0
0 1
12 17
0 1
1 1
0 1
16 9
1 2
1 0
4 8
319 341
0 1
0 1
14 20
29 51
3 9
20 19
4 2
0 0
17 16
0 0
0 0
2 5
0 0
0 1
15 14
106 80
0 1
0 0
9 8
24 36
0 0
3 11
4 3
13 16
0 0
7 9
----- -----
760 869
744 860
55-59 60-64 65
0 1 1
8 6 4
9 7 9
5 2 1
0 0 0
0 0 0
6 4 1
2 0 1
0 0 0
2 5 6
9 10 1
4 4 4
60 63 4
29 32 2
3 2 1
22 20 2
13 16 1
11 11 1
0 2 0
1 0 1
21 16 1
1 2 1
2 0 0
2 1 2
16 11 1
1 1 0
0 0 0
1 1 3
288 198 11
1 3 0
2 0 0
11 3 9
86 98 5
6 2 4
25 19 1
0 3 1
0 0 0
12 15 6
0 1 0
0 0 0
4 7 3
1 1 0
0 1 0
12 8 6
61 34 1
0 0 0
1 0 0
11 5 2
32 53 3
0 0 0
6 6 3
3 5 2
17 6 8
0 0 0
15 12 1
----- ----- --
822 697 50
806 686 48
-69 70-74 75+
1 0 3
4 6 5
9 4 14
1 1 3
0 1 0
0 0 0
1 4 2
1 2 3
0 0 0
6 5 16
14 9 25
4 1 5
46 35 63
21 15 37
1 0 0
20 21 22
17 23 27
16 17 17
0 1 1
1 1 3
17 14 25
1 1 0
0 1 2
2 2 7
13 16 47
0 0 0
0 1 2
3 3 5
18 99 132
0 1 1
0 0 1
9 8 15
56 43 45
4 3 4
16 18 22
1 1 1
0 0 0
6 12 14
0 1 0
0 0 0
3 9 16
0 0 0
0 1 1
6 9 8
18 9 32
0 0 0
0 0 1
2 5 4
38 27 53
0 0 0
3 5 4
2 6 5
8 2 4
0 1 2
13 15 18
--- ----- -----
02 459 717
89 443 670
61
Total (%)
0.10%
0.60%
0.80%
0.40%
0.00%
0.00%
0.80%
0.20%
0.00%
0.70%
1.50%
0.40%
6.10%
3.50%
0.10%
1.70%
1.50%
1.40%
0.10%
0.10%
2.00%
0.10%
0.70%
0.30%
2.30%
0.10%
0.10%
1.00%
30.40%
0.10%
0.10%
1.50%
6.20%
0.50%
3.00%
0.20%
0.10%
1.90%
0.00%
0.00%
0.80%
0.00%
0.20%
2.10%
11.60%
0.30%
0.10%
3.10%
5.10%
0.00%
0.70%
1.40%
2.10%
0.20%
1.50%
-----
100.00%
97.70%
62 62
Table (per 1
ICD (10th)
C00
C01-C02
C03-C06
C07-C08
C09
C10
C11
C12-C13
C14
C15
C16
C17
C18
C19-C20
C21
C22
C23-C24
C25
C30-C31
C32
C33-C34
C37-C38
C40-C41
C43
C44
C45
C46
C47;C49
C50
C60
2
C62
C63
C64
C65
C66
C67
C68
C69
C70-C72
C73
C74
C75
C81
C82-C85;C96
C88
C90
C91
C92-C94
C95
Other
All
Not C44
5.1.3 : Age-S00,000) by Pr
Site
Lip
Tongue
Mouth
Salivary glands
Tonsil
Other Oropharynx
Nasopharynx
Hypopharynx
Pharynx unspec.
Oesophagus
Stomach
Small intestine
Colon
Rectum
Anus
Liver
Gallbladder etc.
Pancreas
Nose, sinuses etc.
Larynx
Trachea,Bronchus,Lung
Other Thoracic organs
Bone
Melanoma of Skin
Other Skin
Mesothelioma
Kaposi sarcoma
Connective,Soft tissue
Breast
Penis
Prostate
Testis
Other male genital
Kidney
Renal Pelvis
Ureter
Bladder
Other Urinary organs
Eye
Brain, Nervous system
Thyroid
Adrenal gland
Other Endocrine
Hodgkin disease
Non-Hodgkin lymphoma
Immunoproliferative dis
Multiple Myeloma
Lymphoid Leukaemia
Myeloid Leukaemia
Leukaemia unspec.
Other & unspecified
All sites Total
All sites but C44
Spesific Inciderimary Site a
All Ages
Age unk
16 0
60 0
59 0
23 0
3 0
4 0
154 0
7 0
2 0
78 1
207 0
37 0
581 5
374 0
24 0
290 0
80 0
170 1
18 0
69 0
298 1
16 0
93 1
14 0
207 1
11 0
27 0
89 1
42 0
4 0
405 0
123 1
3 0
196 0
7 0
8 0
229 0
7 0
30 0
212 0
222 0
22 0
5 0
265 0
a 469 0
. 0 0
72 0
165 0
142 0
27 0
137 1
----- -----
5803 13
5596 12
ence Rate (Aand Age grou
0-4 5-9 10
0 0 0
0 0
0.1 0 0
0 0
0 0
0 0
0 0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0 0
0.3 0
0 0
0 0
0 0
0 0
0 0
0.1 0
0.4 0.9 1
0 0
0.1 0.1 0
0 0
0 0
0.5 0.2 0
0 0
0 0
0 0
0.6 0.1 0
0 0
0.4 0.3 0
0 0
0 0
0.2 0
0 0
1.7 0.1
2.2 2.2 1
0 0.1 0
1.1 0.1 0
0 0 0
0.4 2.2 2
1.3 1.6 1
0 0
0 0
3.3 2.2
1.3 0.5 0
0.4 0.3 0
0.5 0.1 0
----- ----- --
14 11
14 11
IR), Age Stanps, 2016.
0-14 15-19 20-24
0.1 0 0
0 0 0
0.1 0 0.2
0 0 0.4
0 0 0
0 0 0
0.4 0.4 0.4
0 0 0
0 0 0
0 0 0
0 0.1 0.3
0 0 0
0 0 0.5
0 0 0.1
0.1 0 0
0 0 0
0 0 0.1
0 0 0
0 0 0.1
0 0 0
0 0 0.1
0 0 0.3
1.4 2.2 1.1
0 0 0
0.1 0.1 0.6
0 0 0
0 0 0
0.5 0.2 1.1
0 0 0.1
0 0 0
0 0.1 0
0.2 1.3 1.6
0 0 0
0.1 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0.1 0.1
1.3 0.2 1.5
0.2 0.4 0.6
0.1 0.2 0.1
0.2 0 0.1
2.5 2.7 3.2
1.2 1.8 2.4
0 0 0
0 0 0
2 1.7 0.8
0.5 1.2 1.2
0.2 0.2 0
0.1 0.1 0.4
---- ----- -----
11 13 17
11 13 17
ndardised In
25-29 30-34
0 0
0.1 0.1
0.1 0.1
0.4 0.3
0 0
0 0
0.3 1.4
0 0
0 0
0.1 0.2
0.2 0.9
0.1 0
0.7 1.8
0.6 1.2
0 0
0.1 0.5
0 0
0.5 0.2
0.2 0.1
0.1 0
0.4 0.6
0.1 0
0.6 0.7
0 0.1
0.9 0.8
0 0.1
0 0
0.9 0.7
0.2 0
0 0
0 0
2.4 3.7
0 0
0.8 0.7
0 0
0 0
0.1 0.3
0 0
0 0
1 1.6
1.8 2.4
0.1 0
0.1 0
3.4 4.4
3 3.5
0 0
0 0.6
0.3 0.6
0.7 1.6
0 0.2
0.1 0.6
----- -----
21 30
20 29
cidence Rate
35-39 40-44 45-4
0 0 0
0.5 0.6 0.6
0.1 0.8 0.4
0.1 0.2 0
0 0 0
0.1 0 0.2
1.7 2.6 4.6
0 0 0
0 0 0.4
0 0.3 0.9
1.3 1.2 1.3
0.1 0.3 0.6
2.6 5.1 10.
2.4 3.7 6.3
0 0.5 0.6
0.5 1.1 0.6
0.1 0.5 1.5
0.3 1.2 2.2
0 0.5 0
0.3 0.6 1.3
0.7 0.9 1.8
0.4 0 0.2
0.5 0.5 1.1
0 0 0
1.3 1.4 1.5
0 0 0
0.3 0 0
1 0.6 0.9
0.3 0.3 1.5
0.1 0 0.2
0 0.2 1.1
0.8 1.2 0.7
0 0 0
1.6 2.5 4.4
0 0 0.2
0 0 0
1 2 2
0 0 0
0.1 0 0
2 1.4 3
3.3 3.1 4.4
0 0.2 0
0 0 0
2.1 0.9 2.8
3.7 4.6 6.3
0 0 0
0.4 0.5 0.6
0.5 0.2 0.6
1.7 1.7 1.7
0.1 0.2 0.2
0.7 0.9 2.4
----- ----- ----
33 42 69
31 41 67
(ASR) Amon
49 50-54 55-59
0.2 1.8
6 1.4 1.5
4 1.6 1.8
0.2 0.3
0.2 0
2 0 0
6 4.4 4.5
0 0.3
4 0 0
9 2.5 2.1
3 3.2 7.7
6 0.9 0.9
.3 17.8 22
3 10.9 14.5
6 0.2 0.3
6 6.5 12.2
5 2.1 2.7
2 3.5 5.9
0.2 0
3 2.3 4.5
8 6.2 15.1
2 0.5 0.3
1 0.2 0.3
0 0.3
5 3 4.7
0.2 0
0.5 1.5
9 1.6 1.2
5 0.7 0.6
2 0.2 0
1 2.3 12.8
7 0.9 0
0.2 0
4 4.2 7.1
2 0 0.6
0.2 0
3.2 11
0.2 0.3
0.2 0.3
3.9 6.5
4 5.8 6.2
0.2 0.3
0 0
8 3.9 3
3 7.9 9.8
0 0
6 0.9 3
6 2.3 1.8
7 2.8 3
2 0 0.6
4 4.6 5.3
-- ----- -----
9 115 178
7 112 174
ng Saudi Mal
60-64 65-69 7
0.4 0.7
2 6.7
2.5 2
0.8 2
0.4 0
0 0
7.8 2
0.4 0
0 0
4.5 4
9 13.5 2
2.5 4.7
31.1 28.3
19.2 26.2 3
1.6 1.3
14.3 25.6
4.1 6.7 1
11.9 12.8 2
1.2 0
2.5 5.4
16.8 36.3 2
0.8 0
0.8 0.7
0.4 0.7
4.5 10.8 2
0 2.7
1.2 2
2 3.4
4.5 2.7
0.4 0
20.9 53.2 6
0.4 2
0.4 0.7
10.6 14.8 1
0.8 0
0.4 0.7
14.7 18.2 1
0.8 0.7
0.8 0
5.7 4
5.7 10.8
0.4 0
0.4 0
2 2.7
16.8 26.2 2
0 0
4.1 6.7
2 3.4
2.5 3.4
1.2 0.7
6.6 5.4
----- ----- -
245 355 4
241 344 4
les
0-74 75+ CrudRate
0.9 3.3 0.2
7.4 8.5 0.6
9.2 8.5 0.6
0.9 1.3 0.2
0 0.7 0
0.9 0.7 0
7.4 5.2 1.5
1.8 2 0.1
0 0 0
6.5 16.3 0.8
27.7 36.4 2
2.8 4.6 0.4
59 68.9 5.7
36.9 38.4 3.6
2.8 3.9 0.2
36 56.6 2.8
15.7 7.8 0.8
26.7 18.2 1.7
4.6 1.3 0.2
6.5 5.9 0.7
29.5 39.7 2.9
0.9 0.7 0.2
2.8 0.7 0.9
0.9 5.9 0.1
21.2 48.1 2
1.8 2 0.1
4.6 4.6 0.3
3.7 3.9 0.9
0.9 3.9 0.4
0 0 0
64.6 93.6 4
0 2 1.2
0 0 0
13.8 11.1 1.9
0 1.3 0.1
1.8 2 0.1
16.6 38.4 2.2
0 1.3 0.1
0 2.6 0.3
2.8 5.9 2.1
4.6 13.7 2.2
0 0 0.2
0 0 0
6.5 3.9 2.6
25.8 39 4.6
0 0 0
6.5 11.1 0.7
5.5 10.4 1.6
4.6 2 1.4
1.8 2 0.3
7.4 15.6 1.3
----- ----- -----
482 653 56.6
461 605 54.6
de e
ASR World
0.2
0.8
0.8
0.3
0
0.1
1.8
0.1
0
1.1
2.9
0.5
7.8
5.1
0.3
4.2
1.2
2.5
0.2
0.9
4.4
0.2
0.9
0.2
2.7
0.2
0.4
1
0.6
0
6.3
1.1
0
2.6
0.1
0.1
3.2
0.1
0.3
2.3
2.5
0.2
0.1
2.6
5.6
0
1
1.8
1.5
0.3
1.7
- -----
6 74.7
6 72
Table 100,00
ICD (10th)
C00
C01-C02
C03-C06
C07-C08
C09
C10
C11
C12-C13
C14
C15
C16
C17
C18
C19-C20
C21
C22
C23-C24
C25
C30-C31
C32
C33-C34
C37-C38
C40-C41
C43
C44
C45
C46
C47;C49
C50
C51
C52
C53
C54
C55
C56
C57
C58
C64
C65
C66
C67
C68
C69
C70-C72
C73
C74
C75
C81
C82-C85;C96
C88
C90
C91
C92-C94
C95
Other
All
Not C44
5.1.4 : Age-S00) by Primar
Site
Lip
Tongue
Mouth
Salivary glands
Tonsil
Other Oropharynx
Nasopharynx
Hypopharynx
Pharynx unspec.
Oesophagus
Stomach
Small intestine
Colon
Rectum
Anus
Liver
Gallbladder etc.
Pancreas
Nose, sinuses etc.
Larynx
Trachea,Bronchus,Lung Other Thoracic organs
Bone
Melanoma of Skin
Other Skin
Mesothelioma
Kaposi sarcoma
Connective,Soft tissue
Breast
Vulva
Vagina
Cervix Uteri
Corpus Uteri
Uterus unspec.
Ovary
Other Female Genital
Placenta
Kidney
Renal Pelvis
Ureter
Bladder
Other Urinary organs
Eye
Brain, Nervous system
Thyroid
Adrenal gland
Other Endocrine
Hodgkin disease
Non-Hodgkin lymphoma Immunoproliferative dis.
Multiple Myeloma
Lymphoid Leukaemia Myeloid Leukaemia Leukaemia unspec. Other & unspecified
All sites Total
All sites but C44
Spesific Incidery Site and A
All Ages
Age unk
0
6 0
47 0
60 0
30 1
2 0 0
2 0
59 0 0
14 0
1 0
50 0
111 0
32 0
447 0
257 0
11 0
127 0
113 0
104 0
5 0
7 0
148 0
10 0 0
53 0 0
25 0
166 0
7 0
4 0
70 0
2240 2
9 0
8 0 0
111 0
454 0
40 0
219 0 0
18 0
4 0
138 0 1
2 0
0 0
59 0
2 0
16 0 0
155 0 1
854 2 0
19 0 1
6 0
230 0 0
372 0 0
0 0
48 0
105 0 3
158 0
13 0 0
110 0 0
----- ----- --
7358 5 1
7192 5 1
ence Rate (AAge groups, 20
0-4 5-9 10-14
0 0 0
0 0 0
0 0 0
0 0 0
0.1 0 0
0 0 0
0.1 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0.1
0 0 0.1
0 0 0
0 0 0
0 0.1 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0.1 0 0
0.1 0.6 1.5
0 0.1 0
0 0 0.1
0 0 0
0 0 0
1 0.1 0.3
0 0 0
0 0 0
0.2 0 0
0 0 0
0 0 0
0 0 0
0.2 0.1 0.1
0 0 0
0 0 0
1.4 0.2 0.1
0 0 0
0 0 0
0 0 0
0 0 0
0.7 0.1 0.2
1.4 1.3 1
0.1 0.2 1
1.1 0.1 0
0 0 0
0.4 0.8 1.4
0.5 0.5 0.9
0 0 0
0 0 0
3.1 1.4 1.4
1 0.7 0.8
0.1 0.3 0.1
0.4 0 0
---- ----- -----
12 6 9
12 6 9
IR), Age Stan016
15-19 20-24 2
0 0
0.1 0
0 0
0.2 0.3
0 0
0 0.1
0.2 0.4
0 0
0 0
0 0
0 0.2
0 0
0.1 0.1
0 0.1
0 0
0.1 0
0 0.2
0 0
0 0
0 0
0 0.1
0 0.1
0.8 0.4
0.1 0
0.2 0
0 0.1
0 0
0.8 0.9
0.2 2.3
0 0.1
0 0.1
0 0.4
0.1 0.1
0 0
0.9 1.5
0.2 0.1
0 0
0.2 0.1
0 0
0 0
0.1 0.1
0 0
0 0.1
0.7 0.4
2.4 6.1
0 0.2
0.1 0.1
4.6 4.7
0.6 2.6
0 0
0 0
0.6 0.3
0.6 0.5
0.3 0.1
0 0.2
----- -----
15 23
14 23
ndardised In
25-29 30-34 35-3
0.1 0 0
0.2 0 0
0 0.4 0.1
0.1 0.2 0.3
0 0 0
0 0 0
0.2 0.4 1.1
0.1 0 0.1
0 0 0
0.1 0.8 0
0.2 0.4 0.7
0.2 0.1 0.1
0.3 1.3 2.8
0.4 0.9 2.2
0 0 0
0.1 0.1 0.3
0 0 0.1
0.2 0.4 0.5
0 0 0
0 0 0
0.6 0.6 1.1
0 0 0.1
0.6 0.2 0.7
0.1 0.1 0.3
0.8 1.8 0.8
0 0 0
0 0 0
0.1 0.9 0.1
5.6 14.5 30.
0 0 0.1
0 0 0.1
0.3 0.6 1.2
0.2 0.8 2.4
0.2 0 0.3
1.7 1.1 1.1
0 0 0
0.1 0.2 0.1
0.1 0.6 0.9
0 0 0
0 0 0
0.1 0.5 0
0 0 0
0 0 0
1 0.8 1.5
9.2 11.8 15.
0 0.2 0.1
0.1 0.1 0
3.4 2.6 1.3
0.7 1.6 3.1
0 0 0
0 0.1 0.9
0.2 0.5 0.3
1.3 2.2 2.6
0 0.1 0
0.7 0.5 0.4
----- ----- ----
30 47 74
29 46 73
cidence Rate
39 40-44 45-49
0 0
0.3 1.2
1 0.3 1.2
3 0.2 0.6
0 0
0 0.2
1 0.6 1.8
1 0 0.6
0 0
0.3 0
7 2.3 1
1 0.3 0.8
8 5 8
2 2.9 6.4
0 0.6
3 0.3 1.2
1 0.2 1.2
5 1 2
0.2 0
0 0
1 1 2.3
1 0.2 0
7 0.2 0.2
3 0.6 0
8 1 3.1
0.2 0.2
0 0.2
1 0.6 0.8
.5 50.7 62.2
1 0 0
1 0 0
2 1.6 2.7
4 2.7 5.7
3 0.8 0.6
1 3.4 3.9
0.5 0.8
1 0 0
9 1.9 3.3
0 0
0 0
1 0.4
0 0
0.2 0
5 1.4 2.9
.6 18.8 20.7
1 0 0
0 0
3 1.9 1.8
1 2.7 4.7
0 0
9 0.3 0.6
3 0.2 0.8
6 1.3 2.5
0 0
4 0.2 1.4
-- ----- -----
4 107 148
3 106 145
(ASR) Amon
50-54 55-59
0 0
1.7 2.6
1.2 2.9
0.7 1.6
0 0
0 0
2.2 1.9
0.2 0.6
0.2 0
1.5 0.6
3.2 2.9
0.7 1.3
17.1 19.4
10.5 9.4
0.5 1
2 7.1
1.7 4.2
1.7 3.6
0 0
0.2 0.3
4.2 6.8
0.2 0.3
0.2 0.6
0.2 0.6
2.2 5.2
0.5 0.3
0 0
2 0.3
83.5 93
0.2 0.3
0.2 0.6
4.9 3.6
12.5 27.8
2.2 1.9
4.7 8.1
0.5 0
0 0
3.9 3.9
0 0
0 0
1.2 1.3
0 0.3
0.2 0
3.4 3.9
19.6 19.7
0.2 0
0 0.3
2 3.6
8.8 10.3
0 0
2.7 1.9
0.7 1
3.9 5.5
0 0
2.2 4.8
----- -----
213 266
211 260
ng Saudi Fem
60-64 65-69 70
0.4 0.6
2.6 2.5
3.1 5.7
0.9 0.6
0 0
0 0
1.8 0.6
0 0.6
0 0
2.2 3.8
4.4 8.9
1.8 2.5
27.6 29.3 3
14 13.4 1
0.9 0.6
8.8 12.7 1
7 10.8 2
4.8 10.2 1
0.9 0
0 0.6
7 10.8 1
0.9 0.6
0 0
0.4 1.3
4.8 8.3 1
0.4 0
0 0
0.4 1.9
86.7 75.1 8
1.3 0
0 0
1.3 5.7
42.9 35.6 3
0.9 2.5
8.3 10.2 1
1.3 0.6
0 0
6.6 3.8 1
0.4 0
0 0
3.1 1.9
0.4 0
0.4 0
3.5 3.8
14.9 11.5
0 0
0 0
2.2 1.3
23.2 24.2 2
0 0
2.6 1.9
2.2 1.3
2.6 5.1
0 0
5.3 8.3 1
----- ----- -
305 319 4
300 311 3
males (per
0-74 75+ CrudRate
0 1.9 0.1
5.4 3.1 0.5
3.6 8.7 0.6
0.9 1.9 0.3
0.9 0 0
0 0 0
3.6 1.2 0.6
1.8 1.9 0.1
0 0 0
4.5 9.9 0.5
8.1 15.4 1.1
0.9 3.1 0.3
31.5 38.9 4.5
13.5 22.9 2.6
0 0 0.1
18.9 13.6 1.3
20.7 16.7 1.1
15.3 10.5 1.1
0.9 0.6 0.1
0.9 1.9 0.1
12.6 15.4 1.5
0.9 0 0.1
0.9 1.2 0.5
1.8 4.3 0.3
14.4 29 1.7
0 0 0.1
0.9 1.2 0
2.7 3.1 0.7
89.1 81.6 22.7
0.9 0.6 0.1
0 0.6 0.1
7.2 9.3 1.1
38.7 27.8 4.6
2.7 2.5 0.4
16.2 13.6 2.2
0.9 0.6 0.2
0 0 0
10.8 8.7 1.4
0.9 0 0
0 0 0
8.1 9.9 0.6
0 0 0
0.9 0.6 0.2
8.1 4.9 1.6
8.1 19.8 8.7
0 0 0.2
0 0.6 0.1
4.5 2.5 2.3
24.3 32.8 3.8
0 0 0
4.5 2.5 0.5
5.4 3.1 1.1
1.8 2.5 1.6
0.9 1.2 0.1
13.5 11.1 1.1
----- ----- -----
413 443 74.5
399 414 72.9
63
de e
ASR World
0.1
0.7
0.8
0.4
0
0
0.7
0.2
0
0.7
1.5
0.4
6.1
3.4
0.2
1.9
1.7
1.5
0.1
0.1
2
0.1
0.5
0.3
2.1
0.1
0.1
0.8
27.2
0.1
0.1
1.4
6.6
0.5
2.7
0.2
0
1.8
0
0
0.8
0
0.2
1.8
8.9
0.2
0.1
2.3
4.9
0
0.6
1.2
1.7
0.1
1.5
-----
91.3
89.2
64 64
Ta(AS
ICD
C00
C01-C
C03-C
C07-C
C09
C10
C11
C12-C
C14
C15
C16
C17
C18
C19-C
C21
C22
C23-C
C25
C30-C
C32
C33-C
C37-C
C40-C
C43
C44
C45
C46
C47;C
C50
C60
C61
C62
C63
C64
C65
C66
C67
C68
C69
C70-C
C73
C74
C75
C81
C82-C
C88
C90
C91
C92-C
C95
Othe
All
Not C
able 5.2.1 : NuSR) Among S
D (10th)
Lip
C02 Tongue
C06 Mouth
C08 Salivary
Tonsil
Other O
Nasoph
C13 Hypoph
Pharyn
Oesoph
Stomac
Small in
Colon
C20 Rectum
Anus
Liver
C24 Gallbla
Pancrea
C31 Nose, si
Larynx
C34 Trache
C38 Other T
C41 Bone
Melano
Other S
Mesoth
Kaposi
C49 Connec
Breast
Penis
Prostat
Testis
Other m
Kidney
Renal P
Ureter
Bladder
Other U
Eye
C72 Brain, N
Thyroid
Adrena
Other E
Hodgki
C85;C96 Non-Ho
Immun
Multipl
Lymph
C94 Myeloid
Leukae
r Other &
All sites
C44 All sites
umber Of CaSaudi Males (
Site
e
y glands
Oropharynx
harynx
harynx
nx unspec.
hagus
ch
ntestine
m
adder etc.
as
inuses etc.
x
a,Bronchus,Lung
Thoracic organs
oma of Skin
Skin
helioma
sarcoma
ctive,Soft tissue
te
male genital
y
Pelvis
r
Urinary organs
Nervous system
d
al gland
Endocrine
in disease
odgkin lymphoma
noproliferative dis.
le Myeloma
oid Leukaemia
d Leukaemia
emia unspec.
& unspecified
s Total
s but C44
ases, Relative ( per 100,000
All Ages Total (%)
0 0.00%
2 0.40%
8 1.60%
1 0.20%
0 0.00%
0 0.00%
9 1.80%
1 0.20%
1 0.20%
5 1.00%
28 5.60%
8 1.60%
51 10.20%
36 7.20%
2 0.40%
35 7.00%
9 1.80%
20 4.00%
2 0.40%
5 1.00%
8 1.60%
2 0.40%
9 1.80%
0 0.00%
21 4.20%
0 0.00%
5 1.00%
7 1.40%
2 0.40%
1 0.20%
43 8.60%
7 1.40%
1 0.20%
11 2.20%
0 0.00%
0 0.00%
16 3.20%
1 0.20%
2 0.40%
10 2.00%
8 1.60%
3 0.60%
0 0.00%
23 4.60%
47 9.40%
0 0.00%
7 1.40%
19 3.80%
7 1.40%
8 1.60%
7 1.40%
----- -----
498 100.00%
477 95.80%
Frequency, C0) by Primary
Asir
Crude Rate ASR
0
0.2
0.9
0.1
0
0
1.1
0.1
0.1
0.6
3.3
0.9
6
4.2
0.2
4.1
1.1
2.3
0.2
0.6
0.9
0.2
1.1
0
2.5
0
0.6
0.8
0.2
0.1
5
0.8
0.1
1.3
0
0
1.9
0.1
0.2
1.2
0.9
0.4
0
2.7
5.5
0
0.8
2.2
0.8
0.9
0.8
-----
58.4
55.9
Crude Incidey Site, Age Gr
R World All Ages
0 0
0.2 2
0.9 0
0.1 0
0 0
0 0
1.2 3
0.2 0
0.1 0
0.5 5
3.9 4
1.1 0
7.5 5
5.4 3
0.2 0
5.1 1
1.4 1
2.8 0
0.2 0
0.7 1
1.1 4
0.2 0
1.1 2
0 0
2.8 12
0 0
0.7 2
1.1 2
0.3 0
0.1 0
6.6 2
0.7 0
0.2 0
1.5 2
0 0
0 0
2.5 5
0.1 0
0.2 1
1.2 2
1 2
0.4 0
0 0
2.6 5
6.5 12
0 0
0.9 1
2.3 0
1 2
1 0
1 1
----- -----
68.7 82
65.9 70
ence Rate (CIroups and Re
Baha
Total (%) Crude R
0.00% 0
2.40% 1.1
0.00% 0
0.00% 0
0.00% 0
0.00% 0
3.70% 1.7
0.00% 0
0.00% 0
6.10% 2.8
4.90% 2.2
0.00% 0
6.10% 2.8
3.70% 1.7
0.00% 0
1.20% 0.6
1.20% 0.6
0.00% 0
0.00% 0
1.20% 0.6
4.90% 2.2
0.00% 0
2.40% 1.1
0.00% 0
14.60% 6.6
0.00% 0
2.40% 1.1
2.40% 1.1
0.00% 0
0.00% 0
2.40% 1.1
0.00% 0
0.00% 0
2.40% 1.1
0.00% 0
0.00% 0
6.10% 2.8
0.00% 0
1.20% 0.6
2.40% 1.1
2.40% 1.1
0.00% 0
0.00% 0
6.10% 2.8
14.60% 6.6
0.00% 0
1.20% 0.6
0.00% 0
2.40% 1.1
0.00% 0
1.20% 0.6
----- -----
100.00% 45.2
85.40% 38.5
IR) Age-Standegions 2016
Rate ASR World
0
0.9
0
0
0
0
1.8
0
0
2.2
2.9
0
2.3
2.2
0
0.7
0.9
0
0
0.8
3.2
0
1.1
0
6.5
0
1.8
1.4
0
0
0.8
0
0
1.4
0
0
3.2
0
0.7
1
1
0
0
2.9
7.2
0
0.7
0
1
0
0.4
- -----
2 49.3
5 42.8
dardised Inci
J
All Ages Total (%)
2 1.30%
8 5.40%
13 8.70%
3 2.00%
0 0.00%
0 0.00%
3 2.00%
0 0.00%
0 0.00%
1 0.70%
5 3.40%
0 0.00%
10 6.70%
7 4.70%
0 0.00%
9 6.00%
2 1.30%
3 2.00%
0 0.00%
1 0.70%
3 2.00%
0 0.00%
3 2.00%
1 0.70%
9 6.00%
0 0.00%
0 0.00%
2 1.30%
2 1.30%
0 0.00%
8 5.40%
3 2.00%
0 0.00%
5 3.40%
0 0.00%
0 0.00%
6 4.00%
0 0.00%
1 0.70%
2 1.30%
3 2.00%
0 0.00%
0 0.00%
5 3.40%
17 11.40%
0 0.00%
0 0.00%
6 4.00%
2 1.30%
1 0.70%
3 2.00%
----- -----
149 100.00%
140 94.00%
idence Rate
Jazan
Crude Rate ASR
0.3
1.3
2.2
0.5
0
0
0.5
0
0
0.2
0.8
0
1.7
1.2
0
1.5
0.3
0.5
0
0.2
0.5
0
0.5
0.2
1.5
0
0
0.3
0.3
0
1.3
0.5
0
0.8
0
0
1
0
0.2
0.3
0.5
0
0
0.8
2.8
0
0
1
0.3
0.2
0.5
----- -
24.7 3
23.2 3
R World
0.4
1.9
3.6
0.6
0
0
0.5
0
0
0.2
1.2
0
2.5
1.4
0
1.8
0.4
0.6
0
0.1
0.8
0
0.5
0.4
2.1
0
0
0.3
0.6
0
2.3
0.4
0
0.9
0
0
1.5
0
0.1
0.3
0.9
0
0
0.7
4.3
0
0
1.1
0.5
0.2
0.7
-----
33.7
31.5
Tabl(ASR
ICD (1
C00
C01-C02
C03-C06
C07-C08
C09
C10
C11
C12-C13
C14
C15
C16
C17
C18
C19-C20
C21
C22
C23-C24
C25
C30-C31
C32
C33-C34
C37-C38
C40-C41
C43
C44
C45
C46
C47;C49
C50
C60
C61
C62
C63
C64
C65
C66
C67
C68
C69
C70-C72
C73
C74
C75
C81
C82-C85;C
C88
C90
C91
C92-C94
C95
Other
All
Not C44
le 5.2.2 : NumR) Among Sa
10th) Si
Lip
Tongue
Mouth
Salivary glan
Tonsil
Other Oroph
Nasopharynx
Hypopharynx
Pharynx unsp
Oesophagus
Stomach
Small intestin
Colon
Rectum
Anus
Liver
Gallbladder e
Pancreas
Nose, sinuses
Larynx
Trachea,Bron
Other Thorac
Bone
Melanoma of
Other Skin
Mesothelioma
Kaposi sarcom
Connective,So
Breast
Penis
Prostate
Testis
Other male ge
Kidney
Renal Pelvis
Ureter
Bladder
Other Urinar
Eye
Brain, Nervou
Thyroid
Adrenal gland
Other Endocr
Hodgkin dise
C96 Non-Hodgkin
Immunoproli
Multiple Mye
Lymphoid Le
Myeloid Leuk
Leukaemia un
Other & unsp
All sites Total
All sites but C
mber Of Caseaudi Males ( p
ite All A
0
1
0
ds 0
0
arynx 1
x 12
x 0
pec. 0
1
12
ne 2
44
17
2
20
etc. 3
8
etc. 2
1
nchus,Lung 14
cic organs 1
6
f Skin 0
8
a 1
ma 0
oft tissue 8
2
1
8
3
enital 0
9
0
0
11
ry organs 0
1
us system 11
7
d 2
rine 1
ase 15
n lymphoma 24
iferative dis. 0
eloma 5
eukaemia 7
kaemia 9
nspec. 4
pecified 9
----
l 293
C44 285
es, Relative Fper 100,000) b
Mad
Ages Total (%)
0.00%
0.30%
0.00%
0.00%
0.00%
0.30%
2 4.10%
0.00%
0.00%
0.30%
2 4.10%
0.70%
4 15.00%
7 5.80%
0.70%
0 6.80%
1.00%
2.70%
0.70%
0.30%
4 4.80%
0.30%
2.00%
0.00%
2.70%
0.30%
0.00%
2.70%
0.70%
0.30%
2.70%
1.00%
0.00%
3.10%
0.00%
0.00%
1 3.80%
0.00%
0.30%
1 3.80%
2.40%
0.70%
0.30%
5 5.10%
4 8.20%
0.00%
1.70%
2.40%
3.10%
1.40%
3.10%
-- -----
3 100.00%
5 97.30%
Frequency, Crby Primary S
dinah
Crude Rate ASR W
0 0
0.1 0.2
0 0
0 0
0 0
0.1 0.2
1.8 2
0 0
0 0
0.1 0.3
1.8 2.4
0.3 0.3
6.5 9
2.5 3.5
0.3 0.4
2.9 4.3
0.4 0.5
1.2 1.3
0.3 0.2
0.1 0.2
2.1 3.3
0.1 0.2
0.9 0.9
0 0
1.2 1.7
0.1 0.1
0 0
1.2 1.3
0.3 0.3
0.1 0.2
1.2 2
0.4 0.5
0 0
1.3 1.6
0 0
0 0
1.6 1.8
0 0
0.1 0.1
1.6 1.7
1 1.2
0.3 0.3
0.1 0.1
2.2 2.2
3.5 4
0 0
0.7 1.3
1 1.2
1.3 1.4
0.6 0.8
1.3 1.5
----- ----
43 54.7
41.8 53
rude IncidencSite, Age Gro
World All Ages
0
2 2
0
2
0
2 0
4
0
0
3 1
4 1
3 1
5
5 7
4 0
3 1
5 0
3 1
2 0
2 3
3 1
2 1
9 5
0
7 2
1 0
1
3 1
3 2
2 0
3
5 2
0
6 2
0
0
8 2
0
1 1
7 2
2 6
3 0
1 0
2 4
9
0
3 0
2 4
4 1
8 0
5 2
-- -----
7 79
3 77
ce Rate (CIRoups and Reg
Hail
Total (%) Crude Ra
0.00% 0
2.50% 0.8
0.00% 0
2.50% 0.8
0.00% 0
0.00% 0
5.10% 1.5
0.00% 0
0.00% 0
1.30% 0.4
1.30% 0.4
1.30% 0.4
6.30% 1.9
8.90% 2.7
0.00% 0
1.30% 0.4
0.00% 0
1.30% 0.4
0.00% 0
3.80% 1.1
1.30% 0.4
1.30% 0.4
6.30% 1.9
0.00% 0
2.50% 0.8
0.00% 0
1.30% 0.4
1.30% 0.4
2.50% 0.8
0.00% 0
3.80% 1.1
2.50% 0.8
0.00% 0
2.50% 0.8
0.00% 0
0.00% 0
2.50% 0.8
0.00% 0
1.30% 0.4
2.50% 0.8
7.60% 2.3
0.00% 0
0.00% 0
5.10% 1.5
11.40% 3.4
0.00% 0
0.00% 0
5.10% 1.5
1.30% 0.4
0.00% 0
2.50% 0.8
----- -----
100.00% 30.1
97.50% 29.3
R) Age-Standaions 2016
ate ASR World
0
0.8
0
1.1
0
0
1.6
0
0
0.6
0.4
0.6
2.3
3
0
0.6
0
0.4
0
1.3
0.5
0.6
1.9
0
0.8
0
0.5
0.3
1.1
0
1.7
0.8
0
0.6
0
0
0.8
0
0.4
0.8
2.4
0
0
1.3
3.9
0
0
1.5
0.4
0
0.9
-----
33.7
33
ardised Incid
All Ages Total (%
0 0.00%
2 0.90%
0 0.00%
2 0.90%
0 0.00%
0 0.00%
11 4.90%
0 0.00%
0 0.00%
4 1.80%
12 5.30%
1 0.40%
29 12.90%
17 7.60%
0 0.00%
10 4.40%
3 1.30%
6 2.70%
0 0.00%
3 1.30%
8 3.60%
1 0.40%
5 2.20%
1 0.40%
11 4.90%
0 0.00%
0 0.00%
1 0.40%
3 1.30%
0 0.00%
11 4.90%
5 2.20%
0 0.00%
7 3.10%
0 0.00%
0 0.00%
6 2.70%
0 0.00%
2 0.90%
7 3.10%
13 5.80%
0 0.00%
0 0.00%
17 7.60%
12 5.30%
0 0.00%
1 0.40%
4 1.80%
6 2.70%
0 0.00%
4 1.80%
----- -----
225 100.00%
214 95.10%
dence Rate
Qassim
) Crude Rate
0
0.4
0
0.4
0
0
2.2
0
0
0.8
2.4
0.2
5.8
3.4
0
2
0.6
1.2
0
0.6
1.6
0.2
1
0.2
2.2
0
0
0.2
0.6
0
2.2
1
0
1.4
0
0
1.2
0
0.4
1.4
2.6
0
0
3.4
2.4
0
0.2
0.8
1.2
0
0.8
-----
% 44.7
42.5
65
ASR World
0
0.6
0
0.6
0
0
2.8
0
0
1
2.8
0.4
7.9
4.8
0
2.8
1.2
1.9
0
0.9
2.7
0.2
1.1
0.2
2.7
0
0
0.2
0.8
0
3.1
0.8
0
1.7
0
0
1.5
0
0.4
1.3
3.1
0
0
3.1
2.8
0
0.3
0.8
1.2
0
0.7
-----
56.5
53.9
66 66
Table (ASR)
ICD (10th)
C00
C01-C02
C03-C06
C07-C08
C09
C10
C11
C12-C13
C14
C15
C16
C17
C18
C19-C20
C21
C22
C23-C24
C25
C30-C31
C32
C33-C34
C37-C38
C40-C41
C43
C44
C45
C46
C47;C49
C50
C60
C61
C62
C63
C64
C65
C66
C67
C68
C69
C70-C72
C73
C74
C75
C81
C82-C85;C96
C88
C90
C91
C92-C94
C95
Other
All
Not C44
5.2.3 : Numb) Among Sau
Site
Lip
Tongue
Mouth
Salivary glands
Tonsil
Other Oropharynx
Nasopharynx
Hypopharynx
Pharynx unspec.
Oesophagus
Stomach
Small intestine
Colon
Rectum
Anus
Liver
Gallbladder etc.
Pancreas
Nose, sinuses etc.
Larynx
Trachea,Bronchus,L
Other Thoracic orga
Bone
Melanoma of Skin
Other Skin
Mesothelioma
Kaposi sarcoma
Connective,Soft tissu
Breast
Penis
Prostate
Testis
Other male genital
Kidney
Renal Pelvis
Ureter
Bladder
Other Urinary organ
Eye
Brain, Nervous syste
Thyroid
Adrenal gland
Other Endocrine
Hodgkin disease
Non-Hodgkin lymphoma Immunoproliferativdis.
Multiple Myeloma
Lymphoid Leukaem
Myeloid Leukaemia
Leukaemia unspec.
Other & unspecified
All sites Total
All sites but C44
ber Of Cases,di Males ( pe
All Ages
Tota
3 3.4
2 2.3
0 0.0
1 1.1
0 0.0
0 0.0
0 0.0
0 0.0
0 0.0
1 1.1
3 3.4
2 2.3
2 2.3
3 3.4
1 1.1
5 5.7
1 1.1
3 3.4
0 0.0
0 0.0
Lung 1 1.1
ans 1 1.1
0 0.0
1 1.1
7 8.0
0 0.0
0 0.0
ue 0 0.0
0 0.0
0 0.0
4 4.6
1 1.1
0 0.0
1 1.1
0 0.0
0 0.0
2 2.3
ns 0 0.0
1 1.1
em 8 9.2
9 10.3
0 0.0
0 0.0
5 5.7
8 9.2
ve 0 0.0
0 0.0
mia 2 2.3
a 3 3.4
1 1.1
d 5 5.7
----- --
87 100.
80 92.0
, Relative Freer 100,000) by
Najran
al (%) Crude Rate
40% 1.4
30% 0.9
00% 0
10% 0.5
00% 0
00% 0
00% 0
00% 0
00% 0
10% 0.5
40% 1.4
30% 0.9
30% 0.9
40% 1.4
10% 0.5
70% 2.3
10% 0.5
40% 1.4
00% 0
00% 0
10% 0.5
10% 0.5
00% 0
10% 0.5
00% 3.2
00% 0
00% 0
00% 0
00% 0
00% 0
60% 1.8
10% 0.5
00% 0
10% 0.5
00% 0
00% 0
30% 0.9
00% 0
10% 0.5
20% 3.7
30% 4.1
00% 0
00% 0
70% 2.3
20% 3.7
00% 0
00% 0
30% 0.9
40% 1.4
10% 0.5
70% 2.3
---- -----
.00% 40
00% 36.8
equency, Cruy Primary Sit
ASR World
All Ages
T
2.3 2
1.6 0
0 2
0.6 1
0 0
0 0
0 3
0 0
0 0
0.9 0
1.9 3
1.5 0
1.3 7
1.9 4
0.5 1
4.3 2
0.6 3
3.3 2
0 1
0 3
0.6 11 1
0.4 0
0 1
0.6 0
4.7 4
0 1
0 0
0 1
0 2
0 0
3.7 5
0.4 0
0 0
0.4 2
0 0
0 0
1.3 4
0 0
0.4 2
4 4
4.8 4
0 0
0 0
2.2 5
3.8 6
0 0
0 0
0.9 3
1.2 0
1 1
2.9 2
----- -----
53.9 92 1
49.2 88 9
ude Incidencete, Age.
Jouf
otal (%) Crude Rate
2.20% 1.1
0.00% 0
2.20% 1.1
1.10% 0.5
0.00% 0
0.00% 0
3.30% 1.6
0.00% 0
0.00% 0
0.00% 0
3.30% 1.6
0.00% 0
7.60% 3.7
4.30% 2.1
1.10% 0.5
2.20% 1.1
3.30% 1.6
2.20% 1.1
1.10% 0.5
3.30% 1.6
12.00% 5.8
0.00% 0
1.10% 0.5
0.00% 0
4.30% 2.1
1.10% 0.5
0.00% 0
1.10% 0.5
2.20% 1.1
0.00% 0
5.40% 2.6
0.00% 0
0.00% 0
2.20% 1.1
0.00% 0
0.00% 0
4.30% 2.1
0.00% 0
2.20% 1.1
4.30% 2.1
4.30% 2.1
0.00% 0
0.00% 0
5.40% 2.6
6.50% 3.2
0.00% 0
0.00% 0
3.30% 1.6
0.00% 0
1.10% 0.5
2.20% 1.1
----- -----
00.00% 48.4
95.70% 46.3
e Rate (CIR) A
ASR World
All Ages
1.6 1
0 0
1.7 0
0.4 1
0 0
0 0
2.4 5
0 1
0 0
0 8
2.9 4
0 1
5.7 11
3.2 2
0.5 0
1.6 6
3.1 5
1.8 1
1.2 0
2.3 3
10.1 14
0 0
0.4 3
0 0
3.7 6
1.2 0
0 1
0.5 4
1.3 2
0 0
5 5
0 4
0 0
1.6 3
0 1
0 1
2.4 7
0 0
0.9 0
2.3 6
2.3 8
0 1
0 0
3 6
4.6 18
0 0
0 2
1.4 5
0 4
1.2 1
1.2 3
----- -----
71.4 154
67.7 148
Age-Standar
Tabuk
Total (%)
Crude Rate
0.60% 0.3
0.00% 0
0.00% 0
0.60% 0.3
0.00% 0
0.00% 0
3.20% 1.4
0.60% 0.3
0.00% 0
5.20% 2.2
2.60% 1.1
0.60% 0.3
7.10% 3
1.30% 0.5
0.00% 0
3.90% 1.6
3.20% 1.4
0.60% 0.3
0.00% 0
1.90% 0.8
9.10% 3.8
0.00% 0
1.90% 0.8
0.00% 0
3.90% 1.6
0.00% 0
0.60% 0.3
2.60% 1.1
1.30% 0.5
0.00% 0
3.20% 1.4
2.60% 1.1
0.00% 0
1.90% 0.8
0.60% 0.3
0.60% 0.3
4.50% 1.9
0.00% 0
0.00% 0
3.90% 1.6
5.20% 2.2
0.60% 0.3
0.00% 0
3.90% 1.6
11.70% 4.9
0.00% 0
1.30% 0.5
3.20% 1.4
2.60% 1.1
0.60% 0.3
1.90% 0.8
----- -----
100.00% 42.1
96.10% 40.4
dised Inciden
ASR World
All Ages
0.6 1
0 0
0 1
0.2 0
0 1
0 0
1.8 0
0.6 0
0 0
4.2 2
2.2 2
0.5 0
4.9 3
0.9 3
0 2
3.3 1
2.1 2
0.6 3
0 1
2 0
8 3
0 0
0.8 2
0 0
3.1 7
0 0
0.6 0
1.2 2
0.9 0
0 0
2.7 4
1.6 3
0 0
1.3 3
0.3 0
0.4 0
3.8 2
0 0
0 0
1.9 2
2.5 2
0.3 1
0 0
1.7 3
7.5 7
0 0
0.7 2
1.4 0
1.2 1
0.2 0
1.4 1
----- -----
67.1 67
64 60
nce Rate
Northern Regio
Total (%) Crude Rate
1.50% 0.7
0.00% 0
1.50% 0.7
0.00% 0
1.50% 0.7
0.00% 0
0.00% 0
0.00% 0
0.00% 0
3.00% 1.4
3.00% 1.4
0.00% 0
4.50% 2.1
4.50% 2.1
3.00% 1.4
1.50% 0.7
3.00% 1.4
4.50% 2.1
1.50% 0.7
0.00% 0
4.50% 2.1
0.00% 0
3.00% 1.4
0.00% 0
10.40% 4.9
0.00% 0
0.00% 0
3.00% 1.4
0.00% 0
0.00% 0
6.00% 2.8
4.50% 2.1
0.00% 0
4.50% 2.1
0.00% 0
0.00% 0
3.00% 1.4
0.00% 0
0.00% 0
3.00% 1.4
3.00% 1.4
1.50% 0.7
0.00% 0
4.50% 2.1
10.40% 4.9
0.00% 0
3.00% 1.4
0.00% 0
1.50% 0.7
0.00% 0
1.50% 0.7
----- -----
100.00% 46.5
89.60% 41.7
on
ASR World
1.6
0
0.9
0
1.1
0
0
0
0
2.1
2
0
3.5
3.3
3.1
1
2.6
4.1
1.5
0
4.2
0
1.1
0
6.7
0
0
1.1
0
0
4.7
3.5
0
3.3
0
0
2.9
0
0
1.1
1.4
0.7
0
2.1
5
0
2.5
0
0.5
0
0.6
-----
69
62.2
Table (ASR)
ICD (10th)
C00
C01-C02
C03-C06
C07-C08
C09
C10
C11
C12-C13
C14
C15
C16
C17
C18
C19-C20
C21
C22
C23-C24
C25
C30-C31
C32
C33-C34
C37-C38
C40-C41
C43
C44
C45
C46
C47;C49
C50
C60
C61
C62
C63
C64
C65
C66
C67
C68
C69
C70-C72
C73
C74
C75
C81
C82-C85;C96
C88
C90
C91
C92-C94
C95
Other
All
Not C44
5.2.4 : Numb) Among Sau
Site
Lip
Tongue
Mouth
Salivary glands
Tonsil
Other Oropharynx
Nasopharynx
Hypopharynx
Pharynx unspec.
Oesophagus
Stomach
Small intestine
Colon
Rectum
Anus
Liver
Gallbladder etc.
Pancreas
Nose, sinuses etc.
Larynx
Trachea,Bronchus,Lu
Other Thoracic organ
Bone
Melanoma of Skin
Other Skin
Mesothelioma
Kaposi sarcoma
Connective,Soft tissue
Breast
Penis
Prostate
Testis
Other male genital
Kidney
Renal Pelvis
Ureter
Bladder
Other Urinary organs
Eye
Brain, Nervous system
Thyroid
Adrenal gland
Other Endocrine
Hodgkin disease
Non-Hodgkin lympho
Immunoproliferative
Multiple Myeloma
Lymphoid Leukaemia
Myeloid Leukaemia
Leukaemia unspec.
Other & unspecified
All sites Total
All sites but C44
ber Of Cases,di Males ( pe
All Ages
1
15
13
4
1
1
50
1
1
23
44
6
183
113
7
101
20
49
3
17
ung 69
ns 3
33
5
55
1
7
e 19
4
0
103
38
2
65
1
5
57
s 4
8
m 71
82
6
1
68
oma 128
dis. 0
13
a 28
40
2
33
-----
1604
1549
, Relative Freer 100,000) by
Riyadh
Total (%) Crude
0.10% 0
0.90% 0.6
0.80% 0.5
0.20% 0.2
0.10% 0
0.10% 0
3.10% 2.1
0.10% 0
0.10% 0
1.40% 1
2.70% 1.8
0.40% 0.3
11.40% 7.7
7.00% 4.7
0.40% 0.3
6.30% 4.2
1.20% 0.8
3.10% 2.1
0.20% 0.1
1.10% 0.7
4.30% 2.9
0.20% 0.1
2.10% 1.4
0.30% 0.2
3.40% 2.3
0.10% 0
0.40% 0.3
1.20% 0.8
0.20% 0.2
0.00% 0
6.40% 4.3
2.40% 1.6
0.10% 0.1
4.10% 2.7
0.10% 0
0.30% 0.2
3.60% 2.4
0.20% 0.2
0.50% 0.3
4.40% 3
5.10% 3.4
0.40% 0.3
0.10% 0
4.20% 2.9
8.00% 5.4
0.00% 0
0.80% 0.5
1.70% 1.2
2.50% 1.7
0.10% 0.1
2.10% 1.4
----- ----
100.00% 67.
96.60% 65
equency, Cruy Primary Sit
Rate ASR World
0
6 1.1
5 0.7
2 0.2
0.1
0.1
1 2.6
0.1
0
1.6
8 2.8
3 0.4
7 11.7
7 7.2
3 0.5
2 7.1
8 1.4
1 3.3
1 0.2
7 1
9 4.6
1 0.1
4 1.4
2 0.3
3 3.3
0.1
3 0.5
8 1
2 0.3
0
3 7.9
6 1.4
1 0.1
7 4
0.1
2 0.4
4 3.8
2 0.3
3 0.4
3.4
4 4.4
3 0.3
0
9 2.7
4 7
0
5 0.8
2 1.4
7 1.9
1 0.1
4 2
-- -----
4 96.4
5 93
ude Incidencete, Age Group
All Ages Tota
3 0.2
14 1.0
14 1.0
3 0.2
0 0.0
2 0.1
29 2.1
1 0.1
0 0.0
20 1.5
58 4.3
7 0.5
119 8.8
92 6.8
5 0.4
57 4.2
23 1.7
42 3.1
4 0.3
14 1.0
77 5.7
6 0.4
9 0.7
3 0.2
33 2.4
2 0.1
7 0.5
23 1.7
10 0.7
1 0.1
114 8.4
23 1.7
0 0.0
45 3.3
3 0.2
2 0.1
64 4.7
2 0.1
5 0.4
46 3.4
32 2.4
5 0.4
2 0.1
63 4.7
100 7.4
0 0.0
21 1.6
59 4.4
41 3.0
6 0.4
41 3.0
----- --
1352 100
1319 97.
e Rate (CIR) Aps and Regio
Makkah
al (%) Crude Rate
20% 0.1
00% 0.6
00% 0.6
20% 0.1
00% 0
10% 0.1
10% 1.3
10% 0
00% 0
50% 0.9
30% 2.6
50% 0.3
80% 5.3
80% 4.1
40% 0.2
20% 2.5
70% 1
10% 1.9
30% 0.2
00% 0.6
70% 3.4
40% 0.3
70% 0.4
20% 0.1
40% 1.5
10% 0.1
50% 0.3
70% 1
70% 0.4
10% 0
40% 5
70% 1
00% 0
30% 2
20% 0.1
10% 0.1
70% 2.8
10% 0.1
40% 0.2
40% 2
40% 1.4
40% 0.2
10% 0.1
70% 2.8
40% 4.4
00% 0
60% 0.9
40% 2.6
00% 1.8
40% 0.3
00% 1.8
---- -----
0.00% 59.9
.60% 58.4
Age-Standarons 2016.
ASR World
0.2
0.8
0.8
0.2
0
0.1
1.4
0
0
1.1
3.3
0.4
6.3
5
0.2
3.3
1.3
2.5
0.2
0.8
4.5
0.3
0.4
0.2
1.9
0.2
0.4
1
0.5
0
7.5
0.9
0
2.4
0.1
0.1
3.6
0.1
0.3
2.3
1.5
0.3
0.1
2.9
5.2
0
1.2
3
2
0.3
2.3
-----
73.2
71.3
dised Inciden
East
All Ages Total (%)
3 0.30%
12 1.10%
8 0.70%
5 0.50%
1 0.10%
0 0.00%
25 2.30%
3 0.30%
0 0.00%
6 0.50%
29 2.70%
9 0.80%
109 10.00%
67 6.10%
4 0.40%
38 3.50%
8 0.70%
31 2.80%
5 0.50%
18 1.60%
82 7.50%
1 0.10%
14 1.30%
3 0.30%
31 2.80%
6 0.50%
4 0.40%
19 1.70%
13 1.20%
1 0.10%
94 8.60%
33 3.00%
0 0.00%
41 3.70%
2 0.20%
0 0.00%
45 4.10%
0 0.00%
6 0.50%
39 3.60%
46 4.20%
4 0.40%
1 0.10%
44 4.00%
81 7.40%
0 0.00%
20 1.80%
28 2.60%
26 2.40%
3 0.30%
26 2.40%
----- -----
1094 100.00%
1063 97.20%
nce Rate
tern Province
) Crude Rate
0.2
0.7
0.5
0.3
0.1
0
1.6
0.2
0
0.4
1.8
0.6
6.8
4.2
0.2
2.4
0.5
1.9
0.3
1.1
5.1
0.1
0.9
0.2
1.9
0.4
0.2
1.2
0.8
0.1
5.8
2
0
2.5
0.1
0
2.8
0
0.4
2.4
2.9
0.2
0.1
2.7
5
0
1.2
1.7
1.6
0.2
1.6
-----
67.9
66
67
ASR World
0.3
1.4
1
0.2
0.1
0
1.9
0.5
0
0.6
2.9
1
10.9
6.4
0.5
4.1
0.9
3.3
0.6
1.8
9.6
0.1
0.9
0.4
3.1
0.8
0.6
1.4
1.3
0.1
11.2
1.8
0
3.9
0.2
0
5.2
0
0.5
2.9
3.4
0.3
0
2.7
6.6
0
2.1
2.5
1.5
0.2
2.4
-----
104.3
101.2
68 68
Table (ASR)
ICD (10th)
C00
C01-C02
C03-C06
C07-C08
C09
C10
C11
C12-C13
C14
C15
C16
C17
C18
C19-C20
C21
C22
C23-C24
C25
C30-C31
C32
C33-C34
C37-C38
C40-C41
C43
C44
C45
C46
C47;C49
C50
C51
C52
C53
C54
C55
C56
C57
C58
C64
C65
C66
C67
C68
C69
C70-C72
C73
C74
C75
C81
C82-C85;C96
C88
C90
C91
C92-C94
C95
Other
All
Not C44
5.3.1 : Numb) Among Sau
Site
Lip
Tongue
Mouth
Salivary glands
Tonsil
Other Oropharynx
Nasopharynx
Hypopharynx
Pharynx unspec.
Oesophagus
Stomach
Small intestine
Colon
Rectum
Anus
Liver
Gallbladder etc.
Pancreas
Nose, sinuses etc.
Larynx
Trachea,Bronchus,Lu
Other Thoracic organ
Bone
Melanoma of Skin
Other Skin
Mesothelioma
Kaposi sarcoma
Connective,Soft tissue
Breast
Vulva
Vagina
Cervix Uteri
Corpus Uteri
Uterus unspec.
Ovary
Other Female Genita
Placenta
Kidney
Renal Pelvis
Ureter
Bladder
Other Urinary organ
Eye
Brain, Nervous system
Thyroid
Adrenal gland
Other Endocrine
Hodgkin disease
Non-Hodgkin lympho
Immunoproliferative
Multiple Myeloma
Lymphoid Leukaemia
Myeloid Leukaemia
Leukaemia unspec.
Other & unspecified
All sites Total
All sites but C44
ber Of Cases,di Females (
All Ages
0
8
11
0
1
0
6
3
0
4
13
3
43
18
0
18
13
4
1
0
ung 11
ns 0
2
1
21
0
0
e 4
103
1
2
2
25
0
18
al 1
1
3
0
0
7
s 0
4
m 12
67
2
0
14
oma 35
dis. 0
4
a 13
14
2
5
-----
520
499
, Relative Freper 100,000)
Asir
Total (%) Crude
0.00% 0
1.50% 0.
2.10% 1.
0.00% 0
0.20% 0.
0.00% 0
1.20% 0.
0.60% 0.
0.00% 0
0.80% 0.
2.50% 1.
0.60% 0.
8.30% 4.
3.50% 2.
0.00% 0
3.50% 2.
2.50% 1.
0.80% 0.
0.20% 0.
0.00% 0
2.10% 1.
0.00% 0
0.40% 0.
0.20% 0.
4.00% 2.
0.00% 0
0.00% 0
0.80% 0.
19.80% 11
0.20% 0.
0.40% 0.
0.40% 0.
4.80% 2.
0.00% 0
3.50% 2.
0.20% 0.
0.20% 0.
0.60% 0.
0.00% 0
0.00% 0
1.30% 0.
0.00% 0
0.80% 0.
2.30% 1.
12.90% 7.
0.40% 0.
0.00% 0
2.70% 1.
6.70% 4
0.00% 0
0.80% 0.
2.50% 1.
2.70% 1.
0.40% 0.
1.00% 0.
----- ---
100.00% 59
96.00% 57
equency, Cruby Primary
e Rate ASR World
0 0
.9 1.1
.3 1.6
0 0
.1 0.1
0 0
.7 0.8
.3 0.4
0 0
.5 0.4
.5 1.6
.3 0.4
.9 5.9
.1 2.3
0 0
.1 2.5
.5 1.8
.5 0.4
.1 0.1
0 0
.3 1.4
0 0
.2 0.2
.1 0.1
.4 2.6
0 0
0 0
.5 0.5
.8 12.6
.1 0.2
.2 0.3
.2 0.2
.9 3.7
0 0
.1 2
.1 0.1
.1 0.1
.3 0.3
0 0
0 0
.8 0.8
0 0
.5 0.5
.4 1.5
.7 7.4
.2 0.3
0 0
.6 1.6
4 5.3
0 0
.5 0.6
.5 1.7
.6 1.8
.2 0.2
.6 0.7
--- -----
9.6 66.2
7.2 63.7
ude IncidenceSite, Age Gro
All Ages Tot
2 2.
2 2.
2 2.
0 0.
0 0.
0 0.
2 2.
0 0.
0 0.
0 0.
4 5.
0 0.
10 12
3 3.
0 0.
0 0.
0 0.
2 2.
0 0.
0 0.
1 1.
0 0.
0 0.
0 0.
5 6.
0 0.
0 0.
1 1.
15 18
0 0.
1 1.
1 1.
7 8.
0 0.
3 3.
1 1.
0 0.
0 0.
0 0.
0 0.
0 0.
0 0.
1 1.
2 2.
5 6.
0 0.
0 0.
1 1.
8 10
0 0.
0 0.
0 0.
0 0.
0 0.
1 1.
----- -
80 100
75 93
e Rate (CIR) Aoups and Reg
Baha
tal (%) Crude Rate
.50% 1
.50% 1
.50% 1
.00% 0
.00% 0
.00% 0
.50% 1
.00% 0
.00% 0
.00% 0
.00% 2
.00% 0
2.50% 5.1
.80% 1.5
.00% 0
.00% 0
.00% 0
.50% 1
.00% 0
.00% 0
.20% 0.5
.00% 0
.00% 0
.00% 0
.20% 2.6
.00% 0
.00% 0
.20% 0.5
8.80% 7.7
.00% 0
.20% 0.5
.20% 0.5
.80% 3.6
.00% 0
.80% 1.5
.20% 0.5
.00% 0
.00% 0
.00% 0
.00% 0
.00% 0
.00% 0
.20% 0.5
.50% 1
.20% 2.6
.00% 0
.00% 0
.20% 0.5
0.00% 4.1
.00% 0
.00% 0
.00% 0
.00% 0
.00% 0
.20% 0.5
----- -----
0.00% 40.9
3.80% 38.3
Age-Standargions 2016
e ASR World
0.7
1.1
1.2
0
0
0
0.8
0
0
0
1.6
0
4.4
1.3
0
0
0
1.1
0
0
0.6
0
0
0
2
0
0
0.6
7
0
0.7
0.3
3.8
0
1.6
0.3
0
0
0
0
0
0
0.6
1.1
2.2
0
0
0.4
3.5
0
0
0
0
0
0.5
-----
37.5
35.5
dised Inciden
All Ages Total (%
1 0.50%
6 2.90%
12 5.80%
4 1.90%
0 0.00%
0 0.00%
0 0.00%
3 1.50%
1 0.50%
3 1.50%
4 1.90%
1 0.50%
6 2.90%
9 4.40%
1 0.50%
3 1.50%
4 1.90%
1 0.50%
0 0.00%
0 0.00%
2 1.00%
0 0.00%
2 1.00%
0 0.00%
6 2.90%
1 0.50%
0 0.00%
2 1.00%
55 26.70%
0 0.00%
0 0.00%
2 1.00%
17 8.30%
2 1.00%
3 1.50%
0 0.00%
0 0.00%
2 1.00%
0 0.00%
0 0.00%
1 0.50%
0 0.00%
0 0.00%
3 1.50%
23 11.20%
0 0.00%
0 0.00%
5 2.40%
12 5.80%
0 0.00%
0 0.00%
4 1.90%
3 1.50%
0 0.00%
2 1.00%
----- -----
206 100.00%
200 97.10%
nce Rate
Jazan
%) Crude Rate
0.2
1
2
0.7
0
0
0
0.5
0.2
0.5
0.7
0.2
1
1.5
0.2
0.5
0.7
0.2
0
0
0.3
0
0.3
0
1
0.2
0
0.3
% 9.4
0
0
0.3
2.9
0.3
0.5
0
0
0.3
0
0
0.2
0
0
0.5
% 3.9
0
0
0.9
2
0
0
0.7
0.5
0
0.3
-----
% 35
% 34
ASR World
0.2
1.3
2.6
0.8
0
0
0
0.5
0.2
0.6
0.8
0.2
1.1
2
0.2
0.5
0.8
0.2
0
0
0.4
0
0.3
0
1.4
0.2
0
0.3
10.4
0
0
0.3
3.5
0.4
0.6
0
0
0.4
0
0
0.2
0
0
0.6
4.1
0
0
0.8
2.6
0
0
0.8
0.5
0
0.4
-----
40.6
39.2
Ta(AS
IC(1
C00
C01-C0
C03-C0
C07-C0
C09
C10
C11
C12-C1
C14
C15
C16
C17
C18
C19-C2
C21
C22
C23-C2
C25
C30-C3
C32
C33-C3
C37-C3
C40-C4
C43
C44
C45
C46
C47;C4
C50
C51
C52
C53
C54
C55
C56
C57
C58
C64
C65
C66
C67
C68
C69
C70-C7
C73
C74
C75
C81
C82-C8
C88
C90
C91
C92-C9
C95
Other
All
Not C4
ble 5.3.2 : NuSR) Among S
CD 0th)
Lip
02 Tongue
06 Mouth
08 Salivary g
Tonsil
Other Oro
Nasophary
13 Hypophar
Pharynx u
Oesophagu
Stomach
Small inte
Colon
20 Rectum
Anus
Liver
24 Gallbladd
Pancreas
31 Nose, sinu
Larynx
34 Trachea,B
38 Other Tho
41 Bone
Melanoma
Other Skin
Mesothelio
Kaposi sar
49 Connectiv
Breast
Vulva
Vagina
Cervix Ute
Corpus Ut
Uterus un
Ovary
Other Fem
Placenta
Kidney
Renal Pelv
Ureter
Bladder
Other Uri
Eye
72 Brain, Ner
Thyroid
Adrenal gl
Other End
Hodgkin d
85;C96 Non-Hodg
Immunopr
Multiple M
Lymphoid
94 Myeloid L
Leukaemi
Other & u
All sites T
44 All sites bu
umber Of CaSaudi Female
Site
glands
opharynx
ynx
rynx
unspec.
us
stine
er etc.
uses etc.
Bronchus,Lung
oracic organs
a of Skin
n
oma
rcoma
ve,Soft tissue
eri
teri
spec.
male Genital
vis
nary organs
rvous system
land
docrine
disease
gkin lymphoma
roliferative dis.
Myeloma
d Leukaemia
Leukaemia
a unspec.
unspecified
otal
ut C44
ses, Relative es ( per 100,0
M
All Ages Total (%
0 0.00%
2 0.60%
1 0.30%
0 0.00%
0 0.00%
0 0.00%
5 1.50%
2 0.60%
0 0.00%
5 1.50%
3 0.90%
2 0.60%
17 5.20%
14 4.30%
1 0.30%
8 2.40%
4 1.20%
2 0.60%
0 0.00%
0 0.00%
3 0.90%
1 0.30%
5 1.50%
3 0.90%
6 1.80%
0 0.00%
0 0.00%
2 0.60%
92 28.00%
0 0.00%
0 0.00%
8 2.40%
25 7.60%
3 0.90%
10 3.00%
0 0.00%
1 0.30%
7 2.10%
0 0.00%
0 0.00%
2 0.60%
0 0.00%
2 0.60%
15 4.60%
24 7.30%
3 0.90%
1 0.30%
10 3.00%
17 5.20%
0 0.00%
2 0.60%
3 0.90%
10 3.00%
1 0.30%
6 1.80%
----- -----
328 100.00
322 98.20%
Frequency, C00) by Prima
Madinah
%) Crude Rate
% 0
% 0.3
% 0.1
% 0
% 0
% 0
% 0.7
% 0.3
% 0
% 0.7
% 0.4
% 0.3
% 2.5
% 2.1
% 0.1
% 1.2
% 0.6
% 0.3
% 0
% 0
% 0.4
% 0.1
% 0.7
% 0.4
% 0.9
% 0
% 0
% 0.3
% 13.6
% 0
% 0
% 1.2
% 3.7
% 0.4
% 1.5
% 0
% 0.1
% 1
% 0
% 0
% 0.3
% 0
% 0.3
% 2.2
% 3.6
% 0.4
% 0.1
% 1.5
% 2.5
% 0
% 0.3
% 0.4
% 1.5
% 0.1
% 0.9
-----
% 48.5
% 47.6
Crude Incideary Site, Age
ASR World
All Ages
0 0
0.5 0
0.2 0
0 1
0 0
0 0
0.9 1
0.5 0
0 0
1.2 0
0.6 3
0.4 1
3.5 13
2.9 10
0.2 0
1.5 1
0.9 3
0.3 2
0 0
0 0
0.5 2
0.1 0
0.7 2
0.4 0
1 2
0 0
0 0
0.3 0
15.9 46
0 0
0 0
1.7 0
5.2 10
0.6 2
1.9 4
0 0
0.1 0
1.8 3
0 0
0 0
0.4 2
0 0
0.3 0
2.5 3
3.7 24
0.5 0
0.2 0
1.5 8
3.8 3
0 0
0.4 0
0.4 0
1.7 2
0.1 0
1.4 3
----- -----
60.6 151
59.6 149
nce Rate (CIGroups and
Hail
Total (%) CR
0.00%
0.00%
0.00%
0.70%
0.00%
0.00%
0.70%
0.00%
0.00%
0.00%
2.00%
0.70%
8.60%
6.60%
0.00%
0.70%
2.00%
1.30%
0.00%
0.00%
1.30%
0.00%
1.30%
0.00%
1.30%
0.00%
0.00%
0.00%
30.50% 1
0.00%
0.00%
0.00%
6.60%
1.30%
2.60%
0.00%
0.00%
2.00%
0.00%
0.00%
1.30%
0.00%
0.00%
2.00%
15.90%
0.00%
0.00%
5.30%
2.00%
0.00%
0.00%
0.00%
1.30%
0.00%
2.00%
-----
100.00% 5
98.70% 5
IR) Age-StandRegions 2016
Crude Rate
ASR World
0 0
0 0
0 0
0.4 0.4
0 0
0 0
0.4 0.3
0 0
0 0
0 0
1.1 1.5
0.4 0.6
4.9 5.6
3.7 4.6
0 0
0.4 0.5
1.1 1.8
0.7 0.8
0 0
0 0
0.7 1
0 0
0.7 0.8
0 0
0.7 0.8
0 0
0 0
0 0
17.2 19
0 0
0 0
0 0
3.7 4.8
0.7 0.9
1.5 1.8
0 0
0 0
1.1 1.5
0 0
0 0
0.7 0.9
0 0
0 0
1.1 1.2
9 9.6
0 0
0 0
3 2.6
1.1 1.2
0 0
0 0
0 0
0.7 0.9
0 0
1.1 1.4
----- -----
56.4 64.6
55.6 63.8
dardised Inci6
Q
All Ages Total (%
1 0.30%
0 0.00%
1 0.30%
3 0.90%
0 0.00%
0 0.00%
7 2.10%
0 0.00%
0 0.00%
2 0.60%
3 0.90%
0 0.00%
22 6.70%
9 2.70%
0 0.00%
4 1.20%
3 0.90%
5 1.50%
0 0.00%
0 0.00%
3 0.90%
1 0.30%
4 1.20%
1 0.30%
4 1.20%
0 0.00%
0 0.00%
5 1.50%
131 39.70%
0 0.00%
1 0.30%
4 1.20%
22 6.70%
2 0.60%
6 1.80%
0 0.00%
0 0.00%
5 1.50%
0 0.00%
0 0.00%
1 0.30%
0 0.00%
2 0.60%
5 1.50%
24 7.30%
1 0.30%
0 0.00%
19 5.80%
18 5.50%
0 0.00%
0 0.00%
1 0.30%
2 0.60%
0 0.00%
8 2.40%
----- -----
330 100.00%
326 98.80%
idence Rate
Qassim
%) Crude Rate
% 0.2
% 0
% 0.2
% 0.6
% 0
% 0
% 1.4
% 0
% 0
% 0.4
% 0.6
% 0
% 4.5
% 1.8
% 0
% 0.8
% 0.6
% 1
% 0
% 0
% 0.6
% 0.2
% 0.8
% 0.2
% 0.8
% 0
% 0
% 1
% 26.7
% 0
% 0.2
% 0.8
% 4.5
% 0.4
% 1.2
% 0
% 0
% 1
% 0
% 0
% 0.2
% 0
% 0.4
% 1
% 4.9
% 0.2
% 0
% 3.9
% 3.7
% 0
% 0
% 0.2
% 0.4
% 0
% 1.6
-----
% 67.2
% 66.4
69
ASR World
0.3
0
0.2
0.7
0
0
1.5
0
0
0.6
0.7
0
6.2
2.4
0
1.2
0.9
1.5
0
0
1
0.4
0.8
0.3
0.9
0
0
1.1
31.7
0
0.2
0.8
6.1
0.4
1.2
0
0
1.1
0
0
0.2
0
0.4
1.1
5.5
0.2
0
3.9
4.5
0
0
0.2
0.5
0
2
-----
80.8
79.9
70 70
Table (ASR)
ICD (10th)
C00
C01-C02
C03-C06
C07-C08
C09
C10
C11
C12-C13
C14
C15
C16
C17
C18
C19-C20
C21
C22
C23-C24
C25
C30-C31
C32
C33-C34
C37-C38
C40-C41
C43
C44
C45
C46
C47;C49
C50
C51
C52
C53
C54
C55
C56
C57
C58
C64
C65
C66
C67
C68
C69
C70-C72
C73
C74
C75
C81
C82-C85;C96
C88
C90
C91
C92-C94
C95
Other
All
Not C44
5.3.3 : Numb) Among Sau
Site
Lip
Tongue
Mouth
Salivary glands
Tonsil
Other Oropharynx
Nasopharynx
Hypopharynx
Pharynx unspec.
Oesophagus
Stomach
Small intestine
Colon
Rectum
Anus
Liver
Gallbladder etc.
Pancreas
Nose, sinuses etc.
Larynx
Trachea,Bronchus,Lu
Other Thoracic organ
Bone
Melanoma of Skin
Other Skin
Mesothelioma
Kaposi sarcoma
Connective,Soft tissue
Breast
Vulva
Vagina
Cervix Uteri
Corpus Uteri
Uterus unspec.
Ovary
Other Female Genital
Placenta
Kidney
Renal Pelvis
Ureter
Bladder
Other Urinary organs
Eye
Brain, Nervous system
Thyroid
Adrenal gland
Other Endocrine
Hodgkin disease
Non-Hodgkin lympho
Immunoproliferative
Multiple Myeloma
Lymphoid Leukaemia
Myeloid Leukaemia
Leukaemia unspec.
Other & unspecified
All sites Total
All sites but C44
ber Of Cases,di Females (
All Ages
T
0
0
0
1
0
0
2
0
0
1
1
1
6
0
0
3
2
3
1
0
ung 0
ns 0
2
1
5
0
1
e 0
31
0
0
1
4
1
7
l 0
0
2
0
0
1
s 0
0
m 1
18
0
0
9
oma 5
dis. 0
1
a 3
4
0
4
-----
122 1
117
, Relative Freper 100,000)
Najran
Total (%) Crude Rate
0.00% 0
0.00% 0
0.00% 0
0.80% 0.5
0.00% 0
0.00% 0
1.60% 0.9
0.00% 0
0.00% 0
0.80% 0.5
0.80% 0.5
0.80% 0.5
4.90% 2.8
0.00% 0
0.00% 0
2.50% 1.4
1.60% 0.9
2.50% 1.4
0.80% 0.5
0.00% 0
0.00% 0
0.00% 0
1.60% 0.9
0.80% 0.5
4.10% 2.3
0.00% 0
0.80% 0.5
0.00% 0
25.40% 14.5
0.00% 0
0.00% 0
0.80% 0.5
3.30% 1.9
0.80% 0.5
5.70% 3.3
0.00% 0
0.00% 0
1.60% 0.9
0.00% 0
0.00% 0
0.80% 0.5
0.00% 0
0.00% 0
0.80% 0.5
14.80% 8.4
0.00% 0
0.00% 0
7.40% 4.2
4.10% 2.3
0.00% 0
0.80% 0.5
2.50% 1.4
3.30% 1.9
0.00% 0
3.30% 1.9
----- -----
100.00% 56.9
95.90% 54.6
equency, Cruby Primary
ASR World
All Ages
0 0
0 0
0 0
0.5 0
0 0
0 0
1.5 2
0 0
0 0
0.7 0
0.8 3
0.7 2
3.6 5
0 5
0 1
2 1
1.4 1
2.5 0
0.8 0
0 0
0 3
0 0
0.8 3
0.8 0
3.3 8
0 1
0.8 0
0 2
17.4 31
0 0
0 0
0.5 0
2.7 3
0.6 1
3.9 7
0 0
0 0
1.5 4
0 0
0 0
0.7 0
0 0
0 1
0.4 1
9.9 16
0 0
0 0
3.9 3
3.4 5
0 0
0.4 0
1.6 3
2.1 6
0 0
2.6 6
----- -----
71.7 124
68.5 116
ude IncidenceSite, Age Gro
Jouf
Total (%) Crude Rate
0.00% 0
0.00% 0
0.00% 0
0.00% 0
0.00% 0
0.00% 0
1.60% 1.1
0.00% 0
0.00% 0
0.00% 0
2.40% 1.6
1.60% 1.1
4.00% 2.7
4.00% 2.7
0.80% 0.5
0.80% 0.5
0.80% 0.5
0.00% 0
0.00% 0
0.00% 0
2.40% 1.6
0.00% 0
2.40% 1.6
0.00% 0
6.50% 4.3
0.80% 0.5
0.00% 0
1.60% 1.1
25.00% 16.8
0.00% 0
0.00% 0
0.00% 0
2.40% 1.6
0.80% 0.5
5.60% 3.8
0.00% 0
0.00% 0
3.20% 2.2
0.00% 0
0.00% 0
0.00% 0
0.00% 0
0.80% 0.5
0.80% 0.5
12.90% 8.7
0.00% 0
0.00% 0
2.40% 1.6
4.00% 2.7
0.00% 0
0.00% 0
2.40% 1.6
4.80% 3.3
0.00% 0
4.80% 3.3
----- -----
100.00% 67.2
93.50% 62.9
e Rate (CIR) Aoups and Reg
ASR World
All Ages
0 0
0 1
0 2
0 1
0 0
0 0
2.1 2
0 0
0 0
0 3
2 3
1.5 2
4.6 13
4.6 2
0.7 0
0.5 2
1.1 5
0 2
0 0
0 0
2.3 7
0 1
1.5 0
0 0
7.3 5
1.1 0
0 0
1.2 3
25 50
0 0
0 0
0 2
3.1 7
1.1 1
4.9 1
0 0
0 1
2.5 5
0 0
0 0
0 2
0 0
0.5 1
0.9 5
9.8 41
0 1
0 0
1.5 9
4.1 8
0 0
0 1
2.2 4
3.5 5
0 1
6 1
----- -----
95.5 200
88.3 195
Age-Standargions 2016.
Tabuk
Total (%) CrudRat
0.00% 0
0.50% 0.3
1.00% 0.6
0.50% 0.3
0.00% 0
0.00% 0
1.00% 0.6
0.00% 0
0.00% 0
1.50% 0.9
1.50% 0.9
1.00% 0.6
6.50% 3.8
1.00% 0.6
0.00% 0
1.00% 0.6
2.50% 1.4
1.00% 0.6
0.00% 0
0.00% 0
3.50% 2
0.50% 0.3
0.00% 0
0.00% 0
2.50% 1.4
0.00% 0
0.00% 0
1.50% 0.9
25.00% 14.4
0.00% 0
0.00% 0
1.00% 0.6
3.50% 2
0.50% 0.3
0.50% 0.3
0.00% 0
0.50% 0.3
2.50% 1.4
0.00% 0
0.00% 0
1.00% 0.6
0.00% 0
0.50% 0.3
2.50% 1.4
20.50% 11.8
0.50% 0.3
0.00% 0
4.50% 2.6
4.00% 2.3
0.00% 0
0.50% 0.3
2.00% 1.2
2.50% 1.4
0.50% 0.3
0.50% 0.3
----- -----
100.00% 57.7
97.50% 56.3
dized Inciden
de e
ASR World
All Ages
0 0
3 0.8 0
6 0.7 0
3 0.2 1
0 0
0 0
6 0.9 0
0 0
0 0
9 1.9 1
9 1.3 0
6 1 0
8 5.6 7
6 0.6 1
0 0
6 0.6 0
4 2.5 0
6 1.2 1
0 0
0 1
4.1 3
3 0.4 0
0 0
0 0
4 2.5 5
0 0
0 0
9 0.8 1
4 19.8 11
0 0
0 0
6 1 1
3.3 1
3 0.3 1
3 0.8 3
0 1
3 0.2 0
4 2.3 0
0 0
0 0
6 0.8 1
0 0
3 0.3 0
4 1.7 1
8 12.9 8
3 0.3 0
0 0
6 2.2 1
3 3.3 3
0 0
3 0.4 0
2 1.1 1
4 1.7 3
3 0.2 0
3 0.2 1
- ----- ----
7 78.1 58
3 75.5 53
nce Rate
Northern Reg
Total (%) CrudRat
0.00% 0
0.00% 0
0.00% 0
1.70% 0.7
0.00% 0
0.00% 0
0.00% 0
0.00% 0
0.00% 0
1.70% 0.7
0.00% 0
0.00% 0
12.10% 4.9
1.70% 0.7
0.00% 0
0.00% 0
0.00% 0
1.70% 0.7
0.00% 0
1.70% 0.7
5.20% 2.1
0.00% 0
0.00% 0
0.00% 0
8.60% 3.5
0.00% 0
0.00% 0
1.70% 0.7
19.00% 7.7
0.00% 0
0.00% 0
1.70% 0.7
1.70% 0.7
1.70% 0.7
5.20% 2.1
1.70% 0.7
0.00% 0
0.00% 0
0.00% 0
0.00% 0
1.70% 0.7
0.00% 0
0.00% 0
1.70% 0.7
13.80% 5.6
0.00% 0
0.00% 0
1.70% 0.7
5.20% 2.1
0.00% 0
0.00% 0
1.70% 0.7
5.20% 2.1
0.00% 0
1.70% 0.7
----- ----
100.00% 40.7
91.40% 37.2
ion de te
ASR World
0
0
0
7 0
0
0
0
0
0
7 0.7
0
0
9 6.8
7 1.4
0
0
0
7 1.4
0
7 0.9
1 4
0
0
0
5 4.4
0
0
7 0.5
7 9.4
0
0
7 1
7 1.2
7 0.9
1 3.4
7 1
0
0
0
0
7 1.1
0
0
7 0.6
6 5.7
0
0
7 1.1
1 2.8
0
0
7 0.8
1 2.1
0
7 1.1
- -----
7 53.8
2 49.5
Tabl(ASR
ICD (1
C00
C01-C02
C03-C06
C07-C08
C09
C10
C11
C12-C13
C14
C15
C16
C17
C18
C19-C20
C21
C22
C23-C24
C25
C30-C31
C32
C33-C34
C37-C38
C40-C41
C43
C44
C45
C46
C47;C49
C50
C51
C52
C53
C54
C55
C56
C57
C58
C64
C65
C66
C67
C68
C69
C70-C72
C73
C74
C75
C81
C82-C85;C
C88
C90
C91
C92-C94
C95
Other
All
Not C44
le 5.3.4 : NumR) Among Sa
10th) Si
Lip
Tongue
Mouth
Salivary glan
Tonsil
Other Oroph
Nasopharynx
Hypopharyn
Pharynx uns
Oesophagus
Stomach
Small intestin
Colon
Rectum
Anus
Liver
Gallbladder
Pancreas
Nose, sinuses
Larynx
Trachea,Bro
Other Thora
Bone
Melanoma of
Other Skin
Mesotheliom
Kaposi sarco
Connective,S
Breast
Vulva
Vagina
Cervix Uteri
Corpus Uter
Uterus unspe
Ovary
Other Femal
Placenta
Kidney
Renal Pelvis
Ureter
Bladder
Other Urinar
Eye
Brain, Nervo
Thyroid
Adrenal glan
Other Endoc
Hodgkin dise
C96 Non-Hodgkin
Immunoprol
Multiple My
Lymphoid L
Myeloid Leu
Leukaemia u
Other & uns
All sites Tota
All sites but C
mber Of Caseaudi Females
ite All Ag
1
7
10
nds 8
0
harynx 1
x 15
nx 2
spec. 0
8
29
ne 9
126
79
1
43
etc. 42
32
s etc. 0
4
onchus,Lung 48
acic organs 5
12
f Skin 11
31
ma 3
oma 1
Soft tissue 21
563
5
1
27
i 129
ec. 15
68
le Genital 6
1
42
1
0
15
ry organs 2
2
ous system 53
341
nd 8
crine 1
ease 57
n lymphoma 95
liferative dis. 0
yeloma 17
eukaemia 24
ukaemia 35
unspec. 2
pecified 34
-----
al 2093
C44 2062
es, Relative F( per 100,000
Riya
es Total (%) C
0.00%
0.30%
0.50%
0.40%
0.00%
0.00%
0.70%
0.10%
0.00%
0.40%
1.40%
0.40%
6.00%
3.80%
0.00%
2.10%
2.00%
1.50%
0.00%
0.20%
2.30%
0.20%
0.60%
0.50%
1.50%
0.10%
0.00%
1.00%
26.90%
0.20%
0.00%
1.30%
6.20%
0.70%
3.20%
0.30%
0.00%
2.00%
0.00%
0.00%
0.70%
0.10%
0.10%
2.50%
16.30%
0.40%
0.00%
2.70%
4.50%
0.00%
0.80%
1.10%
1.70%
0.10%
1.60%
-----
100.00%
2 98.50%
requency, Cr0) by Primary
adh
Crude Rate ASR Wo
0 0.1
0.3 0.5
0.5 0.9
0.4 0.4
0 0
0 0.1
0.7 0.8
0.1 0.2
0 0
0.4 0.5
1.3 2.1
0.4 0.6
5.7 9
3.6 5
0 0.1
1.9 3.7
1.9 3.5
1.4 2.7
0 0
0.2 0.3
2.2 3.4
0.2 0.4
0.5 0.6
0.5 0.7
1.4 1.9
0.1 0.1
0 0.1
0.9 1.2
25.5 33.8
0.2 0.4
0 0
1.2 1.5
5.8 10.6
0.7 1
3.1 4.2
0.3 0.3
0 0
1.9 2.6
0 0.1
0 0
0.7 1.1
0.1 0.2
0.1 0.1
2.4 2.9
15.4 16.6
0.4 0.4
0 0
2.6 2.5
4.3 6.3
0 0
0.8 1.3
1.1 1.3
1.6 1.7
0.1 0.1
1.5 2.5
----- -----
94.6 130.1
93.2 128.2
rude Incidency Site, Age.
orld All Ages T
1
16
10
7
1
1
14
3
0
16
23
3
100
48
3
24
17
23
2
2
27
1
15
3
36
1
2
17
578
1
1
34
115
3
53
6
0
37
1
0
11
0
1
32
135
2
2
46
97
0
11
26
41
4
20
-----
1 1673 1
2 1637
ce Rate (CIR
Makkah
Total (%) Crude Rat
0.10% 0
1.00% 0.7
0.60% 0.5
0.40% 0.3
0.10% 0
0.10% 0
0.80% 0.6
0.20% 0.1
0.00% 0
1.00% 0.7
1.40% 1
0.20% 0.1
6.00% 4.6
2.90% 2.2
0.20% 0.1
1.40% 1.1
1.00% 0.8
1.40% 1
0.10% 0.1
0.10% 0.1
1.60% 1.2
0.10% 0
0.90% 0.7
0.20% 0.1
2.20% 1.6
0.10% 0
0.10% 0.1
1.00% 0.8
34.50% 26.3
0.10% 0
0.10% 0
2.00% 1.5
6.90% 5.2
0.20% 0.1
3.20% 2.4
0.40% 0.3
0.00% 0
2.20% 1.7
0.10% 0
0.00% 0
0.70% 0.5
0.00% 0
0.10% 0
1.90% 1.5
8.10% 6.2
0.10% 0.1
0.10% 0.1
2.70% 2.1
5.80% 4.4
0.00% 0
0.70% 0.5
1.60% 1.2
2.50% 1.9
0.20% 0.2
1.20% 0.9
----- -----
100.00% 76.2
97.80% 74.6
R) Age-Standa
te ASR World
0
0.9
0.6
0.4
0.1
0
0.6
0.2
0
0.9
1.2
0.2
5.7
2.7
0.2
1.5
1
1.4
0.1
0.1
1.4
0.1
0.6
0.2
2
0
0.1
0.8
29.7
0
0
1.8
6.7
0.2
3
0.4
0
2
0.1
0
0.6
0
0.1
1.6
5.9
0.1
0.1
2.1
5.2
0
0.6
1.3
1.9
0.2
1.2
-----
87.7
85.7
ardised Incid
Easte
All Ages Total (%
0 0.00%
5 0.30%
11 0.80%
3 0.20%
0 0.00%
0 0.00%
3 0.20%
1 0.10%
0 0.00%
6 0.40%
22 1.50%
8 0.60%
77 5.30%
59 4.10%
4 0.30%
19 1.30%
18 1.20%
26 1.80%
1 0.10%
0 0.00%
37 2.60%
1 0.10%
6 0.40%
5 0.30%
32 2.20%
1 0.10%
0 0.00%
12 0.80%
526 36.40%
2 0.10%
2 0.10%
29 2.00%
87 6.00%
9 0.60%
35 2.40%
3 0.20%
0 0.00%
28 1.90%
0 0.00%
0 0.00%
16 1.10%
0 0.00%
2 0.10%
20 1.40%
127 8.80%
2 0.10%
2 0.10%
45 3.10%
65 4.50%
0 0.00%
11 0.80%
23 1.60%
33 2.30%
3 0.20%
18 1.20%
----- -----
1445 100.00%
1413 97.80%
ence Rate
ern Province
%) Crude Rate
0
0.3
0.7
0.2
0
0
0.2
0.1
0
0.4
1.5
0.5
5.2
4
0.3
1.3
1.2
1.8
0.1
0
2.5
0.1
0.4
0.3
2.2
0.1
0
0.8
35.4
0.1
0.1
2
5.9
0.6
2.4
0.2
0
1.9
0
0
1.1
0
0.1
1.3
8.6
0.1
0.1
3
4.4
0
0.7
1.5
2.2
0.2
1.2
-----
% 97.3
95.2
71
ASR World
0
0.4
1
0.3
0
0
0.3
0.2
0
0.6
2.1
0.7
7.9
5.7
0.5
2.1
2.2
2.8
0.1
0
3.7
0.1
0.4
0.5
2.7
0.1
0
0.9
46.7
0.2
0.2
2.7
9.1
0.9
3.1
0.3
0
2.5
0
0
1.8
0
0.1
1.6
9.6
0.1
0.1
3
6.4
0
0.9
2
2.6
0.3
1.7
-----
131.3
128.6
72 72
Tabl
ICD (10t
C00
C01-C02
C03-C06
C07-C08
C09
C10
C11
C12-C13
C14
C15
C16
C17
C18
C19-C20
C21
C22
C23-C24
C25
C30-C31
C32
C33-C34
C37-C38
C40-C41
C43
C44
C45
C46
C47;C49
C50
C60
C61
C62
C63
C64
C65
C66
C67
C68
C69
C70-C72
C73
C74
C75
C81
C82-C85;C
C88
C90
C91
C92-C94
C95
Other
All
Not C44
le 5.4.1 : Num
th) Site
Lip
Tongue
Mouth
Salivary glands
Tonsil
Other Oropharyn
Nasopharynx
Hypopharynx
Pharynx unspec.
Oesophagus
Stomach
Small intestine
Colon
Rectum
Anus
Liver
Gallbladder etc.
Pancreas
Nose, sinuses etc.
Larynx
Trachea,Bronchu
Other Thoracic o
Bone
Melanoma of Ski
Other Skin
Mesothelioma
Kaposi sarcoma
Connective,Soft t
Breast
Penis
Prostate
Testis
Other male genit
Kidney
Renal Pelvis
Ureter
Bladder
Other Urinary or
Eye
Brain, Nervous sy
Thyroid
Adrenal gland
Other Endocrine
Hodgkin disease
C96 Non-Hodgkin lym
Immunoprolifera
Multiple Myelom
Lymphoid Leuka
Myeloid Leukaem
Leukaemia unspe
Other & unspecif
All sites Total
All sites but C44
mber Of Case
All Ages
4
33
24
8
2
nx 1
32
0
1
25
73
18
173
126
10
42
11
33
11
28
us,Lung 124
organs 9
31
in 11
135
5
5
tissue 33
20
2
144
29
al 0
89
2
2
92
rgans 2
3
ystem 73
68
5
1
43
mphoma 133
ative dis. 0
ma 15
aemia 39
mia 42
ec. 3
fied 57
-----
1872
1737
es Among Non
Age unk 0-4 5
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 2
0 0
0 0
0 1
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
1 0
0 0
0 2
0 8
0 0
0 0
0 0
0 1
0 3
0 0
0 0
0 4
0 2
0 0
0 0
----- ----- --
1 23 2
1 21 2
n-Saudi Male
5-9 10-14 15-19
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 1 1
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 1 0
0 0 0
0 1 1
0 0 0
2 9 1
0 0 0
0 0 1
0 0 1
0 0 0
2 0 1
0 0 0
0 0 0
0 0 0
0 0 1
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
2 2 2
0 0 0
0 0 0
0 0 0
2 5 5
4 6 5
0 0 0
0 0 0
6 3 3
2 1 0
0 0 1
0 0 0
---- ----- -----
20 29 23
20 29 22
es by Primar
20-24 25-29 3
0 0
1 1
0 1
0 1
0 0
0 0
3 2
0 0
0 0
1 0
0 1
0 0
2 2
0 1
0 0
0 0
0 0
0 0
1 0
0 0
0 1
1 4
5 2
0 1
1 4
0 0
0 0
1 3
1 1
0 0
0 0
4 6
0 0
0 1
0 0
0 0
0 5
0 0
0 0
6 6
1 6
0 0
0 0
2 7
4 7
0 0
0 0
0 3
3 1
0 0
1 1
----- -----
38 68
37 64
y Site And A
30-34 35-39 40-44
1 0 2
1 5 4
2 2 1
3 0 0
0 0 0
0 0 0
4 3 2
0 0 0
0 0 0
1 1 5
3 6 8
1 0 3
5 16 14
7 7 14
1 1 0
1 1 2
0 0 2
0 1 5
1 0 0
0 0 2
4 2 4
1 1 0
0 1 4
1 1 3
7 5 8
0 0 0
0 1 2
5 2 4
0 1 1
0 2 0
0 1 1
6 5 2
0 0 0
3 4 8
0 0 1
0 0 0
2 5 2
0 0 0
1 0 0
7 10 6
12 10 5
1 1 0
1 0 0
8 3 3
10 10 13
0 0 0
0 1 1
1 3 3
2 7 4
0 1 0
6 3 4
----- ----- -----
109 123 143
102 118 135
Age Groups, 2
4 45-49 50-54
0 0
6 6
6 3
2 0
0 1
0 0
3 5
0 0
0 1
2 3
9 10
3 3
19 24
18 21
0 1
3 5
2 1
7 5
5 0
2 3
12 10
1 0
1 1
0 3
10 16
2 1
0 0
3 2
6 3
0 0
1 7
1 2
0 0
14 15
0 0
0 0
3 12
0 0
0 0
3 8
7 9
1 0
0 0
3 1
16 13
0 0
1 2
2 1
3 4
1 0
6 8
- ----- -----
184 210
174 194
2016.
55-59 60-64 65
0 0 0
2 4 0
3 2 0
2 0 0
0 1 0
0 1 0
3 4
0 0 0
0 0 0
3 3 3
14 7 6
3 3 0
21 27 2
19 11 1
1 2 3
6 13 3
1 2 2
8 3 2
2 0
5 6 6
22 22 2
1 0 0
1 4 0
0 2 0
29 15 1
0 0
0 0 2
4 3 2
5 1 0
0 0 0
27 30 3
0 2 0
0 0 0
17 12 5
0 1 0
0 0
13 16 1
0 0 0
0 0 0
6 4
6 5 2
1 1 0
0 0 0
0 2 0
11 12 9
0 0 0
5 2 2
4 0 2
2 8 0
0 0 0
16 6 3
----- ----- --
263 237 17
234 222 16
-69 70-74 75+
0 0 1
0 1 2
0 1 3
0 0 0
0 0 0
0 0 0
1 0 0
0 0 0
0 0 0
3 1 2
6 2 7
0 1 1
21 10 12
17 6 5
3 1 0
3 4 4
2 1 0
2 1 1
1 0 0
6 2 2
21 10 14
0 0 0
0 0 0
0 0 0
11 9 17
1 0 0
2 0 0
2 0 0
0 1 0
0 0 0
33 22 22
0 0 0
0 0 0
5 4 6
0 0 0
1 1 0
13 6 14
0 1 1
0 0 0
1 1 1
2 0 5
0 0 0
0 0 0
0 1 0
9 3 7
0 0 0
2 0 1
2 2 2
0 0 3
0 0 0
3 1 2
--- ----- -----
73 93 135
62 84 118
Total (%)
0.20%
1.80%
1.30%
0.40%
0.10%
0.10%
1.70%
0.00%
0.10%
1.30%
3.90%
1.00%
9.20%
6.70%
0.50%
2.20%
0.60%
1.80%
0.60%
1.50%
6.60%
0.50%
1.70%
0.60%
7.20%
0.30%
0.30%
1.80%
1.10%
0.10%
7.70%
1.50%
0.00%
4.80%
0.10%
0.10%
4.90%
0.10%
0.20%
3.90%
3.60%
0.30%
0.10%
2.30%
7.10%
0.00%
0.80%
2.10%
2.20%
0.20%
3.00%
-----
100.00%
92.80%
Tabl
ICD (10t
C00
C01-C02
C03-C06
C07-C08
C09
C10
C11
C12-C13
C14
C15
C16
C17
C18
C19-C20
C21
C22
C23-C24
C25
C30-C31
C32
C33-C34
C37-C38
C40-C41
C43
C44
C45
C46
C47;C49
C50
C51
C52
C53
C54
C55
C56
C57
C58
C64
C65
C66
C67
C68
C69
C70-C72
C73
C74
C75
C81
C82-C85;C
C88
C90
C91
C92-C94
C95
Other
All
Not C44
le 5.4.2 : Num
th) Site
Lip
Tongue
Mouth
Salivary glands
Tonsil
Other Oropharyn
Nasopharynx
Hypopharynx
Pharynx unspec.
Oesophagus
Stomach
Small intestine
Colon
Rectum
Anus
Liver
Gallbladder etc.
Pancreas
Nose, sinuses etc.
Larynx
Trachea,Bronchu
Other Thoracic o
Bone
Melanoma of Ski
Other Skin
Mesothelioma
Kaposi sarcoma
Connective,Soft t
Breast
Vulva
Vagina
Cervix Uteri
Corpus Uteri
Uterus unspec.
Ovary
Other Female Ge
Placenta
Kidney
Renal Pelvis
Ureter
Bladder
Other Urinary or
Eye
Brain, Nervous sy
Thyroid
Adrenal gland
Other Endocrine
Hodgkin disease
C96 Non-Hodgkin lym
Immunoprolifera
Multiple Myelom
Lymphoid Leuka
Myeloid Leukaem
Leukaemia unspe
Other & unspecif
All sites Total
All sites but C44
mber Of Case
All Ages
1
11
12
2
0
nx 0
8
1
0
6
39
8
83
39
7
15
16
22
2
2
us,Lung 33
organs 2
13
in 4
36
0
0
tissue 27
787
3
1
51
78
13
77
enital 3
1
26
1
0
18
rgans 0
4
ystem 31
146
2
0
31
mphoma 65
ative dis. 0
ma 10
aemia 22
mia 22
ec. 5
fied 40
-----
1826
1790
es Among Non
Age unk 0-4 5
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 1
0 0
0 0
0 0
0 0
0 0
0 5
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 3
0 2
0 0
0 1
0 0
1 1
0 1
0 0
0 0
0 5
0 0
0 0
0 4
----- ----- --
1 23 1
1 23 1
n-Saudi Fem
5-9 10-14 15-19
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 1
0 0 0
0 0 0
1 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 1
0 0 0
1 2 1
0 0 0
0 1 0
0 0 0
0 0 0
2 2 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 1 3
0 0 0
0 0 1
2 0 0
0 0 0
0 0 0
0 0 0
0 0 0
1 0 0
4 2 3
0 0 1
0 0 0
0 0 0
0 1 0
0 0 6
0 0 0
0 0 0
5 4 0
1 3 1
0 1 1
0 0 0
---- ----- -----
17 17 19
17 16 19
males by Prim
20-24 25-29 3
0 0
0 2
0 0
0 0
0 0
0 0
1 1
0 0
0 0
0 0
2 2
0 0
1 0
1 0
0 0
0 1
0 0
0 0
0 1
0 0
0 3
0 0
2 1
0 0
0 3
0 0
0 0
1 1
2 31
0 0
0 0
0 3
1 1
0 0
3 4
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
1 4
6 16
0 0
0 0
3 7
3 3
0 0
0 0
0 0
0 3
0 0
0 1
----- -----
27 88
27 85
ary Site And
30-34 35-39 40-44
1 0 0
1 1 1
0 0 1
0 0 0
0 0 0
0 0 0
1 1 0
0 0 0
0 0 0
0 0 0
2 2 7
2 0 2
2 7 9
1 7 4
0 0 1
0 1 1
1 0 0
2 2 2
0 0 0
0 0 0
1 1 2
0 0 0
2 0 0
0 0 0
2 3 0
0 0 0
0 0 0
4 1 1
53 102 123
0 0 0
0 0 0
4 11 5
3 3 6
0 0 2
6 2 9
0 0 0
0 0 0
2 2 3
0 0 0
0 0 0
1 1 0
0 0 0
0 0 0
1 0 5
27 21 22
0 1 0
0 0 0
6 5 1
11 2 3
0 0 0
0 1 0
1 1 0
1 3 1
0 0 1
2 1 1
----- ----- -----
140 182 213
138 179 213
Age Groups
4 45-49 50-54
0 0
0 1
2 0
0 1
0 0
0 0
1 1
0 1
0 0
1 1
3 6
0 1
6 14
2 4
1 1
1 1
3 0
0 3
0 0
1 1
3 7
1 0
0 0
0 1
3 3
0 0
0 0
2 1
130 116
1 1
0 0
6 5
9 14
4 2
9 6
1 2
0 0
4 3
0 0
0 0
0 3
0 0
0 0
1 2
18 11
0 0
0 0
2 0
5 8
0 0
0 2
0 1
4 2
0 0
5 11
- ----- -----
229 237
226 234
s, 2016.
55-59 60-64 65
0 0 0
1 1
0 2 3
0 1 0
0 0 0
0 0 0
0 2 0
0 0 0
0 0 0
1 0 3
3 1 5
0 1
10 7 1
8 4 3
3 0 0
2 1 2
1 3 2
3 5
1 0 0
0 0 0
4 6 0
0 0 0
2 0 0
1 1 0
4 4 6
0 0 0
0 0 0
2 0 3
96 53 3
1 0 0
0 0 0
5 5
14 13 7
2 1
15 7 4
0 0 0
0 0 0
2 4
1 0 0
0 0 0
2 3
0 0 0
0 0 0
3 0
7 4 4
0 0 0
0 0 0
3 1 0
6 4 4
0 0 0
4 0 2
1 0 2
0 0
0 1 0
8 0 4
----- ----- --
216 135 1
212 131 10
-69 70-74 75+
0 0 0
1 0 2
3 2 2
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
3 0 0
5 3 3
1 1 0
12 6 8
3 1 4
0 0 1
2 3 1
2 1 5
1 1 3
0 0 0
0 0 0
0 2 3
0 0 0
0 0 2
0 1 0
6 3 4
0 0 0
0 0 0
3 1 1
37 22 22
0 0 0
0 0 1
1 1 5
7 4 3
1 0 1
4 4 4
0 0 0
0 0 0
1 2 1
0 0 0
0 0 0
1 4 3
0 0 0
0 0 0
1 1 1
4 6 3
0 0 0
0 0 0
0 0 0
4 3 6
0 0 0
2 0 1
2 1 1
1 0 2
0 1 0
4 1 2
--- ----- -----
12 75 95
06 72 91
73
Total (%)
0.10%
0.60%
0.70%
0.10%
0.00%
0.00%
0.40%
0.10%
0.00%
0.30%
2.10%
0.40%
4.50%
2.10%
0.40%
0.80%
0.90%
1.20%
0.10%
0.10%
1.80%
0.10%
0.70%
0.20%
2.00%
0.00%
0.00%
1.50%
43.10%
0.20%
0.10%
2.80%
4.30%
0.70%
4.20%
0.20%
0.10%
1.40%
0.10%
0.00%
1.00%
0.00%
0.20%
1.70%
8.00%
0.10%
0.00%
1.70%
3.60%
0.00%
0.50%
1.20%
1.20%
0.30%
2.20%
-----
100.00%
98.00%
74 74
Table (per 1
ICD (10th)
C00
C01-C02
C03-C06
C07-C08
C09
C10
C11
C12-C13
C14
C15
C16
C17
C18
C19-C20
C21
C22
C23-C24
C25
C30-C31
C32
C33-C34
C37-C38
C40-C41
C43
C44
C45
C46
C47;C49
C50
C60
C61
C62
C63
C64
C65
C66
C67
C68
C69
C70-C72
C73
C74
C75
C81
C82-C85;C96
C88
C90
C91
C92-C94
C95
Other
All
Not C44
5.4.3 : Age-S100,000) by P
Site
Lip
Tongue
Mouth
Salivary glands
Tonsil
Other Oropharynx
Nasopharynx
Hypopharynx
Pharynx unspec.
Oesophagus
Stomach
Small intestine
Colon
Rectum
Anus
Liver
Gallbladder etc.
Pancreas
Nose, sinuses etc.
Larynx
Trachea,Bronchus,Lung Other Thoracic organs
Bone
Melanoma of Skin
Other Skin
Mesothelioma
Kaposi sarcoma
Connective,Soft tissue
Breast
Penis
Prostate
Testis
Other male genital
Kidney
Renal Pelvis
Ureter
Bladder
Other Urinary organs
Eye
Brain, Nervous system
Thyroid
Adrenal gland
Other Endocrine
Hodgkin disease
Non-Hodgkin lymphoma Immunoproliferative dis.
Multiple Myeloma
Lymphoid Leukaemia
Myeloid Leukaemia
Leukaemia unspec.
Other & unspecified
All sites Total
All sites but C44
Spesific IncidePrimary Site a
All Ages Age unk
4 0
33 0
24 0
8 0
2 0
1 0
32 0
0 0
1 0
25 0
73 0
18 0
173 0
126 0
10 0
42 0
11 0
33 0
11 0
28 0
124 0
9 0
31 0
11 0
135 0
5 0
5 0
33 0
20 0
2 0
144 0
29 0
0 0
89 0
2 0
2 0
92 1
2 0
3 0
73 0
68 0
5 0
1 0
43 0
133 0
0 0
15 0
39 0
42 0
3 0
57 0
----- -----
1872 1
1737 1
ence Rate (Aand Age grou
0-4 5-9 10-1
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0.3
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0.3
0 0 0
0 0 0.3
0 0 0
0 0.6 3.1
0 0 0
0.7 0 0
0 0 0
0 0 0
0.4 0.6 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0.7 0 0
2.9 0.6 0.7
0 0 0
0 0 0
0 0 0
0.4 0.6 1.7
1.1 1.1 2.1
0 0 0
0 0 0
1.4 1.7 1
0.7 0.6 0.3
0 0 0
0 0 0
----- ----- ----
8 6 10
8 6 10
IR), Age Stanups, 2016.
14 15-19 20-24
0 0
0 0.4
0 0
0 0
0 0
0 0
3 0.4 1.1
0 0
0 0
0 0.4
0 0
0 0
0 0.7
0 0
0 0
0 0
0 0
0 0
3 0 0.4
0 0
3 0.4 0
0 0.4
1 0.4 1.8
0 0
0.4 0.4
0.4 0
0 0
0.4 0.4
0 0.4
0 0
0 0
0.4 1.4
0 0
0 0
0 0
0 0
0 0
0 0
0 0
7 0.8 2.1
0 0.4
0 0
0 0
7 2.1 0.7
1 2.1 1.4
0 0
0 0
1.3 0
3 0 1.1
0.4 0
0 0.4
-- ----- -----
0 10 14
0 9 13
ndardised In
25-29 30-34 3
0 0.1
0.1 0.1
0.1 0.2
0.1 0.3
0 0
0 0
0.3 0.4
0 0
0 0
0 0.1
0.1 0.3
0 0.1
0.3 0.5
0.1 0.8
0 0.1
0 0.1
0 0
0 0
0 0.1
0 0
0.1 0.4
0.6 0.1
0.3 0
0.1 0.1
0.6 0.8
0 0
0 0
0.4 0.5
0.1 0
0 0
0 0
0.8 0.6
0 0
0.1 0.3
0 0
0 0
0.7 0.2
0 0
0 0.1
0.8 0.8
0.8 1.3
0 0.1
0 0.1
1 0.9
1 1.1
0 0
0 0
0.4 0.1
0.1 0.2
0 0
0.1 0.6
----- ----- -
10 12
9 11
cidence Rate
5-39 40-44 45-49
0 0.2 0
0.4 0.3 0.6
0.1 0.1 0.6
0 0 0.2
0 0 0
0 0 0
0.2 0.2 0.3
0 0 0
0 0 0
0.1 0.4 0.2
0.4 0.6 0.9
0 0.2 0.3
1.2 1.1 2
0.5 1.1 1.9
0.1 0 0
0.1 0.2 0.3
0 0.2 0.2
0.1 0.4 0.7
0 0 0.5
0 0.2 0.2
0.1 0.3 1.3
0.1 0 0.1
0.1 0.3 0.1
0.1 0.2 0
0.4 0.6 1.1
0 0 0.2
0.1 0.2 0
0.1 0.3 0.3
0.1 0.1 0.6
0.1 0 0
0.1 0.1 0.1
0.4 0.2 0.1
0 0 0
0.3 0.6 1.5
0 0.1 0
0 0 0
0.4 0.2 0.3
0 0 0
0 0 0
0.7 0.5 0.3
0.7 0.4 0.7
0.1 0 0.1
0 0 0
0.2 0.2 0.3
0.7 1 1.7
0 0 0
0.1 0.1 0.1
0.2 0.2 0.2
0.5 0.3 0.3
0.1 0 0.1
0.2 0.3 0.6
----- ----- -----
9 11 19
9 10 18
(ASR) Amon
9 50-54 55-59
0 0
0.9 0.5
0.5 0.8
0 0.5
0.2 0
0 0
0.8 0.8
0 0
0.2 0
0.5 0.8
1.5 3.6
0.5 0.8
3.7 5.4
3.3 4.9
0.2 0.3
0.8 1.6
0.2 0.3
0.8 2.1
0 0.5
0.5 1.3
1.5 5.7
0 0.3
0.2 0.3
0.5 0
2.5 7.5
0.2 0
0 0
0.3 1
0.5 1.3
0 0
1.1 7
0.3 0
0 0
2.3 4.4
0 0
0 0
1.9 3.4
0 0
0 0
1.2 1.6
1.4 1.6
0 0.3
0 0
0.2 0
2 2.8
0 0
0.3 1.3
0.2 1
0.6 0.5
0 0
1.2 4.1
----- -----
33 68
30 61
ng Non-Saud
60-64 65-69 70-
0 0 0
1.9 0 3
1 0 3
0 0 0
0.5 0 0
0.5 0 0
1.9 1.4 0
0 0 0
0 0 0
1.4 4.2 3
3.4 8.4 6.
1.4 0 3
13 29.2 30
5.3 23.7 18
1 4.2 3
6.3 4.2 12
1 2.8 3
1.4 2.8 3
0 1.4 0
2.9 8.4 6.
10.6 29.2 30
0 0 0
1.9 0 0
1 0 0
7.2 15.3 27
0 1.4 0
0 2.8 0
1.4 2.8 0
0.5 0 3
0 0 0
14.5 46 66
1 0 0
0 0 0
5.8 7 12
0.5 0 0
0 1.4 3
7.7 18.1 18
0 0 3
0 0 0
1.9 1.4 3
2.4 2.8 0
0.5 0 0
0 0 0
1 0 3
5.8 12.5 9.
0 0 0
1 2.8 0
0 2.8 6.
3.9 0 0
0 0 0
2.9 4.2 3
----- ----- ---
115 241 28
107 226 25
di Males
-74 75+ CrudeRate
0 3.6 0
3 7.3 0.4
3 10.9 0.3
0 0 0.1
0 0 0
0 0 0
0 0 0.4
0 0 0
0 0 0
3 7.3 0.3
.1 25.5 0.9
3 3.6 0.2
0.4 43.6 2.2
8.3 18.2 1.6
3 0 0.1
2.2 14.5 0.5
3 0 0.1
3 3.6 0.4
0 0 0.1
.1 7.3 0.3
0.4 50.9 1.5
0 0 0.1
0 0 0.4
0 0 0.1
7.4 61.8 1.7
0 0 0.1
0 0 0.1
0 0 0.4
3 0 0.2
0 0 0
6.9 80 1.8
0 0 0.4
0 0 0
2.2 21.8 1.1
0 0 0
3 0 0
8.3 50.9 1.1
3 3.6 0
0 0 0
3 3.6 0.9
0 18.2 0.8
0 0 0.1
0 0 0
3 0 0.5
.1 25.5 1.7
0 0 0
0 3.6 0.2
.1 7.3 0.5
0 10.9 0.5
0 0 0
3 7.3 0.7
--- ----- -----
83 491 23.3
56 429 21.6
e ASR World
0.1
0.5
0.4
0.1
0
0
0.4
0
0
0.5
1.4
0.3
3.7
2.3
0.3
1.1
0.2
0.5
0.2
0.7
3.4
0.1
0.7
0.1
3.3
0.1
0.1
0.5
0.2
0
5.2
0.4
0
1.6
0
0.1
2.6
0.1
0.1
1.3
1
0
0
0.8
2.6
0
0.3
1
0.8
0
0.8
-----
39.9
36.6
Table (per 1
ICD (10th)
C00
C01-C02 C03-C06 C07-C08
C09
C10
C11
C12-C13
C14
C15
C16
C17
C18
C19-C20
C21
C22
C23-C24
C25
C30-C31
C32
C33-C34 C37-C38 C40-C41
C43
C44
C45
C46
C47;C49
C50
C51
C52
C53
C54
C55
C56
C57
C58
C64
C65
C66
C67
C68
C69
C70-C72
C73
C74
C75
C81
C82-C85;C9
C88
C90
C91
C92-C94
C95
Other
All
Not C44
5.4.4 : Age-S00,000) by Pr
Site
Lip
Tongue
Mouth
Salivary glands
Tonsil
Other Oropharynx
Nasopharynx
Hypopharynx
Pharynx unspec.
Oesophagus
Stomach
Small intestine
Colon
Rectum
Anus
Liver
Gallbladder etc.
Pancreas
Nose, sinuses etc.
Larynx
Trachea,Bronchus,Lung
Other Thoracic organs
Bone
Melanoma of Skin
Other Skin
Mesothelioma
Kaposi sarcoma
Connective,Soft tissue
Breast
Vulva
Vagina
Cervix Uteri
Corpus Uteri
Uterus unspec.
Ovary
Other Female Genital
Placenta
Kidney
Renal Pelvis
Ureter
Bladder
Other Urinary organs
Eye
Brain, Nervous system
Thyroid
Adrenal gland
Other Endocrine
Hodgkin disease
Non-Hodgkin lymphoma
Immunoproliferative dis
Multiple Myeloma
Lymphoid Leukaemia
Myeloid Leukaemia
Leukaemia unspec.
Other & unspecified
All sites Total
All sites but C44
Spesific Inciderimary Site a
All Ages
Age unk
1 0
11 0
12 0
2 0
0 0
0 0
8 0
1 0
0 0
6 0
39 0
8 0
83 0
39 0
7 0
15 0
16 0
22 0
2 0
2 0
g 33 0
2 0
13 0
4 0
36 0
0 0
0 0
27 0
787 0
3 0
1 0
51 0
78 0
13 0
77 0
3 0
1 0
26 0
1 0
0 0
18 0
0 0
4 0
31 0
146 0
2 0
0 0
31 1
a 65 0
s. 0 0
10 0
22 0
22 0
5 0
40 0
----- -----
1826 1
1790 1
ence Rate (Aand Age grou
0-4 5-9 10-1
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0.3 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0.4 0 0
0 0.3 0.7
0 0 0
0 0 0.4
0 0 0
0 0 0
1.9 0.6 0.7
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0.4
0 0 0
0 0 0
0 0.6 0
0 0 0
0 0 0
0 0 0
0 0 0
1.1 0.3 0
0.8 1.2 0.7
0 0 0
0.4 0 0
0 0 0
0.4 0 0.4
0.4 0 0
0 0 0
0 0 0
1.9 1.5 1.5
0 0.3 1.1
0 0 0.4
1.5 0 0
----- ----- ----
9 5 6
9 5 6
IR), Age Stanps, 2016.
14 15-19 20-24
0 0
0 0
0 0
0 0
0 0
0 0
0 0.5
0 0
0 0
0 0
0 1
0 0
0.5 0.5
0 0.5
0 0
0 0
0 0
0 0
0 0
0 0
0.5 0
0 0
7 0.5 1
0 0
4 0 0
0 0
0 0
7 0 0.5
0 1
0 0
0 0
0 0
0 0.5
0 0
4 1.4 1.4
0 0
0.5 0
0 0
0 0
0 0
0 0
0 0
0 0
7 1.4 0.5
0.5 2.9
0 0
0 0
4 0 1.4
2.7 1.4
0 0
0 0
5 0 0
1 0.5 0
4 0.5 0
0 0
-- ----- -----
9 13
9 13
ndardised In
25-29 30-34 35
0 0.2
0.5 0.2 0
0 0
0 0
0 0
0 0
0.2 0.2 0
0 0
0 0
0 0
0.5 0.5 0
0 0.5
0 0.5
0 0.2
0 0
0.2 0 0
0 0.2
0 0.5 0
0.2 0
0 0
0.7 0.2 0
0 0
0.2 0.5
0 0
0.7 0.5 0
0 0
0 0
0.2 1 0
7.4 12.7
0 0
0 0
0.7 1 2
0.2 0.7 0
0 0
1 1.4 0
0 0
0 0
0 0.5 0
0 0
0 0
0 0.2 0
0 0
0 0
1 0.2
3.8 6.5 3
0 0 0
0 0
1.7 1.4 0
0.7 2.6 0
0 0
0 0 0
0 0.2 0
0.7 0.2 0
0 0
0.2 0.5 0
----- ----- -
21 34
20 33
cidence Rate
5-39 40-44 45-49
0 0 0
0.2 0.2 0
0 0.2 0.8
0 0 0
0 0 0
0 0 0
0.2 0 0.4
0 0 0
0 0 0
0 0 0.4
0.4 1.4 1.1
0 0.4 0
1.3 1.8 2.3
1.3 0.8 0.8
0 0.2 0.4
0.2 0.2 0.4
0 0 1.1
0.4 0.4 0
0 0 0
0 0 0.4
0.2 0.4 1.1
0 0 0.4
0 0 0
0 0 0
0.6 0 1.1
0 0 0
0 0 0
0.2 0.2 0.8
19 25.2 49.5
0 0 0.4
0 0 0
2.1 1 2.3
0.6 1.2 3.4
0 0.4 1.5
0.4 1.8 3.4
0 0 0.4
0 0 0
0.4 0.6 1.5
0 0 0
0 0 0
0.2 0 0
0 0 0
0 0 0
0 1 0.4
3.9 4.5 6.9
0.2 0 0
0 0 0
0.9 0.2 0.8
0.4 0.6 1.9
0 0 0
0.2 0 0
0.2 0 0
0.6 0.2 1.5
0 0.2 0
0.2 0.2 1.9
----- ----- -----
34 44 87
33 44 86
(ASR) Amon
50-54 55-59
0 0
1 1.6
0 0
1 0
0 0
0 0
1 0
1 0
0 0
1 1.6
6.1 4.7
1 0
14.2 15.5
4.1 12.4
1 4.7
1 3.1
0 1.6
3 4.7
0 1.6
1 0
7.1 6.2
0 0
0 3.1
1 1.6
3 6.2
0 0
0 0
1 3.1
117.5 148.8
1 1.6
0 0
5.1 7.8
14.2 21.7
2 3.1
6.1 23.3
2 0
0 0
3 3.1
0 1.6
0 0
3 3.1
0 0
0 0
2 4.7
11.1 10.9
0 0
0 0
0 4.7
8.1 9.3
0 0
2 6.2
1 1.6
2 0
0 0
11.1 12.4
----- -----
240 335
237 329
ng Non-Saud
60-64 65-69 70-
0 0 0
2.2 3.5 0
4.3 10.5 10.
2.2 0 0
0 0 0
0 0 0
4.3 0 0
0 0 0
0 0 0
0 10.5 0
2.2 17.6 16.
2.2 3.5 5.4
15.2 42.2 32.
8.7 10.5 5.4
0 0 0
2.2 7 16.
6.5 7 5.4
10.8 3.5 5.4
0 0 0
0 0 0
13 0 10.
0 0 0
0 0 0
2.2 0 5.4
8.7 21.1 16.
0 0 0
0 0 0
0 10.5 5.4
114.8 130 119
0 0 0
0 0 0
10.8 3.5 5.4
28.2 24.6 21.
2.2 3.5 0
15.2 14.1 21.
0 0 0
0 0 0
8.7 3.5 10.
0 0 0
0 0 0
6.5 3.5 21.
0 0 0
0 0 0
0 3.5 5.4
8.7 14.1 32.
0 0 0
0 0 0
2.2 0 0
8.7 14.1 16.
0 0 0
0 7 0
0 7 5.4
0 3.5 0
2.2 0 5.4
0 14.1 5.4
----- ----- ---
293 393 40
284 372 39
di Females
74 75+ CrudeRate
0 0 0
0 18.4 0.3
.9 18.4 0.3
0 0 0.1
0 0 0
0 0 0
0 0 0.2
0 0 0
0 0 0
0 0 0.2
.3 27.5 1.1
4 0 0.2
.6 73.4 2.3
4 36.7 1.1
0 9.2 0.2
.3 9.2 0.4
4 45.9 0.4
4 27.5 0.6
0 0 0.1
0 0 0.1
.9 27.5 0.9
0 0 0.1
0 18.4 0.4
4 0 0.1
.3 36.7 1
0 0 0
0 0 0
4 9.2 0.7
9.7 201.
9 21.4
0 0 0.1
0 9.2 0
4 45.9 1.4
.8 27.5 2.1
0 9.2 0.4
.8 36.7 2.1
0 0 0.1
0 0 0
.9 9.2 0.7
0 0 0
0 0 0
.8 27.5 0.5
0 0 0
0 0 0.1
4 9.2 0.8
.6 27.5 4
0 0 0.1
0 0 0
0 0 0.8
.3 55.1 1.8
0 0 0
0 9.2 0.3
4 9.2 0.6
0 18.4 0.6
4 0 0.1
4 18.4 1.1
-- ----- -----
08 872 49.5
92 835 48.6
75
e ASR World
0
0.7
1.1
0.1
0
0
0.3
0.1
0
0.5
2.3
0.4
5.8
2.4
0.5
1.1
1.6
1.6
0.1
0.1
2.1
0.1
0.8
0.3
2.7
0
0
1.3
33.8
0.1
0.2
2.6
4.8
0.7
4.2
0.1
0
1.4
0.1
0
1.7
0
0.2
1.3
4.8
0.1
0
0.8
3.8
0
0.8
1.2
1
0.3
2.3
-----
92.1
89.4
76 76
Acknowle
We wo
Report’ R
Dr. Al
for Can
Hospita
Dr. Ha
Center,
Fahad S
Main Office
Mr. M
Assista
Informa
Ms. M
Cancer
Ms. W
Mr. Ah
Ms. G
Central R
Dr. Mu
Mr. M
Mr. M
Mr. Im
Western R
Dr. Ha
Mr. Sa
Mr. Ah
Mr. W
Southern
Dr. Ab
Mr. Sy
Mr. Sa
edgment
ould like to e
Reviewers
i Al-Zahrani -
ncer Control and
al & Research)
ani Al-Hashm
Hematology an
Specialist Hosp
e
ohammed A
nt of Health Dat
ation Center
Malak Al-Jam
r Registry
Wafa Al-Zahra
hmed Al-Raw
Ghadi Al-Gosa
Region
ushabab As
ohammed H
ohamed Kam
man Daggal
Region
assnah Al-G
ameer Kaifah
hmed Al-Nem
Waleed Al-Qa
Region
bdurahman A
yed Zafar Iqb
aleh Al-Olyan
express our d
for their invaluable contribution and support.
:
- (Executive dir
d Prevention, K
mi - (Director, O
nd Stem Cell Tra
pital
Al-Shehri - Ge
ta Management
aan - Acting M
ani
waji
abi
siri - Director
ayder (CTR)
mal Abdulqad
Ghamdi- Direc
h
mari
htani
Al-Shehri- Di
bal
ni
deepest grat
ector, Gulf Cen
King Faisal Spec
Oncology
ansplant Center
neral Manager
t, National Heal
Manager, Saudi
r
)
der (CTR)
ctor
rector
titude to the members of SCR committee and staff of the registry
ter
cialist
r, King
th
East
D
M
Mad
D
M
M
Dr. Shouk
Medical Onc
Research)
Dr. Suliem
Health & Pe
Cancer Cen
Dr. Hind
Registries
Ms. Ama
Registry
Mr. Zeya
Mr. Fawa
tern Region
Dr. Ali Al.Am
Mr. Abdulma
inah & Nort
Dr. Amal Al-B
Mr. Yousef A
Mr. Akram Z
ki Bazarbsh
cology, King Fa
man Al-Sheh
ediatrics Genera
nter
Al-Mutlaq -
Department
al Al- Madouj
ad Al-Shahra
az Al-Omran
mri- Director
ajeed Alam
thern Region
Behani- Dire
Abdulhadi (C
amzami
i - (Head, Sect
aisal Specialist H
hri - Consultant
al Director of Sa
Manger, Nation
j - Adviser, Sau
ani
n
n
ctor
TR)
ion of
Hospital &
t Public
audi National
al Health
udi Cancer
Ca
ancer InSa
ncidencudi Ara2016
ce Repabia
ort
77
78 78
تقيم ن والمس اللاهودجكن وي هودجكن
بنسبة) حالة
لجهاز العصبي ن اللمفاوي طا) حالة ٢٩( ين
سرطان الكلى
%١٦,٥٨,١ ٧,٠ ٥,٨ ٥,١ ٥,٠ ٤,٦ ٣,٩ ٣,٨ ٣,٧
%٢٩,١ ١٥,٥ ١٣,٤ ١١,٠ ٧,١ ٥,٠ ٣,٧ ٣,١ ٢,٤ ٢,١
ان القولونرططان اللمفاوي سرطان اللمفاو
ح٤٤٦(الرئة .% ٣,١نسبة
الدماغ وا نثم السرطا %
العين سرطانل منهما، ثم س
٥٨٠٣٩٥٥ ٤٦٩ ٤٠٥ ٣٣٤ ٢٩٨ ٢٩٠ ٢٦٥ ٢٢٩ ٢٢٢ ٢١٢
٣٨١١١١ ٥٩ ٥١ ٤٢ ٢٧ ١٩ ١٤ ١٢ ٩ ٨
تلاه سر %١ثم السرط % ٨يليه الس % ٤
يليه سرطان بن) حالة ٤٠٥
سين
تلاه سرطا % %١١,٦ بنسبة
، يليه % ٧,٣ لكل % ٤,١بة ٢ %.
جكن
ن
صبي
سين
صبين
جكن
جنسين
٧,٣بنسبة ٨,٢بنسبة ) لة٦,بنسبة ) ة
ي % ٣,٤سبة ٥( البروستات
ن لכא אلجنس
٣٠,٤بنسبة ب) حالة ٧٦(
بنسبة ) حالةبنسبة) حالة٢٣,بنسبة ) لة
جنسين
الذكورستقيموالم لون
اللاهودج مفاويوستاتالدم ضاض
ةد
دجكنهو مفاويةالدرقية ةوالجهازالعص اغ
ن لכא אلجنس
الذكور الدم ضاض
والجهازالعص اغهودجكن مفاوياللاهودج مفاويظامينالكظرية ة
الضامة سجةلخصية ى
ديين لכא אلج
)حالة ٢٢٨حال١٠٧٦(ية حالة ٦١٠(دم نسب) حالة ٤٥
خيرا سرطان
ل אلسعوديين
) حالة ٢٠٠( (ي هودجكن
ح ٤٨( لعظام٢٧(ة الضامة
حال ١٥( رقية
ديين لכא אلج
%٣٠ القول١١ الليم٩ البرو٦ ابيض٥ الرئة٣ الكبد٣ الليم٣ المثانة٢ الغدة٢ الدما
ل אلسعوديين
%ابيض ٣٢الدما ١٣الليم ٩,الليم ٧,العظ ٦,العين ٦,الغد ٥,الأنس ٤,الخص ٤,الكلى ٣,
بين אلسعود
٨٢(ة الأولى ن الغدة الدرقي ابيضاض الد
٥٤( ن الرحم وأ % ٣,٢سبة
بين אאطفאل
لمرتبة الأولى رطان اللمفاوي
ال ثم سرطان رية والأنسجةان الغدة الدرق
بين אلسعود
% ٧٢ ٠,٤١,٦ ,٦ ,٢ ,١ ,٨ ,١ ,٠ ,١ ,٠
بين אאطفאل
% ٢٢,٢ ٣,٤ ,١ ,٦ ,٥ ,٥ ,٤ ,٧ ,٣ ,٦
כثر شيوعא ب
لثدي المرتبةسرطان ثم %ثم سرطان %ثم سرطان %
بنس) حالة ٤١
כثر شيوعא ب
ضاض الدم المرلسرطثم ا %
% ٩,١نسبة ة الكظر الغدا سرطا وأخير
כثر شيوعא ب
٧٣٥٨٢٢٤٠ ٨٥٤ ٧٠٤ ٤٥٤ ٣٧٢ ٢٧٦ ٢٣٠ ٢١٩ ١٥٥ ١٤٨
כثر شيوعא ب
٢٧٦٨٩ ٣٧ ٢٥ ٢١ ١٨ ١٨ ١٥ ١٣ ١٢ ١٠
אلعشرة אאכ
السرطان ل ١٢,٦بنسبة ) % ٦,٤بنسبة
٣,٨بنسبة ) ٧(طان الكبد
אلعشرة אאכ
ل سرطان ابيض١٤,٦بنسبة
بن) حالة ٦٠(ثم سرطان ،
، % ٤,٠نسبة
אلعشرة אאכ
لاناث
ةتقيم
لاهودجكنم
ودجكن
از العصبي لج
אلعشرة אאכ
لأناثم
ازالعصبي لجودجكن
دجكنلاهوضامةيةة
אلسرطאنאت
احتل)حالة ١٦٥٩() حالة ٨٤١(
)حالة ٤٩٥( ثم سرط% ٣,٤
אلسرطאنאت
احتلب) حالة ٩٦(
(اللاهودجكن % ٤,٤بنسبة
بن) حالة ٢٦(
אلسرطאنאت
الا الثدي
الغدة الدرقية القولون والمست
الرحم الليمفاوي اللا ابيضاض الدم الليمفاوي هو
المبيض الدماغ والجها
الرئة
אلسرطאنאت
االدم ابيضاض
والجها الدماغ
هو الليمفاوي
العظام الكلى
اللا الليمفاوي
الض الأنسجة
الكظري الغدة
الدرقية الغدة
العين
א
)))
א
)اب)
א
א
ركز الأبحاث المملكة ناطق
يناير في عام تحلل البيانات على صفحة
ية الحكومية وغير % ,٧٨
سبة أجمالية %.
اموع
٣٦٩٨
٩١,٣النساء بمعدل عمري منطقة مكة ة ، و منطقة لسرطان لدى
١٠٠٠٠٠كل ١٠٠٠٠٠لكل
2016عאم
لتخصصي ومرسة فروع في مني ومات من شهرة العالمية وتحنموذج خاص
لمرافق الصحي١يين بنسبة
حالة بنس ٥% ٥٥,٩قدرها
سعوديين نثى
١٨٢
سمة ، وبين ابم بين الذكور
نسمة، ثم ١٠نسمة ١٠٠٠٠
بالس للإصابة حالة لك ,١٣٠
حالة ٨٧,٧ل
عودية لع
الملك فيصل ال السجل خمسةفي جمع المعلومنظمة الصحةصائية وفق نم
https://nhic
من مختلف المسعودي ١٣١٦١
٥٨٠٣ الذكور ق إجماليةسبة
غير سأن
٢٦
نس ١٠٠٠٠٠ لات السرطان
٠٠٠٠لة لكل ٠حالة لكل ٧
رية المعيارية١اض بمعدل
المكرمة بمعدل
ربية אلسع
بمستشفى ا) ميضم . لحكومية
سجل نشاطه المعتمد من منبمعلومات إحص
c.gov.sa/eSer
و المسجلة ٢١ ذه الحالات
ى السعوديين حالة بنس ٧٣
ذكر
١٨٧٢
حالة لكل ٧٤ لحدوث حالا
حال ٩٦,٤ عدل٧١,٤ ف بمعدل
لمعدلات العمرا منطقة الريا منطقة مكة ا
ملכة אلعر
م١٩٩٢(هـ ١ الصحية الحك
بدأ الس .صحيةحسب النظام
ة والباحثين بم
rvices/Pages
٠١٦ في عام ، من بين هذ السرطان لدى
٥٨سعوديات
اموع
١٣١٦١
٤,٧ين الرجال ة أعلى معدل ة الرياض بمعمنطقة الجوف
كما بلغت ا. نسمة تليها ١
نسمة ثم ١٠٠ .نسمة ١
ن في אلمم
٤١٢ في عام من القطاعات القطاعات الصات وتدخل حلجهات المختصة :حي السعودي
/TumorRegis
طان المكتشفةحالة ١٦٨٥٩
عدد حالات لدى الإناث الس
سعوديين أنثى
٧٣٥٨
لسرطان بينطقة الشرقيةة تلتها منطقة
نسمة ثم م ١.نسمة ١٠٠٠
٠٠٠٠٠ة لكل ٠٠٠حالة لكل٠٠٠٠٠لة لكل
אلسرطאن
رאم
ورام عودي للأة وبمشاركة من
عدد من ب في البيانا وترميز
ل بتزويد الجلمجلس الصحstration.aspx
٢٠١٦ م
حالات السرط٩ة السعودية
وكان . % ٢١عدد الحالات ل
ذكر
٥٨٠٣
ي للإصابة باسجلت المنط.
نسمة ١٠٠٠٠٠٠٠٠٠ لكل ٠٠٠لكل ٦٩,٠
حالة ١٣١,٣ ح٩٥,٥بمعدل
حالة ٨٠,٨عدل
אحصאئيאت
عودي لאو
ئ السجل السع وزارة الصحةلى وجود مكاتبث يتم جمع و
يقوم السجل وقع الرسمي للx
لسرطאن لعא
إجمالي عدد ملكة العربية
٩, بنسبة ٣٦بينما بلغ ع %
لكلي
ذ ١
٣
المعدل المعيارينسمة ١٠٠٠٠
٠حالة لكل ١حالة ٧٣,٢ل
٠ الية بمعدلالشرقية طقةالجوف بم طقة
ة القصيم بمعد
א
אلسجل אلسع
أنشئتحت إشراف بالإضافة إلى
م، حيث ١٩٩٤. بشكل دوريالسجل في المو
אحصאئيאت אل
بلغ إوالخاصة بالمم
٦٩٨سعوديين % ٤٤,١قدرها
اموع ال
١٦٨٥٩
بلغ ا٠٠ة لكل حال
١٠٤,٣معياري بمعدل المكرمة
الحدود الشمافبالمنطالنساء
نسمة ، ثم منطنسمة ومنطقة
79
א
تحب
با
א
وسق
حمااانن
آله وصحبه
يكم التقريرجل وأنشطته فق الصحية
، بنسبة )يين
، بينما % ٤٤
يف الصحي، ضع الحقيقي
طويلة المدى طان وتبادل
عم حكومتنا ذلك بجهود داد البرامج
א"
محمد وعلى آ
ضع بين أيدينجازات السج
المرافمختلف من السعودي(
٤,١ها ية قدر.
برامج التثقي تعكس الوض
.لجغرافيوطنية ط جية
لمرضى السرط
عالى ثم بدع، وكذ- االله
وقاموا بإعد
אא" في
، نبينا مح لين
صحية أن يضى أحدث إنجن كافة من مخ
حالة "١٣١٦
نسبة إجمالي% ٥٥,٩درها
التوعوية وب دقيقة التيمر والموقع ا
إستراتيجيذ ة المقدمة لمر
ل من االله تعأيدهما -ين
عناية كبيرة
ه الزملاء في .كة
:))نبياء والمرسل
للمعلومات الصي يحتوي علىلات السرطان
٦١"من بينها .% ٢١,٩غت حالات، بن" ٥
ة إجمالية قدعم الجهود بالبيانات الدب النوع والعمف على تنفي
صحيةعاية ال.
ا جاء بفضلعهده الأمينض السرطان ع
ر الذي قام بهكافة في المملك
:;<ى أشرف الأن
كز الوطني لالذي م،٢٠١٦
تسجيل حالاحالة، م)١٦٨
، بنسبة بلغ)٥٨٠٣"لذكور
حالة بنسبة على د" سجل
في المملكة، شيوعاً حسب قام بالإشراستويات الرع.مية المختلفةحي في بلادنا وسمو ولي ي أولوا مرض
لجهد المستمرت السرطان ك
אאא
<والسلام على ة
ممثلاً في المرك٦لأورام لعام
ت في رصد وت٨٥٩( تي بلغت
)ير السعوديين السعوديين ال
" ٧٣٥٨"يات الس"درة عن
ل السرطان واع السرطان حي السعودي ر وتحسين مسعات الحكوميفي اال الصحين الشريفين لمؤسسات الذي
ل الدؤوب واحالات تسجيل
K
والصلاة ، ين
ي السعودي مم السعودي للأ
وتمثلت ، خراً، التي المملكة
من غير( حالة سرطان لدى لإناث السعوديصائيات الصادصين في مجاديد أكثر أنولس الصحي
وتطوير ، نبية في القطار ملموس في خادم الحرمينوالهيئات والمؤ
.قاية منه
نتيجة العمله وأهدافه لت
الله رب العالمين ،،د
لس الصحيمال السجل تي تمت مؤخلخاصة في ا
ح"٣٦٩٨"، و%دد حالات السلحالات لدى الإعدت الإحصحثين والمختصفي المملكة، وتحد أنوه بأن ا
حة السرطانين المراكز الطبراه من تطورعلى رأسها خاطاع الصحي لتوعوية للوق
..لختامقرير تحقق نحقيق رسالته
الحمد اللهأجمعين، وبعد
سر ايالسنوي لأعموبرامجه التيالحكومية وا
% ٧٨,١بلغت وكان عدبلغ عدد الحاوقد ساعوتزويد الباحللسرطان في وأود أن لعلاج ومكافحالخبرات بينإنّ ما نرالرشيدة وعمنسوبي القطالعلاجية والوفي الختهذا التقمشكورين، لتح
أ
اواب
ب
ول
لا
اما
م
ة
ي
صحية
م
سرطאن
لسعودية
لسعودي
ومאت אلص
ي لאورאم
مرض אلسر
لعربية אل
لصحي אل
ي للمعلو
سعودي
אصאبة بم
٢٠١٦
لمملכة א
مجلس א
ز אلوطني
لسجل אلس
معدل אא
אل
אلم
אلمرכز
א
رتقري
2019 يو يوليحرر في ح